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General Introduction. 
Late-life anxiety: Fact and fiction 
This chapter is partly based on: 
Schuurmans, J. & Weijnen, I. J. C. (2003). [Angststoornissen bij ouderen]: Anxiety 
disorders in older adults. In A.Bak, W. T. M. Berlo & J. J. L. Derksen (Eds.), Handboek 
Klinische Psychologie (22 ed., pp. 1-26). Houten: Bohn Stafleu van Loghum. 
Preface
Until recently, the concept of anxiety in late life has been disregarded, both in clinical 
practice and in the scientific community. This disregard is still often thought to be 
justified by the fact that older adults with anxiety disorders rarely present themselves 
to mental health care settings. In fact, a recent study in the Netherlands revealed that 
only a very small percentage of older adults (aged 55 years and over) with an anxiety 
disorder were in contact with a community mental health care centre (3.8%) or a 
psychiatrist (2.6%) (de Beurs et al., 1999). In light of these circumstances, it is 
understandable that clinicians and researchers alike hold that anxiety is not very 
prevalent in late life. Other frequently voiced notions about late-life anxiety include 
the idea that depression is much more prevalent in late life, as well as the conviction 
that ‘pure’ anxiety disorders are hardly ever present in older adults and that anxiety 
in late life is almost exclusively a secondary by-product of a depressive disorder or a 
prelude to dementia. In recent years, all these assumptions have been refuted by 
epidemiological research, which will be discussed in the following paragraph. 
Prevalence and comorbidity of anxiety in late life 
Estimated prevalence rates of late life anxiety disorders in recent epidemiological 
studies center around 10% (Beekman et al., 1998; Flint, 1994), which is not very 
different from the estimated prevalence of 12.4% found in mixed-age populations 
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(18-65 years old; Bijl, Ravelli & van Zessen, 1998). Anxiety disorders are even found 
to be more prevalent in late life than depression (1.7%), dysthymia (3-5%) (Beekman 
& Heeren, 2001) and dementia (3-7%; (Verhey & Kat, 2001)). In contrast to the 
common clinical notion that anxiety in late life is either comorbid to depression or a 
symptom of mixed anxiety-depression, most older adults (74%) with an anxiety 
disorder do not suffer from a comorbid depression whilst depression without 
comorbid anxiety is much less common in late life (Beekman et al., 2000). 
Furthermore, mixed anxiety-depression is less prevalent in late life than either major 
depression or anxiety disorders (Schoevers, Beekman, Deeg, Jonker & van Tilburg, 
2003). Although symptoms of agitation and anxiety frequently accompany dementia, 
the prevalence of anxiety disorders among persons with dementia is comparable to 
the prevalence of anxiety disorders in the general population of older adults 
(Chemerinski, Petracca, Manes, Leiguarda & Starkstein, 1998). In a report on the 
comorbidity of anxiety disorders in older adults in the Netherlands, no significant 
association was found between the presence of an anxiety disorder and the presence 
of cognitive impairment (van Balkom et al., 2000). When trying to establish whether 
anxiety could possibly be a prelude to dementia, it is important to closely investigate 
the etiology of anxiety symptoms. Most anxiety disorders in late life have an onset in 
early or middle adulthood (Flint, 1994), which makes it highly unlikely that there is 
any connection with dementia.  
Recognition and presentation of late-life anxiety disorders 
In light of the high prevalence of anxiety in late life, it is puzzling that only a very 
small minority of older adults that are referred to mental health care settings are 
diagnosed with an anxiety disorder. Several factors may contribute to the fact that 
anxiety disorders are not easily identified in older adults. 
First of all, older adults may be more inclined to verbalize psychological symptoms 
in somatic terms (Godderis, van de Ven & Wils, 1992). Psychological terminology is 
less familiar to older adults and anxiety symptoms are often described in terms of 
physical illness: e.g. “I feel sick”. Furthermore, older adults with anxiety are most 
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frequently seen in a primary care setting rather than in a specialized mental health 
care setting, and the general practitioner is inclined to give high priority to somatic 
complaints in an older adult. Justifiably so, since older adults have a greatly 
increased risk of somatic illness (Haley, 1996), but in the process of excluding a 
somatic cause, the possibility of an anxiety disorder is often overlooked.
Secondly, the current generation of older adults is probably more reluctant to share 
their personal problems with other people, as they were raised to solve their own 
problems and not to involve other people in private matters (Weijnen, 2001). 
Additionally, clinical experience tells us that older adults are more inclined to think 
of anxiety symptoms as a personality trait that can not be altered or cured, especially 
when their symptoms have an onset in childhood or early adulthood. For older 
adults who have been struggling with anxiety symptoms for decades and who have 
never been (adequately) treated, it is not very logical to suddenly start demanding 
treatment for their ailment, particularly when they have the impression that such a 
treatment does not exist. Therefore, it does not come as a surprise that anxiety 
symptoms are rarely spontaneously reported by older adults.  
Anxiety in late life may also go unnoticed through effective avoidance behavior. It is 
probably easier for older adults to avoid certain activities since they have less 
obligations than younger adults and society readily accepts the fact that older adults 
are incapable of physical exercise or of doing their own shopping (Weijnen & de 
Beurs, 2001). People surrounding an older individual (e.g. children, neighbors) are 
probably more prone to relieve the older adult of the burden of certain tasks than 
they would be when confronted with a younger adult with similar problems. 
Although well intended, this helpfulness may contribute to the onset and persistence 
of avoidance behavior and the camouflaging of anxiety symptoms. 
Another related factor contributing to the lack of appropriate identification and 
referral of anxiety in late life lies within the (mental) health care profession rather 
than within the anxious older adult. Ageism (Lindesay, 1991) is probably involved in 
the fact that anxiety and avoidance behavior in late life are often interpreted as 
‘normal’ or ‘realistic’ (Fuentes & Cox, 2000) and, therefore, deemed untreatable. For 
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example, when an older person’s mobility is affected by arthritis or other age-related 
ailments, or when an older person trips and falls in the street, it is often considered 
an appropriate response for that person to be too anxious to leave the house or travel 
by bus, train or tram. On the same note, when we are confronted with an older 
person who obsesses over the possibility of becoming seriously ill or cognitively 
impaired, our own fears of what might happen when we grow old may hinder the 
correct appraisal of such obsessive thoughts as symptoms of an anxiety disorder. 
Furthermore, the phenomenology of anxiety in late life may be different from anxiety 
in early adulthood: older adults may fear different stimuli or situations or may have 
a different reason for fearing certain stimuli or situations than younger adults 
(Schuurmans & Weijnen, 2003). Current diagnostic instruments and the DSM-IV 
classification system may not be cut out to identify late-life anxiety disorders. 
In the next paragraph, an account is given of the prevalence of different anxiety 
disorders and of the way they may present themselves in late life.
Prevalence and clinical presentation of specific anxiety 
disorders in late life 
In diagnosing anxiety disorders in late life it is sensible to discriminate between early 
and late onset of anxiety (Flint, 1997; Sheikh & Salzman, 1995b). In early onset 
anxiety (before the age of 60), the clinical presentation may be similar between older 
and younger adults. In late onset anxiety (at or after the age of 60), it is plausible that 
more age-related features are present. Late-onset anxiety is not as rare as current 
clinical lore holds. In fact, it is present in 30 to 40% of late-life anxiety disorders (Le 
Roux, Gatz & Wetherell, 2005; Flint, 1994). 
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Table 1. The prevalence of anxiety disorders in mixed-age populations (<65)
and older adults (>55) in the Netherlands 
Diagnosis Mixed-age (<65) Older adults (55+) 
All anxiety disorders 12.4% 10.2% 
Panic disorder 2.2% 1.0% 
Agoraphobia 1.6%  
Specific phobia 7.1% 3.1% 
Social phobia 4.8%  
Generalized anxiety disorder 1.2% 7.3% 
Obsessive-compulsive disorder 0.9% 0.6% 
The present thesis focuses on four specific anxiety disorders: generalized anxiety 
disorder, agoraphobia, social phobia and panic disorder, as these are generally 
regarded to be most prevalent in late life. 
Generalized anxiety disorder (GAD) 
GAD appears to be the most prevalent anxiety disorder in late life with an estimated 
prevalence rate in the Netherlands of 7.3% (see table 1; Beekman et al., 1998), which 
is almost six times as high as the estimated prevalence of GAD in younger adults 
(1.2%; Bijl, van Zessen & Ravelli, 1997). Early onset GAD shows great resemblance to 
the concept of ‘trait anxiety’. Late-onset GAD is presumably triggered by a major life 
event, such as retirement, the death of one’s partner or the establishment of the 
presence of a physical illness.
In part, the focus of worry symptoms seems to shift with age. Worries about health-
related issues peak in older adults, while younger adults tend to worry more about 
their family and finances (Person & Berkovec, 1995). Fear of crime increases strongly 
with age, even though older adults are not victimized more often than younger 
adults (Clarke & Lewis, 1982). Presumably, this may be attributed to the sense that 
one’s capacity to defend oneself is diminished (Godderis et al., 1992). 
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Agoraphobia
Data on the prevalence of agoraphobia in late life are scarce. However, the estimated 
prevalence of all phobic disorders combined (agoraphobia, social phobia and specific 
phobia) is 3.1% in older adults in the Netherlands (Beekman et al., 1998); see table 1). 
One study found a prevalence rate of 1.4% for agoraphobia in older adults 
(Weissman et al., 1985), which would mean that agoraphobia is the second most 
prevalent anxiety disorder in late life. Although agoraphobia in the classical sense, 
with a history of panic attacks or panic symptoms, is not uncommon in older adults, 
one may also find a completely different etiology of this disorder in late life. Physical 
limitations or an accident are often found to be a trigger for late-onset agoraphobia. 
Especially the fear of falling appears to be common in late life. This fear can be so 
incapacitating that it fits the criteria for an anxiety disorder: the so-called ‘fall phobia’ 
(Spano & Forstl, 1992). Health care professionals tend to regard this fear as realistic 
and therefore, not pathological. However, although a fall may be a valid reason for 
taking the necessary safety precautions, it does not imply that one should never leave 
the house without a chaperone. Incontinence, present to some extent in 60 percent of 
older adults, can also contribute to the onset of agoraphobic symptoms in late life. In 
this case, unfamiliar or crowded places are avoided because a toilet may not be 
readily available. 
Social phobia 
Among people under 65, social phobia is the second most prevalent anxiety disorder. 
Social phobia appears to be less prevalent in older adults (Gretarsdottir, Woodruff-
Borden, Meeks & Depp, 2004), although exact figures are unfortunately not available. 
However, social phobia may take on a different form in late life, which might 
complicate the correct identification of this disorder in older adults. 
With increasing age, the focus of social anxiety seems to shift from the fear of public 
speaking to the fear of eating, drinking and writing in public (Sheikh et al., 1995), the 
feared consequence being that other people will see you spill or tremble. In these 
cases, the adaptation to a life with dentures, paralytic symptoms after a 
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cerebrovascular accident, an age-related tremor or Parkinson’s disease contribute to 
the etiology of a social phobia in late life. Even the fear of developing dementia can 
be interpreted as a form of social phobia when related avoidance behavior is very 
incapacitating. Older adults may become fearful of being perceived by others as 
someone suffering from dementia in reaction to seemingly small incidents, such as 
forgetting someone’s name or not being able to find one’s keys. In company, people 
may become fearful that others will notice their forgetfulness and as a consequence, 
social situations may be avoided. Anxiety and tension may in turn lead to an 
aggravation of forgetfulness through a lack of concentration, which can be 
interpreted as a confirmation of the alleged dementia, not only by the older adult in 
question, but also by relatives and acquaintances. It is important to distinguish this 
phobia from legitimate memory complaints in older adults. In cross-sectional studies, 
evidence has been found that memory complaints are significantly but weakly 
associated with memory impairment (Jonker, Geerlings & Schmand, 2000). 
Longitudinal studies suggest that memory complaints reflect a greater risk for 
dementia or cognitive decline, but only in those older adults with mild cognitive 
impairment at baseline. In highly educated older adults, subjective memory 
complaints may be associated with future cognitive decline or dementia even 
without the presence of such mild cognitive impairment at baseline (Jonker et al., 
2000). However, the evidence for the association between memory complaints and 
cognitive decline is limited and equivocal. Furthermore, it is important to keep in 
mind that the available evidence does not imply that the majority of older adults who 
complain of memory problems will eventually develop dementia.  
Incontinence may also be a factor in the etiology of late-onset social phobia, in which 
case company is avoided because one fears that their incontinence will lead to 
embarrassment.
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Panic disorder
Panic disorder, as described in the DSM-IV, (American Psychiatric Association, 
1994), is less prevalent in late life than in early or middle adulthood. Its prevalence is 
estimated at 0.1-1.0% in people aged 55 years and over (Beekman et al., 1998; Flint, 
1994; Regier et al., 1988) versus 2.2% in younger adults (Bijl et al., 1998). Panic 
symptoms in older adults often do not fit the description of recurrent panic attacks, 
because the symptoms do not follow a short and overwhelming pattern, but instead 
tend to show a more chronic and less “violent” course. This phenomenon is possibly 
caused by normal age-related differences in bio-psychosocial variables that 
contribute to the severity of panic symptoms (Sheikh, Swales, Carlson & Lindley, 
2004; Flint et al., 1998). Effective avoidance behavior may also contribute to the 
absence of panic attacks. For example, if an older person never goes to the 
supermarket at times when it is fairly crowded, panic attacks are easily avoided. 
Late-onset panic disorder has been found to be associated with less severe and fewer 
symptoms than early-onset panic disorder (Seguí et al., 2000; Sheikh, King & Barr 
Taylor, 1991).
The burden of anxiety in late life 
In the previous section of this chapter, the common belief that anxiety disorders are 
rare in late life has been refuted by evidence from epidemiological studies, and 
explanations for the lack of appropriate identification of anxiety disorders in late life 
have been put forward. However, current clinical opinion also proclaims that anxiety 
in late life is not very serious or incapacitating. In fact, recent studies show that the 
opposite is true: late-life anxiety has been proven to be equally disabling as late-life 
depression (de Beurs et al., 1999). The use of somatic health care services (visits to the 
general practitioner, medical specialists, hospital admissions) is increased in anxious 
older adults, while the appropriate use of mental health care services is low (de Beurs 
et al., 1999). Furthermore, findings from recent studies suggest that anxiety is 
associated with an increased mortality rate in male older adults (van Hout et al., 
2004) and in frail or chronically ill older adults (Crockett, Cranston, Moss & Alpers, 
2002; Strik, Denollet, Lousberg & Honig, 2003). In older adults who have suffered 
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from a myocardial infarction, anxiety has been found to be predictive of recurrent 
cardiac events and an increased use of health care services (Strik et al., 2003). Anxiety 
disorders have also been found to be more prevalent in chronically ill older adults 
(Kim, Braun & Kuni, 2001).
Data on the course and long-term outcome of anxiety in late life are nonexistent, but 
studies in mixed-age populations have shown that anxiety disorders that are not 
adequately treated tend to follow a chronic course (Angst & Vollrath, 1991).
Feasibility and effectiveness of treatment for late-life anxiety 
disorders
Psychological interventions 
Despite the prevalence and impact of anxiety in late life, the belief that it is not 
sensible or feasible to undertake a psychological intervention in anxious older adults 
is still common in general practitioners and mental health care professionals. This 
belief dates back to the early days of psychoanalytic theory; Freud proclaimed that 
psychotherapy would not be feasible for an older individual (Jacobs, 1994), because a 
person’s psychological flexibility was supposed to diminish through the years and 
the amount of material that had to be addressed in the analysis would have become 
too expansive.
In response to this reluctance to treat anxious older adults, a counter movement has 
been set in motion that proclaims that the same treatments that have been found to 
be effective in younger adults, can and should be applied to older adults. Research 
efforts that stem from this counter movement, have focused on establishing the 
effectiveness of cognitive behavioral therapy (CBT) for late-life anxiety, as empirical 
evidence suggests that CBT is the most effective form of psychotherapy for anxiety 
disorders in mixed-age populations (Emmelkamp, 2004).  
In the last decade, several studies have been published that provide modest support 
for the effectiveness of CBT in anxious older adults (Stanley et al., 2003; Mohlman et 
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al., 2003; Wetherell, Gatz & Craske, 2003; Barrowclough et al., 2001; Stanley, Beck & 
Glassco, 1996). One of these studies (Wetherell et al., 2003) compared the relative 
effectiveness of CBT to a discussion group focused on worry-provoking topics in 
older adults with a generalized anxiety disorder. Both treatment conditions proved 
to be superior to a wait list control group, but there was only limited evidence of the 
superiority of CBT over the discussion group. In another recent study (Stanley et al., 
2003), CBT was compared to a minimal contact control group in older adults with a 
generalized anxiety disorder (GAD). CBT was found to be superior to the control 
group, with 45% of participants in the CBT group showing significant improvement, 
versus 8% in the control group. The effect remained fairly constant over a follow-up 
period of one year. Only one randomized treatment study included older adults with 
a wider range of anxiety disorders, rather than focusing solely on GAD 
(Barrowclough et al., 2001). In this study CBT was compared to supportive therapy 
for the treatment of older adults with panic disorder, social phobia, GAD and anxiety 
disorder not otherwise specified (ADNOS). Both CBT and supportive therapy proved 
to be effective, with CBT participants showing greater improvement on anxiety 
measures. Also, response rates in the CBT group were higher; 71% of participants 
who received CBT were identified as treatment responders, versus 39% of 
participants who received supportive therapy. These findings are in disagreement 
with findings from an earlier study by Stanley et al. (1996) in which response rates 
for supportive therapy were higher than for CBT (54% vs. 28%). Both studies lacked a 
control group, although a six-week baseline phase was used in the study by 
Barrowclough et al. (2001) in order to ensure the stability of anxiety symptoms.
Although the treatment studies described here provide some support for the 
effectiveness of CBT for late-life anxiety disorders, the superiority of CBT over other 
modes of treatment for this particular group has not been firmly established and 
effect sizes in these studies tend to be smaller than effect sizes found in similar 
studies of mixed-age populations (Mohlman, 2004). Also, most treatment studies of 
late-life anxiety disorders are characterized by relatively high dropout rates (Stanley 
et al., 2003; Wetherell et al., 2003; Stanley et al., 1996) when compared to similar 
studies in younger adults (Gould, Safren, Washington & Otto, 2004). This is an 
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important factor to take into account when evaluating the effectiveness of CBT for 
late-life anxiety, since dropout can be regarded as a type of treatment failure 
(Emmelkamp & van der Hout, 1983) and may lead to a bias of research findings; 
dropouts have been found to differ from those who complete treatment in several 
studies (e.g. Issakidis & Andrews, 2004; Cuijpers, 1998). Finally, since older adults do 
not readily apply for referral to a mental health care setting, recruitment for late-life 
anxiety treatment studies is primarily accomplished through media announcements 
(Akkerman et al., 2001; Wetherell & Gatz, 2001). Media recruitment of participants 
also carries the risk of biased research findings, as has been put forward by several 
publications on media recruitment in mixed-age populations (Rapaport et al., 1996; 
Aronson, 1987; Krupnick, Shea & Elkin, 1986).
It is often stated that cognitive behavioral therapy should be modified to 
accommodate older adults. This is why CBT in studies with older adults is often 
provided in a group format (e.g. Stanley et al., 2003; Wetherell et al., 2003), rather 
than the individual format in which it is usually provided to younger adults. The 
rationale behind this approach is that older adults may be more socially isolated than 
younger adults and will benefit more from treatment in a group (Stanley et al., 2003). 
Other recommended modifications for older adults involve a greater emphasis on 
psycho-education, increasing the patient’s motivation and repeating the explanation 
of new coping strategies. It is often suggested that psycho-education is more 
important in older adults, because the present older cohort may have unrealistic 
views of what psychotherapy entails and may also have more trouble identifying, 
and talking about, psychological problems. More emphasis on increasing the 
motivation of patients is presumed to be needed, because people have often been 
living with their symptoms for decades and are reluctant to believe that recovery is 
possible. Treatment studies described here all claim to have incorporated some or all 
of these modifications in their CBT protocols, but no systematic study has been 
performed to establish if, and which modifications are necessary to improve the 
effectiveness of CBT for late-life anxiety disorders. Recently, a pilot study has been 
published, comparing standard CBT with an adapted CBT protocol for older adults 
in the treatment of GAD, that provides some indication that the adapted protocol 
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might lead to better results (Mohlman et al., 2003). Adaptations involved the use of 
learning and memory aids, more attention to the (repeated) explanation of the 
rationale of treatment and weekly calls from the therapist to help participants with 
any problems they might have encountered in doing the homework assignments.  
In conclusion, although CBT appears to be effective for the treatment of anxiety in 
older adults, the evidence is limited and equivocal. Because CBT in late-life anxiety 
treatment studies is often provided in a group format it is difficult to distinguish 
group effects from treatment-specific effects. Also, because most studies have 
focused on the treatment of GAD, no inferences can be made on the effectiveness of 
CBT for other anxiety disorders in older adults. Surprisingly, none of the 
aforementioned studies included participants with agoraphobia without a history of 
panic disorder, while this may well be one of the most common anxiety disorders in 
older adults (Beekman et al., 1998).  
Pharmacological interventions 
The most common form of treatment for late-life anxiety today is the prescription of 
benzodiazepines. As many as 25% of older adults with an anxiety disorder in the 
Netherlands were found to use a benzodiazepine (de Beurs et al., 1999). In fact, 
benzodiazepines are the most commonly prescribed psychotropic drug in older 
adults, regardless of psychiatric diagnosis (Kirby et al., 1999). This is a troubling 
phenomenon, since a long-term use of benzodiazepines is associated with serious 
adverse effects, especially in older adults, such as a heightened risk of accidents and 
falls, a heightened risk of cognitive impairment and the development of tolerance 
and addiction (Broekhoven et al., 2002; Kan et al., 1997).
In trying to reverse the wide distribution of benzodiazepines among anxious older 
adults, several authors (Nordhus & Pallesen, 2003; Hersen & van Hasselt, 1992) have 
warned against pharmacological treatments of late-life anxiety in general, because 
even the prescription of safer psychotropic drugs, such as selective serotonin 
reuptake inhibitors (SSRIs) might be problematic in older adults. Due to a slower 
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metabolism in older adults, especially in those with one or more chronic diseases, 
there is a greater chance of adverse side-effects. Furthermore, older adults often 
already use a lot of different medications, increasing the chance of negative 
interactions. Although these are valid arguments, they do not provide sufficient basis 
to completely discard any kind of pharmacological approach. In fact, data on the 
prescription of SSRIs for late-life depression indicate similar effectiveness and 
tolerability of these drugs in older adults as in younger populations (Bourin, 2003: 
Mottram, Aswhorth & Abou-Saleh, 2003: Schneider et al., 2003), even in the ‘older 
old’ (aged 75 years and up; Gildengers et al., 2002). Recently, the first randomized 
placebo-controlled trial of an SSRI (citalopram) for the treatment of late-life anxiety 
has been published, providing support for the efficacy of SSRIs for the management 
of anxiety in older adults (Lenze et al., 2005). However, the study sample was rather 
small (n=17 in the citalopram condition versus n=17 in the placebo group) and 
findings need to be replicated in a larger sample. Also, a recent pooled analysis of 
five randomized placebo-controlled trials of venlafaxine for generalized anxiety 
disorder in mixed-age populations suggested that venlafaxine is equally efficacious, 
safe and well tolerated in younger and older patients (Katz, Reynolds, Alexopoulos 
& Hackett, 2002).
How old is an ‘older adult’? 
It should be noted that in the available literature on late-life anxiety, the age that is 
used as a cut-off for defining ‘late life’ often differs between studies. In most studies, 
the cut-off used is 55, 60 or 65 years old. The Dutch ministry of Public Health, Well-
being and Sports defines an older adult as someone aged 55 years or older. In the 
Netherlands, specific mental health care facilities for older adults usually define an 
older adult as someone aged 60 years and over. However, many of us may tend to 
have a higher age in mind to delineate late life.  
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Aims and outline of the present thesis 
The present thesis attempts to contribute to the appropriate identification, prognosis 
and, especially, the effective treatment of late-life anxiety. We hypothesized that 
differences in the phenomenology of anxiety between older and younger adults 
might contribute to the lack of appropriate identification of anxiety disorders in late 
life. Therefore, we conducted a study in the general population that aimed to 
establish differences between the phenomenology of anxiety in older, younger and 
middle-aged adults. In this study, both common measures for anxiety and a new 
questionnaire designed to measure age-related worry symptoms in older adults are 
used in order to find cues for appropriate identification of anxiety in older adults. 
Findings from this study are described in chapter 2.
In order to establish whether anxiety disorders have a similar tendency to show a 
persistent long-term outcome in late life as has been established in younger 
populations (Angst et al., 1991), we studied the outcome of anxiety disorders and 
factors related to outcome in a cohort of anxious older adults in the Netherlands after 
a follow-up period of six years (chapter 3). This chapter also provides data on the use 
of mental health care facilities in order to establish whether efforts made in recent 
years to enhance appropriate referral have taken effect.
As described in a previous section of this chapter, late-life anxiety disorders are 
mostly treated with benzodiazepines. In an effort to find support for the effectiveness 
of more adequate interventions that are successfully applied to younger populations 
for the treatment of anxiety in late life, we performed the first randomized 
comparative trial of CBT versus an SSRI (sertraline) for anxiety disorders in older 
adults. Chapter 4 describes the main findings of the RCT, whilst chapter 5 deals with 
long-term outcome of CBT and sertraline at one-year follow-up and differential 
predictors for treatment effect, in order to establish what treatment might work best 
for whom. As attrition rates in treatment studies of late life anxiety are typically high 
and early termination of treatment can be regarded as a type of treatment failure 
(Emmelkamp et al., 1983), we also studied factors related to treatment dropout. 
Furthermore, we hypothesized that high attrition rates and the recruitment of 
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subjects through media announcements for treatment studies of late-life anxiety 
might be a source of bias for research findings. Therefore, chapter 6 describes an 
investigation of differences between treatment dropouts and completers and 
between recruited and clinically referred participants of our RCT. Finally, in chapter 
7, findings from the studies described in the previous chapters are integrated and 
discussed.
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The phenomenology of anxiety in older adults. 
Abstract  
Objective: Differences in the phenomenology of anxiety between older and younger 
adults may contribute to difficulties in the recognition and treatment of late-life anxiety. In 
order to examine differential aspects of late-life anxiety, young adults, middle-aged adults 
and older adults were compared with respect to differences in fear evoking stimuli (CS) and 
cognitive contents of anxiety (UCS). Method: Data were collected by means of a mail 
survey in a sample of 513 representative participants in the Netherlands, divided equally in 
three age groups of 18-44 years, 45-64 years and 65 years and over. Fear-evoking stimuli 
were measured with the Fear Survey Schedule (FSS). Cognitive contents were measured with 
the Worry Domains Questionnaire-Revised (WDQ-R) and a newly devised instrument, the 
Senior Anxiety Scale (SAS). ANCOVA’s and post-hoc Bonferroni corrected t-tests were 
conducted on all total scores and subscale scores to test for differences between age groups. 
Results: Both middle-aged and older adults scored higher than young adults on the FSS, 
and older adults scored higher on the sex and agression subscale than both middle-aged and 
young adults. The WDQ showed that older adults were less worried about finances than 
their younger counterparts. The SAS revealed a four-factor structure, which explained 54.7% 
of the total variance in scores. Older adults scored higher than young adults on two of the 
factors, one representing the fear of decline of physical and mental health and one 
representing the fear of life-threatening situations. Conclusion: The SAS appeared to be a 
valid instrument for measuring age-related cognitive content of anxiety in older adults. 
Older adults seem to be more worried about the decline of physical and mental health, death 
and criminal assault than their younger counterparts. Further development of measures of 
anxiety incorporating items relevant to the daily life of older adults is needed to firmly 
establish the phenomenological differences between anxiety in younger and older adults. 
This chapter is a modified version of the following manuscript:
Weijnen, I.J.C., Schuurmans, J., Comijs, H.C., Emmelkamp, P.M.G., van Dyck, R. & van Hout, 
M.A. (submitted). Phenomenology of anxiety in older adults: a cue for better recognition? 
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Although several epidemiological studies (Flint, 1994a; Beekman et al., 1998b) have 
shown anxiety symptoms and anxiety disorders to be highly prevalent (10%) and 
disabling in older adults (de Beurs et al., 1999), clinicians in mental health care 
centers often attest to the fact that they are hardly ever confronted with anxious older 
adults. In fact, older adults seem to be underrepresented in clinical practice 
irrespective of psychopathology: only 2 to 5% of the patients in mental health care 
are 65 years or over (Stanley & Averill, 1999). This misrepresentation partly stems 
from problems with recognition of anxiety in older adults, leading to a lack of 
appropriate referral and treatment of anxious older adults (Alwahhabi, 2003; Stanley, 
2002; Sheikh & Salzman, 1995; Lindesay, 1991).
Most explanations that have been put forward for the discrepancy between 
prevalence rates of late-life anxiety in the general population and in daily clinical 
practice focus on age-related differences in the presentation of anxiety symptoms, a 
lack of help-seeking behavior in the present cohort of older adults, and age-related 
diagnostic problems met by professionals in general health care and in psychiatric 
settings. Older individuals themselves are not much inclined to seek mental health 
services for psychological problems (Waxman, Carner & Klein, 1984), but seem to 
remain in primary care settings (Klapow et al., 2002).
In the current study we want to focus on another problem that might contribute to 
the apparent lack of recognition of anxiety symptoms in older adults. In comparing 
anxiety in older versus younger adults, the assumption has typically been that the 
nature of anxiety and anxiety disorders is similar across different age groups. The 
validity of this assumption is unknown. Anxiety is the response that occurs when 
threat is perceived and it may differ between age groups on two crucial dimensions. 
First, the stimuli (CS) that elicit anxiety may differ. Older adults may tend to be 
anxious of different stimuli than younger adults. For example, specific stimuli might 
trigger fear in older adults, such as a hospital, a graveyard, or situations in which one 
might fall (darkness, a wet floor, steps and staircases). Secondly, the nature of feared 
misfortunes (UCS) may differ between age groups. This is the case when the same 
stimulus, for example the street, elicits anxiety in both younger and older adults, but 
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for very different reasons. A younger adult might avoid the street because of the fear 
to get a panic attack and faint; an older adult might avoid it because of the fear to fall 
and break a hip or the fear of being robbed.  
Up to now little is known about the nature and experience of anxiety in the elderly, 
even though many authors claim that the phenomenology of anxiety may be 
different in older adults (e.g. Beck & Stanley, 1997; Fuentes et al., 2000). Research on 
the phenomenology of anxiety in older adults is still in its infancy and is limited to 
clinical impressions and a few recent studies.
As for the clinical impressions, authors mention several fears that seem to be typical 
for older adults, mostly in the sense of feared catastrophes. Fear of falling (Spano et 
al., 1992), fear of suffering from forgetfulness or dementia (Ponds et al., 1995), of 
becoming a victim of criminal assault (Clarke et al., 1982), fear of physical decline 
(illness, pain, going to a hospital), fear of losing autonomy, fear to lose one's partner 
and fear of being alone (Godderis et al., 1992) are examples of supposed geriatric 
anxieties. Clinical impressions suggest that fears in older adults concentrate around 
themes of loss, illness and disability, death and dying, and social changes. 
There are only a few published experimental studies on qualitative differences in 
anxiety between younger and older adults. Liddell and others (Liddell, Locker & 
Burman, 1991) found that older adults (aged 50 years and over) mentioned more  fear 
for the death of a beloved person, illness or injury of a relative, car-accidents, fights, 
and sudden premature death, making a fool of oneself and the fear to  suffocate, than 
did younger adults, as measured by the Fear Survey Schedule (FSS-II; Wolpe & Lang, 
1964). A recent epidemiological study (Gretarsdottir et al., 2004) on social anxiety 
showed that older adults (60-94 years) reported higher levels of anxiety in two 
situations: talking about business, and writing or typing in front of others. When 
analyses were repeated for a subgroup of the sample who scored high on social 
anxiety, older adults appeared to be significantly more anxious in five social 
situations: when speaking in a small informal meeting, when talking about business, 
when having to interact for longer than a few minutes with others, when writing or 
typing in front of others, and when attempting to avoid social situations where there 
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are others. Hunt (Hunt, Wisocki & Yanko, 2003) compared older adults (age 65-86) 
with younger adults on contents of worry and found that older adults expressed 
more worries about health, family concerns, and world issues than their younger 
counterparts.
Psychometric instruments to measure anxiety are largely based on mixed-age 
populations (18-65 years), which might not be suitable for measuring anxiety in older 
adults, since specific age-related fears may not be reflected in these instruments. 
Currently, two questionnaires have been designed to measure age-related worries 
and fears in late life. The Worry Scale (Wisocki, 1988) measures worry about finances, 
health and social conditions. However, in the study that validated this questionnaire 
only a small group of older adults participated that was relatively worry-free. 
Furthermore, a control group of younger adults was not included to ensure that 
items were truly age-specific. The second scale is the Anxiety about Aging Scale 
(Lasher & Faulkender, 1993). The 20 items measure fear of old people, psychological 
concerns, anxiety about physical appearance and fear of loss. Participants in the 
study were of all ages, but no significant age difference was found.  
The purpose of the current study is to provide information about the nature of 
anxiety in older adults as compared to young and middle aged adults in the general 
population. More specifically, to get a better understanding of the fears of older 
individuals our question is twofold: do older and younger adults differ with respect 
to stimuli and situations that elicit fear, and is there a difference between age-groups 
with regard to the cognitive contents of anxiety in a particular situation? For this 
purpose, we have developed a new questionnaire, the Senior Anxiety Scale (SAS), to 
measure age-related worries in older adults. This scale was used along with other 
established measures of anxiety and worry. The current study also aimed to establish 
whether the SAS is a valid questionnaire for measuring the cognitive contents of 
worry in late life.
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Methods 
Participants and procedures 
The study consisted of a mail-survey among the normal population aged 18 years 
and over in the Netherlands. Participants were involved from two different parts of 
the Netherlands, the Western urban part in and around the nation’s capital 
Amsterdam with a very mixed population (region I), and the southern part of the 
country, the province of Limburg, a more rural and foremost Roman Catholic region 
(region II). When combined, these regions are considered to be representative of the 
Dutch population. 
Participants from both regions were randomly drawn from the telephone book. The 
number of participants that was selected was proportionate to the number of 
inhabitants of the particular town. Every tenth address in the telephone book was 
called (3021 calls), 1359 people (45%) could not be included because they were not at 
home, they were not Dutch-speaking, or the number did not belong to a private 
person. Of the 1662 answered phone calls (55%), 615 subjects (37%) agreed to fill in 
questionnaires and 473 (70%) returned the questionnaire. The students who made 
these phone-calls used a standard text to invite the subject to participate in a study 
on anxiety.
All participants received a set of questionnaires and a return post-paid envelop. 
Their cooperation was awarded with a chance to win one of ten gift certificates of 25 
Euro. When participants had not returned the questionnaire set within two weeks, 
they received a letter to remind them, in which they were kindly requested to 
complete the questionnaires. 
At the onset of the study, everyone over 18 was requested to cooperate. At a later 
stage, persons were requested to cooperate depending on their age in order to keep 
the three age groups equal in size. Especially older male respondents were hard to 
find. For that reason, an additional set of 80 questionnaires was sent to members of 
the “Catholic Community for Older adults” (CCOA), a social club for retired older 
adults. 40 completed questionnaires were received (response rate 50%).  
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In total, 513 subjects participated in this study, 249 in the urbanized region and 264 
subjects in the rural region of the Netherlands. Participants were divided in three age 
groups: young adults (18-44 years), middle-aged adults (45-64 years) and older 
adults (>65).
Measures
The Fear Survey Schedule (FSS; Wolpe et al., 1964; Arrindell, 1980) was chosen to 
measure fear-eliciting stimuli. The questionnaire contains 76 stimuli, grouped in 
seven subscales with a 5-point Likert-type scale (score1-5): fear of noises (FSS-g); 
blood, death and somatic injury (FSS-b); agoraphobia (FSS-a); social phobia (FSS-s); 
fear of nature-phenomena (FSS-n); fear of harmless animals (FSS-an); and anxious 
ideations about sex and violence (FSS-sa). The Worry Domains Questionnaire (WDQ; 
Tallis, Eysenck & Mathews, 1992) can be considered as a measure of cognitive 
content of anxiety. The Dutch version, the Worry Domains Questionnaire-Revised 
(WDQ-R; van Rijsoort, Emmelkamp & Vervaeke, 1999) contains 30 questions with a 
5-point Likert-type scale (score 1-5) on worries about five specific domains: relations 
(WDQrel), lack of self-confidence (WDQver), future (WDQfut), work (WDQinc), 
finances (WDQfin) and an additional ‘health worry’ domain (WDQhea). Because no 
scale on specific age-related anxiety and worry in older adults was available, a new 
scale was constructed on the basis of face- and expert validity. This scale was named 
the ‘Senior Anxiety Scale’ (SAS), but respondents were provided the questionnaire 
under the neutral name ‘Anxiety Scale’ to avoid possible bias. The SAS contains a 
selection from items from the Worry Scale (Wisocki, Handen & Morse, 1986) 
transformed as ‘anxiety’ questions, items from the Anxiety about Aging Scale (Lasher 
et al., 1993), items that were derived from our own clinical practice with older 
patients and items based on the available literature on late-life anxiety. It is 
composed of 77 questions on a 5-point Likert-scale (score1-5); the last five items are 
only to be answered if the subject has children and/or a (living) partner. The Eysenck 
Personality Questionnaire-revised, N-subscale (EPQ-R (Eysenck & Eysenck, 1968; 
Eysenck, Eysenck & Barret, 1985)) with 12 yes/no items was included in the set to 
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control for an overall tendency to be anxious as a possible confound. Demographic 
information was gathered through the administration of a biographical 
questionnaire, a simple structured list of questions on age, gender, country of birth of 
the subject and his/her parents, marital status, living situation, level of education 
and religion. Educational level was measured by a Dutch scoring system that consists 
of a 7-point scale ranging from primary education (level 1) to university education 
(level 7). 
Sample characteristics 
Participants (N=513) were almost equally distributed over the three age groups (see 
table 1). Age ranged from 19 to 92 years. Female subjects were overrepresented, but 
this overrepresentation was similar in all age groups. Marital status differed between 
age groups, with a higher proportion of older adults living alone, compared to the 
young and middle-aged group ( 2=54.9. df=2, p<.001). We found an age related 
decline in level of education (F=23.9, df=2,508, p<.001). The three age groups did not 
differ with respect to religion, or in the mean score on neuroticism as measured with 
the EPQ-R. 
Participants from both regions were compared with respect to demographic 
variables. Region samples did not differ with respect to age. Participants from both 
regions did differ with respect to sex (in region II women were overrepresented 
( 2=7.36, df=1, p<.01); education (educational levels 3, 4 and 5 (representing medium 
education) were more prevalent in region II ( 2=20.70, df=6, p<.01) whereas in region 
I there were more subjects with a university level of education); religious background 
( 2=227.44, df=2, p<.001; Roman Catholics were overrepresented in region II whereas 
in region I subjects often stated not to have any religion) and marital status (in region 
II significantly more subjects were living together with a partner ( 2=8.86, df=1, 
p<.01). Sex, level of education, religion and marital status will be included as co-
variates in the analyses. 
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Table 1. The distribution of descriptive variables across the three age groups. 


























Level of education 
Elementary 
Elementary + few yrs1
Lower vocational 
General intermediate 
Intermediate vocational  
General secondary 
Higher vocational/university 















































Mean neuroticism score  1.46  1.47  1.47 
Characteristics of the subsample from the Catholic Community for older adults (CCOA) 
The participants from the 'Catholic Community for older adults' were included 
because of the lack of older participants, especially male older participants. 
1 Elementary education plus a few years of general intermediate or secondary education (not 
completed)
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Compared to the older adults selected by the phone book (N=129) in age group III, 
the CCOA-subjects (N=40) appeared to be significantly younger with a mean age of 
71 (SD=4.3) vs. 74 years (SD=6.4), F=9.111, p<.005. In the CCOA-sample women were 
overrepresented ( 2=.029, df=1, p=.05), whereas in the older sample recruited by 
telephone the distribution of the sexes was nearly equal. The CCOA participants had 
a higher educational level; level 5, 6 and 7 were overrepresented ( 2=.049, df=6, 
p=.05).
Statistical Analyses 
Data were analyzed using SPSS-11. Age groups were compared on demographic 
variables (gender, marital status, level of education, religion) and neuroticism using 
ANOVAs. For all questionnaires, the mean total item score and the mean subscale 
item scores were calculated. A Principal Components Analysis with obimin rotation 
was conducted on the newly constructed Senior Anxiety Scale. For all scales and 
subscales Cronbach’s alpha was computed to determine their level of internal 
consistency. Missing data were imputed by means of a "Missing Value Analysis" in 
SPSS so that all questionnaires could be included in the analyses. Univariate 
Analyses of Variance (ANOVAs) were conducted to explore the differences in mean 
raw total and subscale scores on the three questionnaires (FSS, WDQ-R and SAS) 
between the three age groups. ANCOVAs were conducted using region, sex, level of 
education, marital status and religion as covariates because the two regions, the three 
age groups and the CCOA group differed with respect to these variables. When the 
corrected F-test proved significant, post-hoc t-tests were done to determine specific 
group differences. Bonferroni correction was applied on all analyses because of 
multiple testing, which means for the FSS that the p-value was multiplied by seven 
(the number of subscales), for the WDQ by 5, and for the SAS by 4. The significance 
of mean differences was set at p<.05 after correction.
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Results
Factor structure of the Senior Anxiety Scale (SAS) 
The analysis of the SAS indicated that a four-factor solution was the best fit to the 
data. From the 77 items only 72 items were involved in the analyses, because the last 
five items were exclusively applicable to participants with a living partner and 
children. Items were selected if their factor loading was at least .50 and the loading 
on any of the other factors was smaller than .30; only three out of 72 items loaded less 
than .40 on one of the factors. These three items were excluded from further analyses. 
The correlation between the three factors was between .4 and .5; factor 4 correlated 
lowest with the other factors. 
The total explained variance of the four-factor solution was 54.7 %. Factor 1 (33 items, 
Cronbach’s alpha=.97) explained 43 % and refers to fear of decline of physical and 
mental health and loss of independence. Examples of items loading on this factor 
include: ‘I’m afraid of falling and breaking something’, I’m afraid to forget important 
things’, ‘ I’m afraid I won’t be able to drive my car anymore’. Factor 2 (7 items, 
Cronbach’s alpha=.91) refers to the fear of financial problems and explained 1.5% of 
the total variance. Examples of items for the second factor include: ‘I’m afraid I will 
hardly be able to make ends meet when I am old’ and ‘I’m afraid I won’t be able to 
pay my insurance-premium’. Factor 3 (explained variance 3%, 20 items, Cronbach’s 
alpha=.93) reflects the fear of social isolation or social disapproval. Examples of items 
include: ‘I’m afraid I will be alone’, ‘I’m afraid that people will find me unattractive’. 
Factor 4 (explained variance=3%, 9 items, Cronbach’s alpha=.92) is associated with 
the fear of life-threatening situations (deadly illness, dying and crime). Examples of 
items include: ‘I’m afraid to die’, ‘I’m afraid to get a heart attack’, ‘I’m afraid I will be 
robbed on the street’.
In summary, this questionnaire appears to be a strong measurement instrument with 
a high internal consistency, rendering it appropriate to compare different groups.  
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Comparison between age groups on the FSS, WDQ and SAS 
Table 2 presents results from the ANCOVAs and post-hoc t-tests. The total score and 
all mean subscale scores of the FSS, except the FSS-B (the fear of blood, injections, 
and dead people), differed significantly between the three age groups. On the total 
FSS-scale (FSS-tot) the older (t(337)=3.64, p=.001) and middle-aged subjects 
(t(336)=3.95, p<.001) scored significantly higher than the youngest group, but there 
were no significant differences between older adults and the middle-aged group. 
Similar results were found for the FSS-G (fear of noises; Cronbach’s alpha=.90; 
t(337)=.374, p<.001 and t(336)=3.37, p=.009 resp.), the FFS-A subscale (agoraphobic 
fears (Cronbach’s alpha=.92; t(337)= 3.74, p<.001 and t(336)=4.04, p<.001
respectively), the FSS-N (the fear of nature-phenomena, Cronbach’s alpha=.82; 
t(337)=3.51, p<.001 and t(336)=3.52, p<.001 resp.), and the subscale FSS-AN (fear for 
harmless animals ; Cronbach’s alpha=.80; t(337)=3.58, p=.001 and t(336)=2.63, p=.028,
resp.). On the subscale FSS-S (the fear of social situations; Cronbach’s alpha=.79) the 
scores of the young adult group were significantly lower than the middle-aged group 
(t(336)=2.77, p=.016), but no significant differences were found between older adults 
and middle-aged subjects or between older adults and the young adult group. The 
only subscale that differentiated between both older adults and the middle-aged 
group and between the middle-aged and young adult group was the FSS-SA 
measuring fear of sex and aggression, with older adults scoring higher than middle-
aged subjects t(337)=2.51, p=.039 and middle-aged subjects scoring higher than 
young adults (t(336)=4.37, p<.001).
The three age groups did not differ on the total score of the WDQ (Cronbach’s alphas 
of the subscales were between .70 and .90) or on any of the WDQ subscales except for 
the subscale WDQ-fin (worry about financial matters). The youngest subjects and the 
middle-aged scored significantly higher (t(337)=2.43, p=.044 and t(337)=2.46, p=.043
resp.) on worry about finances than the older subjects.  
The total score on the Senior Anxiety Scale (SAS-tot) increased significantly with age 
(group young<middle-aged, t(336)=3.06, p=.007; group middle aged<old, t(337)=2.51, 
p=.037). When analyzing the different factors, Factor 1, the fear of physical and 
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mental decline, was found to increase significantly with age (group young<middle-
aged, t(336)=4.0, p<001; group young<old t(337)=7.88, p<.001; group middle 
aged<old, t(337)=4.20, p<.001). Factor 2 (the fear of financial problems) and factor 3 
(the fear of social isolation and disapproval), both showed no significant differences 
between the three groups. On factor 4, representing the fear of life threatening 
situations (serious illness, death and criminality), older adults scored significantly 
higher than the youngest group (t(337)=3.67, p=.001).
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Analysis of variance 






1.32 (.60) 1.56 (.59) 1.53 (.60) F(2,496)=7.86,p<.001**3 I < II and III 
FSS-B
(blood, injections) 
1.89 (.70) 2.06 (.69) 1.89 (.71) F(2,496)=3.13,p=.045  
FSS-A  
(agoraphobic stimuli) 
1.44 (.53) 1.67 (.52) 1.67 (.55) F(2,496)=10.02,p<.001** I < II and III 
FSS-S  
(social stimuli) 
1.80 (.71) 2.02 (.70) 1.99 (.73) F(92,496)=4.40,p=.013** I < II 
FSS-N  
(natural phenomena) 
1.61 (.78) 1.91 (.76) 1.92 (.79) F(2,496)=8.25,p<.001** I < II and III 
FSS-AN  
(harmless animals) 
1.55 (.69) 1.75 (.67) 1.83 (.69) F(2,496)=6.91,p<.001** I < II and III 
FSS-SA  
(sex and aggression) 
1.64 (.67) 1.96 (.66) 2.14 (.69) F(2,496)=22.27,p<.001** I < II < III 
FSS-tot  
(total) 
1.66 (.54) 1.89 (.53) 1.88 (.55) F(2,496)=9.61,p<.001** I < II and III 
     
WDQ-rel  
(relations) 
1.52 (.66) 1.53 (.65) 1.42 (.68) F(2,496)=1.22, p=.296  
WDQ-ver
(lack of confidence) 
1.74 (.86) 1.74 (.84) 1.67 (.89) F(2,496)=.322, p=.725  
WDQ-fut
(aimless future) 
1.54 (.78) 1.70 (.77) 1.64 (.79) F(2,496)=1.82, p=.163  
WDQ-Inc
(work incompetence) 
1.66(1.04) 1.69(1.02) 1.61(1.07) F(2,496)=.228, p=.796  
WDQ-fin
(finances) 
1.59 (.73) 1.58 (.71) 1.38 (.74) F(2,496)=3.899,p=.021** I and II > III 
WDQ-lic
(Physical) 
1.80 (.95) 1.95 (.93) 1.99 (.96) F(2,496)=1.834,p=.161  
WDQ-tot  
(total) 
1.64 (.65) 1.70 (.64) 1.62 (.66) F(2,496)=.68,p=.508  
     
SAS: physical and 
mental decline, 
t
1.38 (.75) 1.71 (.74) 2.06 (.77) F(2,496)=31.03,p<.001** I < II < III 
SAS: financial 
problems
1.33 (.62) 1.38 (.61) 1.21 (.63) F(2,496)=2.74, p=.065 
SAS: social isolation 
and disapproval 
1.35 (.58) 1.44 (.57) 1.43 (.59) F(2,496)=1.16, p=.313  
SAS: life threatening 
situations  
1.77 (.89) 1.96 (.88) 2.15 (.91) F(2,496)=6.84, p=.001** I < III 
SAS-tot  
(total) 
1.43 (.64) 1.64 (.62) 1.81 (.65) F(2,496)=14.33,p<.001** I< II < III 
2 M.I.S.= Mean Item Score 
3 **significant after adjustment for multiple comparisons Bonferroni. 
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Discussion
The current study was carried out to examine differences in the nature of anxiety 
between various age groups. This study was the first to make a distinction between 
fear-eliciting stimuli (measured by the FSS), and feared catastrophes in a particular 
situation (measured by the WDQ-R and SAS). The Senior Anxiety Scale (SAS) was 
uniquely designed to measure feared catastrophes in older adults.
Looking for differences in fear-eliciting stimuli of the FSS, there was a significant 
difference between the three age groups on the total score and on all subscales, 
except for the FSS-B, the fear of blood, injections and dead people. Older adults and 
middle-aged subjects were clearly more anxious of stimuli in general and they 
showed more fear of noises, agoraphobic situations, nature phenomena and harmless 
animals than the youngest group of subjects. Social situations elicited more fear in 
the middle-aged group. It is conceivable that this finding arises from the fact that 
middle-aged subjects meet more life circumstances where social anxiety is easily 
provoked while older adults come across such situations less often. These results are 
in concordance with results from a previous study on the phenomenology of social 
anxiety in older adults, in which social anxiety appeared to be less frequent in older 
individuals (Gretarsdottir et al., 2004). The fear of sexual and aggressive scenes 
increased significantly with age (as was expected; at least for aggression). In 
summary, older adults are more anxious of a variety of stimuli than younger adults, 
but most differences appear to develop before the age of 65. The FSS can therefore be 
seen as a sensitive instrument to detect fear-eliciting stimuli in older adults, but it 
shows no specificity for an older population.
With regard to feared catastrophes or cognitive contents it was remarkable that the 
WDQ-R did not differentiate between the three age groups on the total questionnaire 
nor on the subscales, except for the worry about financial matters. The young adults 
and the middle-aged subjects were more anxious about their financial situation than 
the older adult group. This may be a result of the fact that pension arrangements in 
the Netherlands tend to be quite beneficial. As for the other subscales, subjects of all 
ages seemed to worry about the same topics to the same extent.
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On the newly constructed questionnaire designed to measure age-related feared 
catastrophes in older adults, the SAS, we found that the total score was highest in 
older adults, which provides support for the validity of this questionnaire as a 
specific measure for late-life anxiety. Especially the fear of physical and mental 
decline increased significantly with age. In contrast to the WDQ-finance subscale, the 
fear of financial problems as measured by the SAS, showed no significant difference 
between the three groups. In contrast to our expectations based on our clinical 
impressions, we found no differences between the three age groups with regard to 
the fear of social isolation and disapproval. On factor 4 of the SAS, the fear of life-
threatening situations (serious illness, death and criminality) the older adult group 
scored significantly higher than the young adult group. This is in line with the 
hypothesis that older adults tend to be afraid of becoming a victim of criminal assault 
(Clarke et al., 1982) and the common sense notion that older adults tend to be afraid 
of death and dying. In clinical practice, older adults usually mention that they are 
more afraid of the way they might die (with pain and anguish), than of death itself.
Our findings confirm the clinical impressions and earlier studies on anxiety in older 
adults, which suggest that fears in this age group concentrate around themes of 
experiences of loss (especially loss of autonomy), physical and mental illness, death 
and dying, criminal assault and aggression. Specific ‘geriatric’ fears are important to 
take into consideration, because they can lead to activity limitation and avoidance 
behavior comparable to ‘normal’ anxiety disorders. For example, the fear of falling 
can lead to avoidance behavior that resembles agoraphobia. Similarly, the fear to 
forget things, the so called ‘dementia-phobia’ (Ponds et al., 1995) can lead to a pattern 
of anxiety and avoidance behavior that resembles social phobia. The 
acknowledgement of these fears has already led to specific therapeutic interventions, 
in the form of a course for older adults who suffer from the fear of falling (Haastregt 
& Zijlstra, 2002) and a short intervention for older adults who are afraid they might 
develop dementia in spite of good results on psychiatric examination and 
neuropsychological tests (Ponds et al., 1995). 
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The fact that the FSS did not differentiate between middle aged and older adults, 
makes one wonder in what stage in life the apparent shift in fear-eliciting stimuli 
occurs. The cut-off of 65 years for the older group is based on the approximate age of 
retirement. In the literature nowadays many different cut-offs are used indicating 
older adults, including individuals as young as 55. The switch in fear-eliciting stimuli 
probably takes place at an earlier age than 65.
In summary, our results suggest that it is important to ask age-specific questions in 
order to detect anxiety in older adults. The SAS appears to be a valid instrument with 
high internal consistency suitable for this purpose. The differentiation between 
feared stimuli and feared catastrophes or cognitive content has proven meaningful. 
Our results indicate that the largest difference between younger and older adults lies 
in the cognitive contents of anxiety. However, we cannot conclude on the basis of our 
study that it is not possible to detect specific fear-eliciting stimuli for older adults. 
The FSS may not include items that are specifically important for anxiety in late life. 
It would be interesting to develop a scale with fear-eliciting stimuli that might be 
more relevant to situation of older persons, in the same way that we constructed the 
SAS to measure age-related feared catastrophes. The authors of the previously 
mentioned study on the phenomenology of social anxiety (Gretarsdottir et al., 2004) 
also suggest that current measures of social anxiety probably do not include some of 
the most anxiety-provoking situations for older adults. 
One of the limitations of this study concerns the fact that stimuli and feared 
catastrophes are not connected. It would be interesting to find out whether certain 
stimuli evoke specific age-related feared catastrophes. Also it could be worthwhile to 
conduct open-ended personal interviews on feared stimuli and cognitive contents of 
anxiety with older and younger adults, as a valuable completion to self-report 
measures.
Meanwhile it is stressed that while the present data give an indication of age-related 
differences in anxiety in the population at large, the study does not provide data on 
age-related differences in anxiety in clinical groups. Though it is an open question if 
and to what degree the present results can be generalized to clinical populations, the 
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factor structure of the FSS is comparable in clinical and non clinical groups (Arrindell 
et al., 1990; Arrindell & van der Ende, 1986) and it seems plausible to expect a 
comparable pattern in patients with clinical anxiety problems. However, this is an 
empirical issue that awaits investigation. 
Our findings carry important implications for the diagnosis and treatment of late-life 
anxiety. Older adults with anxiety symptoms show a high and inappropriate use of 
health care services and medication and their quality of life is greatly affected (de 
Beurs et al., 1999). Early detection of anxiety might increase appropriate referral and 
help prevent a chronic course of late-life anxiety. To screen carefully for anxiety in 
the older adults, taking into account scientific knowledge of age-related fear-eliciting 
stimuli and feared catastrophes might not only improve diagnosis, it could also give 
relevant information for a tailor-made psychological intervention.  
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The outcome of anxiety disorders in older people
at six-year follow-up: 
results from the Longitudinal Aging Study Amsterdam. 
Abstract 
Objective: To examine long-term outcome of late-life anxiety disorders and utilization of 
mental health care services. Method: A cohort of subjects (aged  55 years) with an anxiety 
disorder (n=112) was identified in the Longitudinal Aging Study Amsterdam (N=3107). At 
six-year follow-up, the rate of persistence and prognostic factors for persistence of anxiety 
were established. Results: Six years after baseline 23% of our sample met the criteria for an 
anxiety disorder. Another 47% suffered from subclinical anxiety symptoms. Persistence of 
anxiety was associated with a high score on neuroticism at baseline. Use of benzodiazepines 
was high (43%), while use of mental health care facilities (14%) and anti-depressants (7%) 
remained low in those with persistent anxiety. Conclusion: Results indicate that those 
high in neuroticism are at greater risk for persistence of anxiety. Efforts to enhance 
appropriate referral of anxious older adults do not seem to have had the desired effect. 
This chapter has been published as:  
Schuurmans, J., Comijs, H. C., Beekman, A. T. F., de Beurs, E., Deeg, D. J. H., Emmelkamp, P. 
M. G. et al. (2005). The outcome of anxiety disorders in older people at six-year follow-up: 
results from the Longitudinal Aging Study Amsterdam. Acta Psychiatr.Scand., 111, 420-428. 
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Although the number of studies dealing with the psychological well-being of older 
people has increased considerably, most of these studies have focused on depression. 
This reflects a commonly held belief in geriatric psychiatry that mood disorders are 
more prevalent in older adults than anxiety disorders. However, recent 
epidemiological studies have shown that anxiety disorders are in fact more common 
in older adults than major depression and dysthymia (Regier et al., 1988; Beekman et 
al., 2001). The prevalence of anxiety disorders in older adults is estimated at 10% 
(Beekman et al., 1998), which is comparable to the prevalence of anxiety disorders in 
younger age groups in the Netherlands (Bijl et al., 1998). Furthermore, recent studies 
have shown that anxiety greatly affects the quality of life in older persons (Wetherell 
et al., 2004) and that it is also associated with an increased use of (non-mental) health 
care services, even when controlling for physical health status (de Beurs et al., 1999).
Studies focusing on younger populations have demonstrated that anxiety disorders 
show a chronic but variable course with intermittent periods of waxing and waning 
of symptoms when left untreated. Spontaneous remission rates in these studies range 
from 12 to 25% (Angst et al., 1991). No data are available on the rates for remission 
and persistence of anxiety disorders in older adults. 
The present study is part of an ongoing longitudinal community based study on 
autonomy and well-being in older adults, aged 55 to 85 years in the Netherlands (the 
Longitudinal Aging Study Amsterdam (Deeg, Knipscheer & van Tilburg, 1993; 
LASA). In a previous 3-year follow-up study by our research group on risk factors 
for persistence of anxiety symptoms in older adults, female sex and neuroticism were 
found to increase the likelihood of persistence of anxiety. Other variables, such as 
health status, socio-economic status, social resources and life events were found to be 
unrelated to the outcome of anxiety symptoms in older people (de Beurs, Beekman, 
Deeg, van Dyck & van Tilburg, 2000). However, at 3-year follow-up of the LASA 
study, measurements did not include psychiatric diagnosis. Instead the score on a 
questionnaire for anxiety (the HADS-A; Zigmond & Snaith, 1983) was used to divide 
the sample into a non-anxious group and a group with anxiety symptoms.
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In spite of the increased use of health care services, anxious older people are rarely 
referred to mental health care (de Beurs et al., 1999). For the most part, anxiety 
disorders in older people are left untreated (and probably unrecognized). The only 
common form of treatment appears to be the prescription of benzodiazepines (de 
Beurs et al., 1999), even though most clinicians and researchers agree that long-term 
use of benzodiazepines is best avoided, especially in older adults (Flint, 1997; 
Salzman, 1990). Regardless of the possible risks of long-term use of benzodiazepines, 
such as memory impairment and an increased risk of accidents and falls (Lader, 1999; 
Petrovic, Mariman, Warie, Afschrift & Pevernagie, 2003) the high risk for 
development of tolerance and dependence are important disadvantages (Kan, 
Breteler & Zitman, 1997). Modern serotonin-based antidepressants, that have been 
proven effective in mixed-age populations (van Balkom, 2000), do not carry the same 
risk for development of dependence (van Broekhoven, Kan & Zitman, 2002). 
Nevertheless, they are rarely prescribed to older adults. In recent years several efforts 
have been made to lower long-term use of benzodiazepines in older adults and to 
enhance recognition and appropriate referral of anxious older adults, but we have no 
data on whether these efforts have paid off.
In LASA, a subgroup (n=112) of older persons with anxiety disorders has been 
identified and reports have been made on comorbidity patterns, utilization of health 
care services, physical functioning and quality of life. The present study reports on 
the outcome of anxiety and the utilization of mental health care services and 
anxiolytic medication by this group, after a follow up period of six years. 
Aims of the study 
Research questions were as follows: What is the long-term outcome of anxiety 
disorders in older persons? What factors are predictive for persistence of anxiety? Is a 
persistent outcome of anxiety disorders related to an adequate use of mental health 
care services and has the use of benzodiazepines decreased? 
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Material and methods 
Sample
Data were derived from the Longitudinal Aging Study Amsterdam (LASA). A 
random sample, stratified on age and sex, was drawn from population registers in 11 
municipalities in three regions of the Netherlands. Ten months prior to LASA, 
respondents had participated in the NESTOR-study on Living Arrangements and 
Social Networks for older adults, which had a response rate of 62.3% (n=3805). All 
participants of the NESTOR-study were approached for the first LASA cycle. 3107 
(81.7%) subjects were enrolled in the baseline LASA interview, which took place 
between September 1992 and September 1993 (T1). Attrition was related to age, but 
not to sex. Subjects with anxiety disorders were identified using a two-stage 
screening design. The Centre for Epidemiological Studies Depression Scale (CES-D; 
Radloff, 1977) was used as screening instrument for depression and anxiety. The 
CES-D has been found to be a good screener for anxiety (Breslau, 1985). All subjects 
scoring  16 (n=386) and a similarly sized random sample of those scoring  16 
(n=380) were selected for the second stage, which involved a diagnostic interview, 
held 2 to 8 weeks after the first LASA assessment. Response was 86%, leaving a 
sample of 659 subjects, 332 screen positives and 327 screen negatives, to be 
interviewed. Anxiety disorders were defined according to DSM-III criteria and 
assessed by means of the Diagnostic Interview Schedule (DIS; Robins, Helzer, 
Croughan & Ratcliff, 1981). A total of 112 subjects met the criteria for an anxiety 
disorder in the last 6 months prior to the interview (Beekman et al., 1998). Those with 
comorbid depression (26%; n=29) were not excluded. All measurements in this report 
are based on this sample. 
Follow-up took place in 1998-1999 (T2), six years after the baseline measurement. 
During follow-up 50 of the 112 subjects with a diagnosed anxiety disorder at T1 were 
lost, leaving a sample of 62 subjects who completed the second diagnostic interview 
(55% of the original sample). Attrition was largely due to death (n=32, 29% of the 
original sample and 64% of the total attrition rate). 7% (n=8) refused to participate 
further, another 7% (n=8) were ineligible due to illness or cognitive impairment and 
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2% (n=2) could not be contacted for follow up due to migration. Variables associated 
to loss to follow up are described in the results section of this article.  
Measures
Assessment of outcome of anxiety 
Anxiety disorders were defined according to DSM-III criteria and assessed by means 
of the Diagnostic Interview Schedule (DIS; Robins et al., 1981). In this study four 
types of anxiety disorders were distinguished: phobic disorders, panic disorder, 
generalized anxiety disorder and obsessive-compulsive disorder. Subsyndromal 
anxiety was defined as the presence of clinically relevant anxiety symptoms without 
meeting the diagnostic criteria for an anxiety disorder according to the DIS. In 
accordance with previous research by our group (de Beurs et al., 1999), the anxiety 
subscale of the Hospital Anxiety and Depression Scale (HADS-A; Zigmond et al., 
1983) was used to discriminate those with subsyndromal anxiety from those with no 
relevant anxiety symptoms. A score halfway between the mean score for the entire 
sample (N=3056) and the mean score of subjects with an anxiety disorder was chosen 
as a cut-off score, since no threshold score for the Dutch version of the HADS-A was 
available to delineate clinical anxiety. The cut-off point was a score between 3 and 4 
(de Beurs et al., 1999). Sensitivity of this cut-off was 58% and specificity 80%, for 6-
month prevalence of any DSM-III anxiety disorder (de Beurs et al., 2000). For the 
outcome of anxiety disorders six years after baseline three possibilities were 
distinguished: i) Persistent anxiety: respondents who met criteria for an anxiety 
disorder at both measurements; ii) Partial remission of anxiety: respondents who did 
not fulfill diagnostic criteria for an anxiety disorder at T2 but who did suffer from 
subsyndromal anxiety; iii) Full remission: respondents who did not meet criteria for 
either an anxiety disorder or subsyndromal anxiety at T2.
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Prognostic factors 
Selected prognostic factors for persistence of anxiety were divided into six groups: 
demographic variables, variables regarding physical health and functioning, illness 
severity, personality characteristics, social support, treatment and life changes. 
Demographic variables included age, sex, level of education, socio-economic status 
and marital status. To establish socio-economic status a weighted score composed of 
the level of education, occupation and income (range 0-100) was used (van Tilburg, 
Dijkstra, Liefbroer & Broese van Groenou, 1995). The presence of chronic diseases 
was assessed by asking the respondents explicitly whether they suffered or had 
suffered from any of the following chronic diseases or disease events: cardiac disease 
(including myocardial infarction), peripheral arthrosclerosis, stroke, diabetes 
mellitus, chronic obstructive pulmonary disease (COPD: asthma, chronic bronchitis 
or pulmonary emphysema), arthritis (rheumatoid arthritis or osteoarthritis) and 
cancer. In a previous study, the validity of this instrument was supported by the 
records of respondents’ general practitioners (Kriegsman, Penninx, van Eijk, Boeke & 
Deeg, 1996). In the present study, we focused on the number of chronic diseases as a 
possible predictor for outcome of anxiety. Other variables regarding physical health 
included in this study were a subjective health rating (CBS, 1989) and functional 
limitations assessed with an adaptation of the Organization of Economic 
Collaboration and Development Questionnaire (OECD; van Sonsbeek, 2004). 
Cognitive functioning was measured with the Mini-Mental State examination 
(Folstein, Folstein & McHugh, 1975). The scale consists of 23 items, which are used to 
measure global cognitive performance. Scores range from 0-30, with a cut-off score of 
 23 as an indicator for cognitive impairment. Alcohol use was assessed during an 
interview with a questionnaire developed by the Dutch Central Bureau of Statistics. 
If respondents drank alcohol, they were asked how many days a week they drank 
alcoholic beverages and how many glasses they would usually drink each time. On 
the basis of these data, alcohol use was categorized as light (average consumption 
one unit per day), moderate (average consumption 2-3 units per day), excessive 
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(average consumption 4-5 units per day) or very excessive (average consumption 6 or 
more units per day; Garretsen, 1983).
Personality characteristics included neuroticism, social inadequacy (dislike and 
avoidance of social interaction), mastery and self-efficacy. Neuroticism and Social 
Inadequacy were measured with the abbreviated subscales of the Dutch Personality 
Inventory (Luteijn, Starren & van Dijk, 1985). Mastery was measured with the 
abbreviated 5-item ‘mastery’ scale (Pearlin & Schooler, 1978) and self-efficacy was 
measured with the 12-item version of the General Self-Efficacy Scale (Sherer et al., 
1982; Bosscher & Smit, 1998). Social support was defined as the reception of both 
instrumental and emotional support and was measured by a questionnaire which 
included detailed questions on both the number and the quality of contacts with 
members of the social network (van Tilburg, Dijkstra & Broese van Groenou, 1992). 
In interviews three years and six years after baseline respondents were asked 
whether stressful life-events had occurred in the three year time interval prior to the 
interview. The following stressful events were assessed: Illness of one's partner, 
death of one's partner, illness of a relative, death of a relative, a major conflict with 
others, income loss, victimized by crime, and relocation. Other life stressors were 
derived from data at both the baseline and follow-up measurements: declined 
physical health (developing a new or additional chronic disease); an increase in 
functional limitations (  1 points increase on the scale) and cognitive decline (> 5 
points deterioration on the MMSE; (Schmand, Lindeboom, Dinkgreve, Hooijer & 
Jonker, 2004). To reduce the number of variables in analyses regarding life events, a 
composite score (labeled as ‘level of distress’) was computed by differentially 
weighing life-events and combining them in one score, representing the impact of the 
events. Weights for the various life-events were derived from Tennant and Andrews 
(Tennant & Andrews, 1976). All scales used in the study had been previously 
validated in the Netherlands or else their psychometric properties had been 
evaluated in LASA pilot studies (Deeg et al., 1993). 
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Mental health care service utilization and use of anxiolytic medication 
Subjects were interviewed about recent visits to physicians, to community health care 
services, to paramedical services, to formal social support and hospital admissions. 
In order to reduce the number of variables in the analyses, a composite score labeled 
as ´mental health care´ was computed, reflecting whether or not a respondent had 
recently visited a psychiatrist, a community mental health care service, a social 
psychiatric service or a social worker. Furthermore, subjects were interviewed about 
their use of medication, and the response was ascertained by inspecting the bottles of 
currently prescribed medication during the home visit. Data on anxiolytic medication 
were grouped into two categories: i) Use of benzodiazepines; ii) Use of 
antidepressants.
Statistical analysis 
To check for selective attrition we compared the 62 participating subjects with the 50 
drop-outs on all variables included at baseline with chi-square tests or t tests. Means, 
standard deviations and percentages for the distribution of all relevant variables 
across the three outcome groups (persistent anxiety, partial remission and full 
remission) were computed. To investigate the prognostic value of demographic and 
clinical variables measured at baseline for the outcome of anxiety, a series of logistic 
regression analysis were run. In the first series of analysis, respondents with 
persistent anxiety were compared with respondents who were in full remission. In 
the second series, respondents who suffered from subsyndromal anxiety (partial 
remission) were compared with respondents who were in full remission. The 
strength of the association between prognostic factors and outcome of anxiety at T2 
was expressed in odds ratios (ORs). To control for the influence of sex, age and 
chronic disease a series of multiple logistic regression analyses were performed in 
which these potentially confounding variables were entered individually in the 
models.
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Results
Characteristics of the sample 
Loss to follow-up was associated with higher age, male sex, more chronic diseases, 
more functional limitations and a lower level of cognitive functioning at baseline. 
Loss to follow-up was not associated with a higher score on anxiety or depressive 
symptoms at baseline. Of the original sample of respondents with an anxiety 
disorder at baseline (n=112), 70% (n=77) had a generalized anxiety disorder at 
baseline, 32% (n=36) had a phobic disorder (this category included agoraphobia), 
21% (n=23) had a panic disorder and 8% (n=9) had an obsessive-compulsive 
disorder. GAD and phobias have been found to be the most prevalent anxiety 
disorders among older adults (Beekman et al., 1998b; Flint, 1994a). Means, standard 
deviations and percentages for the distribution of all relevant variables measured at 
baseline across the three groups representing different outcomes of anxiety are 
presented in Table 1 (next page). 
The outcome of anxiety 
At follow up, 13% (n=14) had an anxiety disorder, 26% suffered from subsyndromal 
anxiety (n=29) and 17% (n=19) were in full remission of anxiety. Twenty-nine percent 
(n=32) were deceased during follow up and 16% (n=18) were lost to follow up due to 
other reasons. 
Thus, of the sample used in the analyses (n=62), 23% had a persistent outcome of 
anxiety, 47% were in partial remission and 31% were in full remission of anxiety. Due 
to small sample size, anxiety disorders were not categorized into different subtypes. 
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Table 1. Distribution of predictor variables measured at baseline 












A Demographic characteristics  
Sex (% female) 85.7 82.8 63.2 77.4
Age (yrs; M (SD)) 67.4 (8.6) 69.7 (8.6) 73.1 (8.7) 70.2(8.7) 
Marital status (% married)  50.0  41.4 52.6 46.8 
Socio-econ. status (M (SD)) 24.9 (13.4) 24.7 (17.4) 36.8 (17.4) 28.5 (17.6) 
B Psychological symptoms
    
Anxiety score (M (SD)) 11.2 (5.0) 7.7 (5.2) 8.3 (4.5) 8.6 (5.1) 
Depressive sympt. (M(SD)) 26.3 (9.5) 21.3 (11.3) 21.0 (10.8) 22.3 (10.8) 
C Personality characteristics
    
Mastery (M (SD)) 13.7 (3.8) 14.1 (3.5) 15.8 (3.3) 14.5 (3.6) 
Perceived self-efficacy (M(SD)) 36.6 (5.9) 39.0 (5.8) 38.5 (5.0) 38.3 (5.6) 
Neuroticism (M (SD)) 18.6 (7.2) 11.7 (6.2) 10.3 (6.7) 12.7 (7.1) 
Social Inadequacy (M (SD)) 11.6 (6.1) 7.7 (5.5) 9.3 (5.9) 8.9 (5.8) 
D Social functioning
    
Emotional support (M (SD)) 1.9 (.9) 1.6 (.8) 2.0 (.4) 1.8 (0.7) 
Loneliness (M (SD)) 3.5 (4.0) 4.4 (3.6) 4.6 (3.1) 4.3 (3.5) 
E Health status
    
Nr. chronic diseases (M(SD)) 2.2 (1.3) 1.5 (1.1) 1.8 (1.6) 1.8 (1.3) 
Self-perceived health (M (SD)) 3.1 (1.0) 3.1 (1.1) 2.8 (.7) 3.1 (1.0) 
Functional limitations (M(SD)) 1.1 (1.0) 1.2 (1.1) .9 (1.1) 1.1 (1.1) 
Cognitive functioning (M(SD)) 27.8 (1.4) 26.7 (2.6) 27.3 (2.3) 27.1 (2.3) 
Alcohol use (%) 





















    
Level of distress (M(SD)) 67.5 (42.7) 59.1 (44.6) 56.8 (35.0) 60.1 (40.8) 
Incr. in chronic diseases (%) 21.4 55.2 50.0 45.9 
Incr. in functional limitations(%) 42.9 25.0 42.1 34.4 
Cognitive decline (%) 0.0 3.6 5.3 3.3 
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Prognostic factors for persistence or remission of anxiety 
Table 2 presents bivariate odds ratios and 95% confidence intervals for all possible 
prognostic factors for the different types of outcome of anxiety (i.e. persistent 
anxiety, partial remission or full remission).
Table 2. Prognostic factors for outcome of anxiety measured at baseline (n=62) 
 Persistence of anxiety 
n=14
 Partial remission 
n=29
 OR 95% CI  OR 95 % CI 
Demographic variables      
Female sex 3.5 .60 – 20.41  2.80 .73 - 10.69 
Age .93 .85 – 1.01  .95 .89 – 1.02 
Not/no longer married .90 .23 – 3.58  1.57 .49 – 5.05 
Socio-economic status .95 .91 – 1.00  .96 .93 -.99 
Health status      
Chronic diseases 1.23 .75 – 2.01  .86 .55 – 1.35 
Perceived health 1.56 .66 – 3.70  1.44 .74 – 2.77 
Functional limitations 1.19 .60 – 2.38  1.27 .73 – 2.21 
Cognitive functioning 1.13 .77 – 1.66  .90 .70 – 1.16 
Alcohol use .69 .27 – 1.77  .57 .26 – 1.22 
Personality characteristics      
Neuroticism 1.19 1.02 – 1.38  1.04 .93 – 1.16 
Social Inadequacy 1.07 .93 – 1.24  .95 .84 – 1.07 
Mastery .84 .67 - 1.04  .85 .70 – 1.03 
Self-efficacy .93 .81 – 1.08  .78 .91 – 1.14 
Psychological symptoms      
Severity of anxiety symptoms 1.15 .97 – 1.35  .98 .87 – 1.10 
Depressive symptoms 1.05 .98 – 1.13  1.00 .95 – 1.06 
Social functioning      
Emotional support  .76 .23 – 2.45  .36 .13 – 1.03 
Loneliness .91 .74 -1.13  .99 .83 – 1.18 
Life changes      
Level of distress 1.01 .99 – 1.03  1.00 .99 – 1.02 
Increase in chronic diseases .27 0.06 – 1.32  .81 .25 - 2.64 
Increased functional limitations 1.03 .26 – 4.17  .46 .13 – 1.60 
Cognitive decline .00 .00 – 0.00  .67 .04 – 11.36 
N.B. Odds ratios in bold typeface indicate a significantly higher chance  
at persistent anxiety or partial remission 
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The results show that a lower socio-economic status was associated with partial 
remission of anxiety, but not with persistent anxiety. When controlling for 
differences in gender, the association between socio-economic status and partial 
remission was no longer significant. Sex, age and marital status were not associated 
with outcome of anxiety. None of the variables related to physical health, 
psychological symptoms, social functioning , treatment and life events were found to 
be associated with outcome of anxiety. Of the variables regarding personality 
characteristics, only neuroticism was related to the outcome of anxiety: a higher score 
on neuroticism at baseline was associated with a persistent outcome of anxiety, even 
when controlling for differences in age, gender, chronic diseases and severity of 
anxiety symptoms at baseline. Social inadequacy, mastery and self-efficacy were not 
associated with outcome of anxiety. 
Mental health care service utilization and use of anxiolytic medication
at follow-up. 
In table 3, rates of mental health care service utilization and use of benzodiazepines 
and antidepressants at baseline and follow-up are presented. The use of 
benzodiazepines remained high for all groups, but was especially high for those with 
a persistent outcome of anxiety (43% vs. 21% for those in partial remission and 21% 
for those in full remission; = 2.75, ns), while use of antidepressants remained low 
(7% in those with a persistent outcome). A striking finding is that only 14% of those 
with a persistent outcome had been in recent contact with a mental health care 
practitioner.  
Table 3. Health care service utilization of older people with an anxiety disorder at baseline 
 Health care service utilization (%) 
 Entire sample (n=62) According to outcome of anxiety 










 n % n % n % n % n % 
Mental health care 9 15 3 5 2 14 1 3 0 0 
Anti-depressants 4 7 4 7 1 7 1 3 2 11 
Benzodiazepines 17 27 16 26 6 43 6 21 4 21 
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Discussion
In the present study we examined the outcome of anxiety disorders in older adults in 
the general population after a follow-up period of six years and we tried to identify 
prognostic factors for persistence of anxiety in older adults. As far as we know, this is 
the first study ever to investigate the long-term outcome of anxiety disorders in older 
adults. In light of previous findings on the low level of mental health care service 
utilization and the high level of benzodiazepine use in older adults with an anxiety 
disorder, this study also aimed to establish whether those with persistent anxiety 
were receiving appropriate care and medication. 
The outcome of anxiety in older adults 
23% of the older adults with an anxiety disorder at baseline who were available for 
follow-up met criteria for a persistent outcome six years after baseline measurement. 
Almost half (47%) of our sample met criteria for subsyndromal anxiety (the partial 
remission group), while approximately a third (31%) was in full remission of anxiety. 
Given the fluctuating course of anxiety disorders in younger populations (Reich, 
1986), one should be careful not to put too much emphasis on the difference between 
a persistent outcome and a ‘partial remission’ outcome. In total, 69% of our sample 
suffered from either subsyndromal or full-blown anxiety at six-year follow-up, 
indicating a rather unfavorable outcome. However, the percentage for full remission 
is relatively high, considering that in studies with younger adults, full remission 
rates over a period of five to ten years range from 12 to 31% (Angst et al., 1991; 
Katschnig & Amering, 1998).
Our results suggest that anxiety disorders may have a different outcome than major 
depression in older adults. In contrast to our findings, rates for persistence have been 
found to be considerably higher for both major and minor depression in older adults 
than in mixed-age populations (Beekman et al., 2002).
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Prognostic factors for a persistent outcome 
Our results revealed only one predictor for a persistent outcome of anxiety: 
neuroticism. In a previous study by our research group, this personality trait had 
also been identified as a strong predictor for remaining anxious in late life (de Beurs 
et al., 2000) and there are a number of studies that have demonstrated an association 
between neuroticism and the onset and prognosis of mood and anxiety disorders (for 
an extensive review of these studies see Clark, Watson & Mineka, 1994). Although 
the OR found in our study (1.19) appears to be rather small, one should hold into 
account that neuroticism was entered into the analysis as a dimensional scale, which 
means that the OR is 1.19 for every one-point difference in scores on the neuroticism 
scale. One could argue that neuroticism is only found to be a predictor for a 
persistent outcome because it shows great conceptual overlap with anxiety. 
However, we found that neuroticism was still a strong predictor for a persistent 
outcome when controlling for the influence of severity of anxiety symptoms at 
baseline (OR=1.17, 95% confidence interval = [1.02-1.36]), which makes it highly 
unlikely that the overlap between anxiety and neuroticism is to be held accountable 
for this finding.
Also, in concordance with findings from community and general practitioner studies 
in mixed-age populations (Angst et al., 1991), female sex was not found to be related 
to persistence of anxiety. In some studies on the outcome of anxiety in mixed-age 
populations, stressful life events (Giel, ten Horn, Ormel, Schudel & Wiersma, 1978), 
the presence of comorbid medical disorders (Giel et al., 1978; Huxley, Goldberg, 
Maguire & Kincey, 1979), comorbid depression (Vollrath & Angst, 1989) and severity 
of illness (Woodman, Noyes, Jr., Black, Schlosser & Yagla, 1999) have been identified 
as prognostic factors for persistence of anxiety. None of these factors was related to 
persistence of anxiety in our sample of older adults. However, when looking at the 
raw data (see table 1) one could argue that certain prognostic factors for persistence 
of anxiety (such as female sex, low socio-economic status, severity of illness and 
stressful life events) failed to reach statistical significance due to small sample size 
(see section on ‘limitations of the study’ in this study). 
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Mental health care and anxiolytic medication 
The use of benzodiazepines remains high for the entire group (26%), even in those in 
full remission of anxiety (21%), but is especially high in those with a persistent 
outcome (43%). In contrast, appropriate treatment for older adults suffering from 
anxiety remains disturbingly low: of those with a persistent outcome, only 7% used 
anti-depressants and 14% had been in recent contact with a mental health care 
facility. This implies that efforts to enhance appropriate referral of anxiety in older 
adults and to lower the use of benzodiazepines in this group in the Netherlands have 
not yet had the desired effect. 
Limitations of the study 
In any longitudinal research effort with respondents of old age, attrition rates are 
considerable and in our case, attrition due to death increased even further due to 
over-sampling of men and the ´older old´. Furthermore, a recent LASA publication 
shows that mortality rates were elevated in men (but not in women) with a 
diagnosed anxiety disorder (van Hout et al., 2004), which might also contribute to the 
high death rates in our sample. In order to establish whether selective attrition may 
have been a source of bias in the present study, we compared respondents lost to the 
follow-up assessment with those who were included on all relevant measures. Loss 
to follow-up was related to male sex; if anything, this may have led to an 
overestimation of the association between female sex and a persistent outcome. As 
we found no significant association between female sex and a persistent outcome, it 
is unlikely that the loss of male subjects biased our results. Furthermore, drop outs 
were older, less healthy and had a lower level of cognitive functioning at baseline 
measurement. Therefore, we may have failed to demonstrate the prognostic value of 
health-related factors for a persistent outcome of anxiety due to the loss of unhealthy 
subjects for follow up measurement. No differences between responders and drop 
outs were found on any of the other predictor variables, such as severity of anxiety 
and depressive symptoms, personality characteristics, socio-economic status or social 
functioning.
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Our study sample included those with a comorbid depression (n=29, 26%). 
Excluding those with a comorbid depression may have rendered a clearer picture of 
the outcome of ‘pure’ anxiety disorders. However, it would also have limited 
generalizibility of our findings since comorbidity with depression is typically high in 
anxious older adults (van Balkom et al., 2000). Another limitation to our study was 
the large time interval between measurements. 
Unfortunately, no data were available for the outcome of anxiety at regular time 
intervals during the six-year follow-up, making it difficult to make any precise 
inferences on the course of anxiety in older people on the basis of our results.  
Post-traumatic stress disorder, anxiety disorder not otherwise specified and mixed 
anxiety-depression were not included as anxiety disorders in the present study, 
while these might be common forms of anxiety in older adults.
Another shortcoming is that information regarding utilization of mental health care 
services was only available for a six-month period leading up to baseline and follow-
up measurements. Respondents may have received treatment for anxiety in between 
measurements, which may in turn have influenced the outcome of anxiety at follow-
up.
In this study, we tried to identify prognostic factors for a persistent outcome, partial 
remission or full remission of anxiety. One might argue that the difference between a 
persistent outcome and a partial or full remission could result from the absence of a 
single criterion in a diagnostic interview or the difference of one point on a screening 
instrument for anxiety. Therefore, multiple regression analyses were repeated on a 
dimensional scale for anxiety symptoms at follow-up, the HADS-A (Zigmond et al., 
1983), while correcting for the influence of anxiety symptoms at baseline. Again, 
neuroticism was found to be the strongest prognostic factor for severity of anxiety 
symptoms at follow-up. 
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Concluding remarks 
Our findings are indicative of a rather unfavorable long-term outcome of anxiety in 
older adults, with a substantial proportion meeting criteria for a persistent outcome 
after a follow-up period of six years. However, no conclusive inferences can be made 
on this subject, as follow-up data were restricted to only one point in time. 
Neuroticism was found to be a strong prognostic factor for a persistent outcome of 
anxiety in later life. In future studies, it would be recommendable to ensure a larger 
sample size to be able to discern other prognostic factors for a persistent outcome of 
anxiety, as attrition rates are typically high in longitudinal research efforts with 
participants in the older age categories. Also, future longitudinal studies should 
entail observations regarding anxiety at regular time intervals, in order to firmly 
establish the course of anxiety in later life. 
Despite several efforts in recent years to amplify the recognition and referral of 
anxiety disorders in later life, adequate treatment remains rare, while utilization of 
benzodiazepines remains high, especially in those with a persistent outcome of 
anxiety. Appropriate treatment may lead to a significant reduction of health care-
related costs in anxious older adults. 
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A randomized controlled trial of the effectiveness of 
cognitive-behavioral therapy and sertraline versus a 
wait-list control group for anxiety disorders in older 
adults.
Abstract 
Objective: This study is the first to investigate the relative effectiveness of CBT compared 
to a SSRI (sertraline) in a RCT on the treatment of anxiety disorders in older adults. 
Method: 84 patients of 60 years and over with a principal diagnosis of GAD, panic 
disorder, agoraphobia or social phobia were randomly assigned to one of three conditions: 
15 sessions of CBT, pharmacological treatment with an SSRI (sertraline; maximum dosage 
150mg) and a wait list control group. Participants completed measures of primary outcome 
(anxiety) and coexistent worry and depressive symptoms at baseline, post-treatment and at 
three-month follow-up. Results: Attrition rates were high in both treatment groups. 
Consequently, findings are based on a relatively small sample of completers (n=52). 
Although both CBT and sertraline led to significant improvement in anxiety, worry and 
depressive symptoms both at post-treatment and at three-month follow-up, sertraline 
showed superior results on worry symptoms. Effect size estimates for CBT were in the small 
to medium range, both at post-treatment (mean d = .42) and at three-month follow-up (mean 
d =.35), whereas effect sizes for sertraline fell into the large range (post-treatment mean d = 
.94 and three-month follow-up mean d = 1.02). The wait-list condition showed virtually no 
effects (post-treatment mean d =.03). Conclusions: Our findings strongly suggest that the 
pharmacological treatment of late-life anxiety with SSRIs has not been given the proper 
attention in research to date. 
Schuurmans, J., Comijs, H.C., Emmelkamp, P.M.G., Gundy, C.M., Weijnen, I.J.C., van Hout, M.A., 
van Dyck, R. A revised version of this chapter has been accepted for publication by the 
American Journal of Geriatric Psychiatry. 
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Anxiety disorders are highly prevalent in older adults (Beekman et al., 1998) and are 
associated with increased disability, a great negative impact on quality of life 
(Wetherell et al., 2004) and an inadequate use of health care services and 
psychotropic medication (de Beurs et al., 1999). Hersen & van Hasselt (Hersen et al., 
1992) have argued for the development of psychosocial interventions, because the 
prescription of benzodiazepines or even of safer psychotropic drugs such as selective 
serotonin reuptake inhibitors (SSRIs), might be problematic in older adults due to 
comorbidity with physical illness and potential negative interactions with other 
drugs. Although this is a valid argument, a pharmacological approach should not be 
discarded too hastily. In fact, randomized controlled trials of SSRIs in older adults 
with depression, although limited in number, have provided evidence for the 
effectiveness and tolerability of these drugs in older adults (Schneider et al., 2003), 
even in the ‘older old’ (Gildengers et al., 2002). Recently, the first randomized 
placebo-controlled trial evaluating the effectiveness of an SSRI (citalopram) in the 
treatment of late-life anxiety has been published (Lenze et al., 2005), providing 
preliminary evidence for the effectiveness and tolerability of this drug in anxious 
older adults. However, this study awaits replication in a larger sample.
Despite the argument for the development of psychosocial interventions for the 
treatment of anxiety in older adults, randomized controlled trials in this area are 
scarce. In mixed-age populations, empirical evidence suggests that cognitive 
behavioral therapy is the most effective form of psychotherapy for anxiety disorders 
(Emmelkamp, 2004). In recent years, several research efforts have been made, 
providing some evidence for the effectiveness of CBT in anxious older adults 
(Stanley et al., 2003a; Wetherell et al., 2003a; Barrowclough et al., 2001; Stanley et al., 
1996), but the evidence is limited and not unequivocal (Mohlman, 2004).
Our study is one of the first to investigate the effectiveness of an SSRI (sertraline) in a 
randomized controlled trial of the treatment of anxiety disorders in older adults. 
Sertraline was chosen because it has been found to be effective and well tolerated, 
both in anxious mixed-age populations (McRae & Brady, 2001; Pohl, Wolkow & 
Clary, 1998; Allgulander et al., 2004; Liebowitz et al., 2003) and in depressed older 
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adults (Forlenza, Almeida, Stoppe, Jr., Hirata & Ferreira, 2001), even in case of 
comorbid medical illness (Sheikh et al., 2004). Also, in contrast to most research 
efforts in this area, our study will examine the effectiveness of individual rather than 
group CBT in anxious older adults and it will include other anxiety disorders than 
GAD, namely panic disorder, agoraphobia and social phobia. Furthermore, the 
current investigation is the first to compare CBT with a SSRI and a wait-list control 
group among older adults with an anxiety disorder. This study was approved by the 
Medical Ethical Review Board of the University Medical Centre of Maastricht. 
Method 
Participants
Participants included 84 adults, aged 60 years and over, with a principal Diagnostic 
and Statistical Manual of Mental Disorders (4th ed., American Psychiatric 
Association, 1994) diagnosis of GAD, panic disorder (either with or without 
agoraphobia), agoraphobia without a history of panic disorder or social phobia. 
Exclusion criteria were the presence of an organic condition that provided a contra-
indication for the use of selective serotonin reuptake inhibitors, current use of 
antidepressant medication, a comorbid diagnosis of alcohol dependency, current 
participation in psychotherapy, a history of psychosis or cognitive impairment as 
indicated by clinical impression and a score of less than 26 on the Mini-Mental State 
Examination (Folstein, Folstein & McHugh, 1975a). Individuals stabilized on 
benzodiazepines were asked not to change their dose or type of medication for the 
duration of the study. Therapists were instructed to ensure that participants did not 
change their use of benzodiazepines. Individuals with comorbid depression, 
dysthymia, or other anxiety disorders were not excluded from participation, as long 
as their principal diagnosis was GAD, panic disorder, agoraphobia or social phobia. 
Principal diagnosis was defined as the most severely disabling disorder at the 
present time. Participants were recruited from 2000 to 2003 through media 
announcements, distribution of information leaflets in pharmacies and clinics for 
general practice and among referrals for treatment to community mental health 
centres and out-patient clinics in five cities in the western and southern part of the 
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Netherlands. All participants were selected on the basis of a structured diagnostic 
interview (SCID 2.0; First, Spitzer, Gibbon & Williams, 1999), administered by 
psychologists who had received extensive training in this instrument. 
Over a 3.5 year recruitment period, 160 subjects received a diagnostic interview, of 
whom 115 people (72%) fit the inclusion criteria and were invited to participate in the 
research. Thirty-one patients (27%) refused before providing preliminary data. 
Eighty-four participants remained who were randomized into the study. Table 1 
presents demographic and diagnostic information about the sample.
Table 1. Descriptives of the sample (prior to attrition) 







Age M(SD) 70.71(6.58) 69.79(5.49) 66.85(5.96) 69.80(6.20) 
Duration of anxiety (yrs) M(SD) 23.33(23.46) 29.86(22.86) 27.22(25.52) 26.16(23.46) 
Female n (%) 31 (73.8) 22 (75.9) 9 (69.2) 62 (73.8) 
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4 With or without agoraphobia 
5 without a history of panic disorder 
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Procedures
All participants read and signed an informed consent form prior to being randomly 
assigned to one of three conditions: 15 weeks of CBT (n =42), sertraline (n=29) or a 15 
week-waiting period (n=13). Randomization procedures were as follows: one 
envelope was filled with 62 labels stating ‘CBT’, 62 labels stating ‘sertraline’ and 26 
labels stating ‘wait-list’. Based on the assumption that the wait-list condition would 
show no effects, as is the case in comparable treatment studies (Wetherell et al., 2003), 
we planned for fewer subjects in the wait-list condition. This distribution would 
yield maximum power to detect differences between CBT and sertraline, while still 
allowing for enough power to differentiate between the active treatment conditions 
and the wait-list condition (Woods et al., 1998). When a participant had completed 
the screening procedure, the principal researcher would then blindly take one label 
out of the envelope which would then be excluded from further randomization 
procedures. However, even though we allowed for a lengthy recruitment period and 
great efforts were made to contact potential participants, we could only assign 84 
participants and the remaining 66 labels were not used in the randomization 
procedure, which is why sample sizes are unequal.
Trained psychologists and a trained research assistant performed assessment 
interviews at pre-test and post-test and at three-month follow-up. Participants in the 
CBT condition were treated individually by a certified behavior therapist in 15 
weekly one-hour sessions. CBT consisted of relaxation training, cognitive 
restructuring and exposure. Treatment protocols for CBT were derived from 
prevailing treatment protocols of panic disorder (Clark & Salkovskis, 1986), GAD 
(Borkovec & Costello, 1993) and social phobia (Scholing & Emmelkamp, 1995) in 
mixed-age populations which were adapted for use with older adults (our CBT 
protocol consisted of 15 sessions, allowing more attention to psycho-education and 
repeated explanation and revision of new information and newly learned coping 
skills). Participating therapists took part in regular supervision meetings, which were 
led by certified supervisors for behavior therapy (P.M.G. Emmelkamp and I.J.C. 
Weijnen). Although sessions were not taped and rated for adherence to the protocols, 
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therapists were repeatedly and explicitly instructed to contact their project 
supervisor if they felt that they needed to deviate from the protocol. Their supervisor 
would then talk through the problem at hand to ensure that therapists would adhere 
to the protocol.
In the sertraline condition patients were treated by a psychiatrist or a resident-
psychiatrist in eight 20-minute sessions over a period of fifteen weeks. The protocol 
for sertraline included a dosage schedule adapted for older adults, in which the 
starter dose was lower (25 mg) and the dosage was built up more gradually than in 
the customary procedure (up to a minimum dose of 100 mg which had to be reached 
within four weeks and a maximum dose of 150 mg on the basis of tolerability and 
lack of clinical response). Medication was maintained during a  three-month follow-
up.
Measures
Outcome was assessed at post-treatment and at three-month follow-up. Pre and post-
treatment measures consisted of self-report measures and a structured interview. The 
interview consisted of the Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959; 
Cronbach’s alpha = .82). The HARS was performed by two members of the research 
group. Interrater agreement on the HARS was measured in the initial stages of the 
project. Weighted kappa was .58, constituting moderate interrater agreement. Self-
report measures included the Beck Anxiety Inventory (BAI; Beck & Steer, 1990; 
Cronbach’s alpha = .93) and the Dutch adaptation of the Worry Domain 
Questionnaire (WDQ; Rijsoort, Emmelkamp & Vervaeke, 1999; Cronbach’s alpha = 
.92). Items related to work situations in the WDQ were omitted because they were 
not considered appropriate for an older population. Depressive symptoms were 
measured with the Centre for Epidemiological Studies Depression Scale (CES-D; 
Radloff, 1977; Cronbach’s alpha= .90). The BAI and the HARS should be considered 
as the primary outcome measures of this study. Assessment at three-month follow-
up consisted solely of self-report measures, which were distributed by mail, unless 
CHAPTER 4  A RANDOMIZED CONTROLLED TRIAL OF THE EFFECTIVENESS OF CBT AND SERTRALINE VERSUS 
A WAIT-LIST CONTROL GROUP FOR ANXIETY DISORDERS IN OLDER ADULTS
83
participants preferred a personal interview with the researcher. In that case, 
questionnaires were handed out and filled in on site or taken home by the 
participant. Side effects to medication were measured with the Fawcett checklist 
(Fawcett, 1987) at the last session of the sertraline protocol. 
Data Analysis 
ANOVAs and chi-square tests were used to compare participants assigned to the 
three conditions on pre-treatment demographic and clinical variables, including 
number of coexistent diagnoses, number of chronic diseases and baseline anxiety 
measurements.
Therapy outcome was assessed with paired t tests and ANCOVAs on the outcome 
scores of both post-treatment and follow-up measurements using pre-treatment 
scores as a covariate (Gibbons et al., 1993). When outcome scores were missing, 
scores were imputed using scores from the next follow-up measurement if possible. 
When data were not normally distributed, wilcoxon signed rank tests were 
performed in stead of paired t tests. Two measures of clinically significant change 
were assessed: (1) Treatment response for anxiety, defined as an improvement of 20% 
on two measures of anxiety (BAI and HARS) and endstate functioning for anxiety, 
defined as a score of less than ten on both the BAI and the HARS (which equals a 
score within the normal range). The 20% reduction criterion of treatment response in 
a composite measure of both self-report and interview-rated instruments is 
frequently used in the treatment literature of anxiety in older adults (Wetherell et al., 
2003; Barrowclough et al., 2001; Stanley et al., 1996). Rates of treatment response and 
endstate functioning were only available for post-treatment measurements. 
Results
Attrition 
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Ten (12%) of 84 patients refused participation in the trial immediately after 
randomization, four of whom were assigned to sertraline, three to CBT and three to 
the wait-list condition. 17 (23%) of the remaining 74 participants dropped out of the 
trial before completing CBT (n=9), sertraline (n=7) or wait list conditions (n=1), 
culminating in a total attrition rate of 32% (27 of the initial sample of 84 participants). 
There were no significant differences in attrition rates across treatment groups. One 
participant randomized to sertraline switched to venlafaxine in one of the first weeks 
of treatment due to adverse side-effects and was excluded from outcome analysis. 
For completer analyses, data from 56 participants were available who completed CBT 
(n=30), sertraline (n=17) and wait-list conditions (n=9). Another four participants 
failed to turn in their pre-treatment questionnaires although they did complete the 
HARS interview, one of which was assigned to sertraline, two to CBT and one to the 
wait-list condition. Reasons mentioned for dropout from CBT included: Treatment 
was found to be too straining or confronting (n=2); treatment was found to be too 
time-consuming (n=2); participants did not agree with the treatment rationale (n=5) 
and spontaneous remission of symptoms (n=4). Reasons mentioned for dropout from 
sertraline included: long-term illness (n=1), deceased due to natural causes before 
starting medication (n=1), side-effects (n = 4), anticipated side-effects before actually 
starting medication (n=1) and spontaneous remission of symptoms (n=1). 
No significant differences between dropouts and completers were found for sex, age, 
marital status, level of education, main psychiatric diagnosis, medication use, chronic 
illness or duration of symptoms. Non completers were found to have a higher score 
at pre-treatment on the HARS (t=2.33, df=79, p < .05), but not on any of the other 
outcome variables. 
At three-month follow-up, four participants (9%) refused to fill in their 
questionnaires. During follow-up, three participants (two CBT and one sertraline 
participant) were given an alternative psychopharmacological treatment because 
their symptoms had not sufficiently improved. These participants were excluded 
from follow-up analyses, leaving a sample of 39 participants (25 CBT and 14 
sertraline) who were included in follow-up analyses. Wait-list participants were not 
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included in follow-up analyses, as they were reassigned to one of the active 
treatment conditions after completing the 15-week waiting period.
Differences between therapy groups at pre-treatment 
A comparison on all pre-treatment demographic and clinical variables, including the 
distribution of principal diagnosis and severity of anxiety symptoms at baseline 
using 2 tests and ANOVA’s demonstrated no significant differences (table 1). After 
attrition, sertraline participants had a higher rate of comorbid depression at baseline 
than CBT or wait-list participants ( 2 = 7.18(2), p <.05). 
Treatment outcome 
Paired t tests were performed to assess within-treatment effects for each group 
between pre-treatment and post-treatment and between pre-treatment and three-
month follow-up. Results from wilcoxon signed rank tests showed the same results. 
Table 2 (page 85) presents t and p values, effect size estimates and percentage of 
change over time by condition. 
At post-treatment, both CBT and sertraline participants had improved significantly 
on every outcome measure. Improvement was largely maintained during the three-
month follow-up. Participants in the wait-list condition did not show significant 
change on any of the outcome measures. Effect size estimates were calculated as the 
difference between mean pre-and post-treatment scores divided by the pooled 
standard deviations from the baseline and post-treatment scores (Cohen’s d; Cohen, 
1988). In general, effect sizes for CBT were in the small to medium range, both at 
post-treatment (mean d=.42) and at three-month follow-up (mean d=.35) whereas 
effect sizes for sertraline were in the large range (post-treatment mean d=.94 and 
three-month follow-up mean d=1.02). The wait-list condition showed virtually no 
effects (post-treatment mean d=.03).
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At post-treatment, there were significant differences between CBT and WL on only 
one outcome measure; the HARS (F=10.19(1, 35), p<.01). Sertraline performed better 
than WL on all outcome measures except the BAI (CES-D: F=4.49(1,18), p<.05; HARS: 
F=8.50(1, 22), p<.01; WDQ: F= 4.44(1, 20), p<.05). In a comparison of the active 
treatment conditions, sertraline showed superior performance over CBT on the 
WDQ, but not on any of the other outcome measures, both at post-treatment, F 
(1,41)=5.80, p<.05 and at three-month follow-up, F(1,35)=5.11, p<.05.  
Treatment response and endstate functioning 
At post-treatment, 44% of CBT participants, 57% of sertraline participants and one 
wait-list participant (11%) could be classified as treatment responders. Separate 2
analyses of the three group comparisons revealed significant differences in treatment 
response rates between sertraline and wait-list ( 2 = 4.87(1), p<.05), but not between 
CBT and wait-list ( 2 = 3.25(1), p=.08) or between CBT and sertraline ( 2 = .60 (1), p = 
.33).
Prior to treatment, 2 analyses did not reveal any significant differences between 
conditions with regard to level of functioning for anxiety. Following treatment, 48% 
of CBT participants, 47% of sertraline participants and none of the wait-list 
participants fit criteria for high endstate functioning; 2 = 6.88(2), p<.05.
Adverse effects in the sertraline treatment group 
Adverse effects that were reported by medication completers and that were deemed 
moderate to very severe by the (resident) psychiatrist at the last session of treatment 
were anorexia (n=1), tinnitus (n=1), stiffness (n=1), ataxia (n=1), dry mouth (n=1), 
hypertension (n=1), heart palpitations (n=2), miction problems (n=2), agitation (n=2), 
increase in appetite (n=2), tremors (n=2), nausea/vomiting (n=2), drowsiness (n=2), 
fatigue (n=3), headache (n=3), anxiety and nervousness (n=3), transpiration (n=3), 
insomnia (n=3), reduction of frequency of sex (n=4), problematic erection or 
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lubrication (n=4), absence of orgasm (n=4), lessened intensity of orgasm (n=4) 
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Discussion
Implications of our findings 
Our study was the first to compare the effectiveness of a SSRI with CBT for the 
treatment of anxiety disorders in older adults. We found that although both 
treatments led to significant improvement on all measures of outcome, sertraline 
showed superior results on symptoms of worry as measured with the WDQ. Also, 
sertraline participants performed better than wait-list participants on 3 of 4 outcome 
measures, whilst CBT performed better than wait-list participants on only one 
outcome measure; the HARS. Moreover, effect sizes for CBT were relatively small 
(.31 -.58), while effect sizes for sertraline fell into the large range (.85 -1.08). However, 
treatment response rates and rates of high endstate functioning were not significantly 
different between treatment groups. Some of our findings run contrary to what one 
might expect on the basis of results from similar studies in mixed-age populations In 
most RCT’s of the treatment of anxiety disorders, SSRIs and CBT are found to be 
equally effective (Emmelkamp, 2004).
Our findings indicate that the reluctant attitude of both researchers and general 
practitioners toward the use of SSRIs in late-life may be unjustified. Given the fact 
that 4 participants (14%) did report side-effects as a reason for dropping out of the 
trial, which is comparable to dropout rates due to side-effects in studies of sertraline 
for depression in late life (11-19%; Sheikh et al., 2004; Bondareff et al., 2000; 
Newhouse et al., 2000), patients should be closely monitored and better informed on 
what to expect from an SSRI by their physician, in order to increase treatment 
adherence.
In concordance with most other treatment studies in late-life anxiety (Stanley et al., 
2003; Wetherell et al., 2003; Stanley et al., 1996), effect sizes for CBT were 
substantially lower and attrition rates for both CBT and sertraline were considerably 
higher than those found in comparable treatment studies in mixed-age populations 
(mean attrition rate approximately 10%; Gould et al., 2004). These findings imply that 
it is important that we find ways to increase treatment adherence in older anxious 
adults.
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CBT did not perform as well as expected on the basis of similar treatment studies in 
older adults. The only comparable trial that investigated individual format CBT in 
anxious older adults (with mixed anxiety disorders) was the study by Barrowclough 
et al. (2001), which yielded more positive results for CBT than our study. However, 
participants in Barrowclough’s study were mostly treated in their own homes, which 
may have positively influenced both the effectiveness of treatment as well as 
treatment adherence. Also, 51% of participants in the Barrowclough study used 
antidepressants during the treatment phase, which may well have biased the results. 
Although treatment response rates were higher in the Barrowclough study (71% at 
12-month follow-up), effect sizes for Barrowclough et al. (2001) were also in the small 
to medium range at .34. Also, participants in other treatment studies (Stanley et al., 
2003; Wetherell et al., 2003; Stanley et al., 1996) were mostly well educated, while in 
our study 45% of CBT participants had only finished primary school.
Finally, problems with homework completion may play an important role in the 
moderate outcome of CBT in our study. Although we did not measure homework 
completion in a standardized manner, we do recall that one of the topics that came 
up frequently in our supervision meetings was the trouble that therapists 
encountered in getting participants to complete the homework. Reasons for this 
phenomenon were related to participants’ disbelief in the usefulness of homework 
assignments, insecurity and difficulties in dealing with assignments and lack of time. 
Limitations
The main limitation to the present study was its lack of power due to large attrition 
rates and the differences in sample size between conditions, which resulted from the 
fact that our randomization procedures were unsuccessful due to unforeseen 
recruitment problems. As a consequence, our study is not as persuasive as it might 
have been if other randomization procedures would have been used. 
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It should be taken into account that all outcome analyses in this study were based on 
completers. Due to high attrition rates and small sample size, no valid and 
meaningful way for performing intent-to-treat analyses was available.
Also, the follow-up period of this study was relatively short (three months), 
considering the fact that in mixed-age populations, the outcome of CBT tends to 
improve after termination of treatment (Gould et al., 2004). However, our results 
showed no improvement of CBT outcome during the three-month follow-up.  
The fact that the use of sertraline was largely maintained during follow-up, may 
have biased the comparison with CBT, since evidence from younger populations 
suggests that anxiety symptoms tend to recur after termination of pharmacological 
treatment (Emmelkamp, 2004). Unfortunately, the Dutch review board for medical 
ethics did not grant us permission to allocate older adults to a placebo condition. As 
a consequence, we could not reliably establish whether treatment effect and reported 
side-effects should be attributed to sertraline. The fact that treatment in our study 
lasted for 15 weeks (more than twice the length of most pharmacological studies in 
younger populations) and the fact that treatment results were largely maintained 
during three-month follow-up, makes it less plausible that treatment effect is 
attributable to a placebo-effect. 
Relating to the inclusion of different anxiety disorders, the fact that we chose not to 
include measures on phobic avoidance or the frequency of panic attacks might be 
considered as a limitation. However, such measures would not have been 
appropriate for all subjects, which is why we chose two outcome measures for 
general anxiety symptoms, the BAI and the HARS, as the main outcome measures of 
this study. Also, the inclusion of different anxiety disorders might limit the 
generalizibility of our findings. The inclusion of agoraphobia without panic disorder 
in particular might induce comments on the fact that there is no specific evidence on 
the effectiveness of SSRIs for the treatment of this disorder. However, repeated 
outcome analyses excluding those with a main diagnosis of agoraphobia without 
panic disorder yielded similar results. 
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Finally, it should be noted that assessment was not blind and that follow-up 
assessments were solely based on self-report measures. 
Recommendations and conclusions 
Future randomized controlled trials might incorporate other psychological 
interventions that might be more suitable for use with older adults (such as 
reminiscence therapy which has shown positive results for the treatment of late-life 
depression (Bohlmeijer, Smit & Cuijpers, 2003). Also, more research is needed to 
firmly establish if and what modifications are needed for the appropriate use of CBT 
with an older population. Finally, our findings strongly suggest that the 
pharmacological treatment of late-life anxiety with SSRIs has not been given the 
proper attention in research to date. 
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Long-term effectiveness and prediction of treatment 
outcome in cognitive behavioral therapy and sertraline 
for late-life anxiety disorders. 
Abstract 
Objective: The present study aims to establish long-term outcome of CBT and sertraline 
for the treatment of late-life anxiety and is the first to attempt to identify differential 
predictors for treatment outcome of sertraline and CBT for late-life anxiety disorders. 
Method: Participants of an RCT comparing sertraline and CBT for the treatment of late-life 
anxiety were contacted one year after completing CBT and sertraline treatments, so that 
predictors for both short-term and long-term treatment outcome could be established. 
Predictor variables included age, education, duration of symptoms, anxiety symptoms, 
depressive symptoms, agoraphobic symptoms, neuroticism and perceived health. Results:
Sertraline showed superior performance over CBT on anxiety (HARS) and worry (WDQ) 
ratings at one-year follow-up. A poor CBT outcome was predicted by poor perceived health, 
comorbid depressive symptoms and higher neuroticism scores. The strongest predictor for 
short-term CBT outcome was poor perceived health, explaining 40% of the variance in post-
treatment residual gain scores on the HARS. The strongest predictor for long-term CBT 
outcome was neuroticism, explaining 20.0% of the variance in residual gain scores at one-
year follow-up. Higher pre-test anxiety was found to be predictive of greater short-term 
improvement of anxiety symptoms in sertraline participants, explaining 41% of post-
treatment residual gain scores. Analyses revealed no significant predictors for long-term 
treatment outcome in sertraline participants. Conclusions: Our study suggests that 
sertraline might be more beneficial for late-life anxiety than CBT. Poor perceived health and 
neuroticism are predictive of less improvement after CBT in anxious older adults. Greater 
initial severity of anxiety seems to be predictive of a greater short-term treatment effect of 
sertraline in anxious older adults. 
Schuurmans, J., Comijs, H.C., Emmelkamp, P.M.G., Weijnen, I.J.C., van Hout, M.A., van Dyck, R. 
This chapter has been submitted for publication. 
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Although anxiety disorders are among the most prevalent mental disorders among 
older adults (Flint, 1994b), randomized controlled trials of treatment effectiveness for 
late-life anxiety are scarce and have focused primarily on the effectiveness of 
psychotherapeutic interventions, more specifically: of CBT (Mohlman, 2004). 
Recently, our research group completed the first randomized controlled trial of the 
effectiveness of individual format CBT versus an SSRI (sertraline) for the treatment of 
late-life anxiety disorders (see chapter 4). Although both treatments resulted in 
statistically significant improvement in outcome scores, effect sizes for CBT were 
relatively small (post-treatment mean d = .34), whereas effect sizes for sertraline were 
in the large range (post-treatment mean d = 1.00). This is in concordance with a 
recent review of the treatment of late-life GAD (Mohlman, 2004), which concluded 
that effect sizes found in treatment studies of CBT for anxiety in older adults tend to 
be markedly lower than in similar studies in younger adults.
As yet, there have been no systematic studies investigating prognostic factors for the 
outcome of CBT for late-life anxiety. In mixed-age populations, studies on the 
prediction of treatment outcome for anxiety disorders are relatively scarce and often 
provide conflicting results. Documented predictors of the outcome of psychological 
interventions for anxiety in mixed-age populations include duration of illness 
(Scheibe & Albus, 1997), older age (Scheibe et al., 1997), initial severity of anxiety 
(Seivewright, Tyrer & Johnson, 1998; Butler, 1993), agoraphobic avoidance (Scheibe et 
al., 1997; Scheibe & Albus, 1996), pre-treatment depression (Scholing & Emmelkamp, 
1999) and certain personality dimensions or disorders such as avoidant personality 
(Scholing et al., 1999). Documented predictors of the outcome of drug treatment for 
anxiety in younger and mixed-age populations seem to be similar to some extent, 
including such factors as symptom severity (Solvason, Ernst & Roth, 2003; Denys, 
Burger, van Megen, de Geus & Westenberg, 2003; Stein, Stein, Pitts, Kumar & 
Hunter, 2002), duration of symptoms (Solvason et al., 2003; Stein, Montgomery, 
Kasper & Tanghoj, 2001; Slaap & den Boer, 2001; Katschnig et al., 1995), depressive 
symptoms (Denys et al., 2003; Stein et al., 2001), agoraphobic avoidance (Slaap et al., 
2001; Katschnig et al., 1995) and certain personality disorders or traits (Slaap et al., 
2001).
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Although these data suggest that the same factors may be of influence in determining 
treatment effect for CBT and psychopharmacological treatment, the evidence remains 
tentative as studies on differential predictors of treatment effect in comparative trials 
of psychological interventions versus drug treatments for anxiety are nonexistent. 
Also, not all findings from studies in mixed-age populations might be applicable to 
older adults, as treatment effectiveness studies of late-life anxiety have already 
proven. The different nature of both treatment modalities and the fact that we found 
some differences in degree of effectiveness between CBT and sertraline for the 
treatment of late-life anxiety calls for the study of differential predictors of treatment 
effect in this population.  
The present study aims to establish long-term outcome of CBT and sertraline for the 
treatment of late-life anxiety and to identify differential predictors for treatment 
outcome of sertraline and CBT for late-life anxiety disorders. For the present study, 
participants of the original RCT were contacted and measured one year after 
completing CBT and sertraline conditions, so that predictors for both short-term and 
long-term treatment outcome could be investigated. Predictor variables included age, 
educational level, duration of symptoms, initial severity of anxiety, depressive 
symptoms, agoraphobic symtoms, neuroticism and perceived health. 
Methods 
The treatment study 
Participants included 47 adults, aged 60 years and over, with a prinicipal Diagnostic 
and Statistical Manual of Mental Disorders (4th ed.; American Psychiatric 
Association, 1994) diagnosis of GAD, panic disorder, agoraphobia (either with or 
without a history of panic disorder) or social phobia. Exclusion criteria were the 
presence of an organic condition that provided a contra-indication for the use of 
selective serotonin reuptake inhibitors, current use of antidepressant medication, a 
comorbid diagnosis of alcohol dependency, current participation in psychotherapy, 
cognitive impairment as indicated by a score of less than 26 on the Mini-Mental State 
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Examination (Folstein et al., 1975) or a history of psychosis. Individuals stabilized on 
benzodiazepines were asked not to change their dose or type of medication for the 
duration of the study. Individuals with comorbid depression, dysthymia, or other 
anxiety disorders were not excluded from participation, as long as their principal 
diagnosis was GAD, panic disorder, agoraphobia or social phobia. 
All participants completed a fifteen-week CBT (n=30) or sertraline (n=17) treatment 
after randomized assignment to these conditions (see chapter 4). Measurements took 
place before and after completing treatment conditions, and at follow-up, one year 
post-treatment.
Age at pre-test varied from 61 to 81, with a mean age of 70. Age of onset was ‘early’ 
(below the age of 60) in 28 participants (59.6%) and duration of anxiety varied from 2 
months to 63 years, with a mean duration of 29 years. Thirty-seven participants 
(78.7%) suffered from some form of chronic somatic disease. Chronic diseases that 
were most common among participants were hypertension (n=14; 29.8%), arthritis 
(n=10; 21.3%) and cardiovascular diseases (n=10; 21.3%). Twenty-three participants 
(48.9%) used one or more benzodiazepines. Further information regarding the 
distribution of descriptives across the treatment conditions can be found in table 1 
(next page). 
Measures of treatment outcome 
Outcome was assessed at post-treatment and at one-year follow-up. Pre-test, post-
test and follow-up measurements consisted of self-report measures and a structured 
interview. The interview consisted of the Hamilton Anxiety Rating Scale (HARS; 
Hamilton, 1959; Cronbach’s alpha = .82). The HARS was performed by two members 
of the research group. Interrater agreement on the HARS was measured in the initial 
stages of the project. Weighted kappa was .58, constituting moderate interrater 
agreement. Self-report measures included the Beck Anxiety Inventory (BAI; Beck et 
al., 1990; Cronbach’s alpha = .93) and the Dutch adaptation of the Worry Domain 
Questionnaire (WDQ; Rijsoort et al., 1999; Cronbach’s alpha = .92). Items related to 
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work situations in the WDQ were omitted because they were not considered 
appropriate for an older population. Depressive symptoms were measured with the 
Centre for Epidemiological Studies Depression Scale (CES-D; Radloff, 1977; 
Cronbach’s alpha= .90).
Table 1. Descriptives 
Variable CBT (n=30) Sertraline (n=17) 
Age at pre-test M(SD) 70.60(6.52) 69.35(5.88) 
Duration of symptoms (yrs) M(SD) 27.85(25.20) 30.47(23.52) 
Female n(%) 21 (70.0) 12 (70.6) 
Married n (%) 17 (56.7) 13 (76.5) 
Education
  Low 
  Medium 











   GAD 
   Panic disorder6
   Agoraphobia7













Chronic medical disorder n (%) 26 (86.7) 11 (64.7) 
Benzodiazepine use n (%) 14 (46.7) 9 (52.9) 
BAI pre-test M(SD) 18.12 (11.92) 22.69 (13.60) 
HARS pre-test M(SD) 14.48 (8.00) 17.86 (8.22) 
Depressive symptoms pre-test M(SD) 19.59 (10.37) 23.78 (9.51) 
Agoraphobic symptoms pre-test M(SD) 36.50 (18.69) 37.03 (15.35) 
Neuroticism pre-test M(SD) 7.37 (3.32) 9.10 (2.36) 
Perceived health M(SD) 15.63 (5.54) 13.69 (4.81) 
6 With or without agoraphobia 
7 Without a history of panic disorder 
CHAPTER 5  LONG-TERM EFFECTIVENESS AND PREDICTION OF TREATMENT OUTCOME 
IN CBT AND SERTRALINE FOR LATE-LIFE ANXIETY DISORDERS
104
Predictor variables of treatment outcome 
Predictor variables of treatment outcome were measured at pre-test and included 
age, educational level, duration of symptoms in years, anxiety symptoms as 
measured with the BAI (Beck et al., 1990), depressive symptoms as measured with 
the CES-D; Radloff, 1977), agoraphobic symptoms as measured with the 
Agoraphobia Scale (AS; Ost, 1990; Cronbach’s alpha= .96), neuroticism as measured 
with the neuroticism subscale of the Eysenck Personality Questionnaire-revised, 
(EPQ-R; Eysenck et al., 1968; Eysenck et al., 1985; Cronbach’s alpha = .78) and 
perceived health (a subscale of the MOS-20; Stewart, Hays & Ware, Jr., 1988; 
Cronbach’s alpha= .86). Items related to driving a car were omitted from the analysis 
of the AS, since a large proportion of participants did not own or no longer owned a 
driver’s license. 
Data analysis 
T tests and chi-square tests were used to compare participants assigned to CBT and 
sertraline on all predictor variables measured at pre-test. Therapy outcome at one-
year follow-up was assessed with paired t tests and ANCOVAs on the outcome 
scores of follow-up measurements using pre-treatment scores as a covariate for all 
patients who completed treatment (Gibbons et al., 1993). Two measures of clinically 
significant change were assessed: (1) Treatment response for anxiety, defined as an 
improvement of 20% on two measures of anxiety (BAI and HARS) and high end state 
functioning for anxiety, defined as a score of less than ten on both the BAI and the 
HARS (which equals a score within the normal range). The 20% reduction criterion of 
treatment response in a composite measure of both self-report and interview-rated 
instruments is common in the treatment literature of anxiety in older adults 
(Wetherell et al., 2003a; Barrowclough et al., 2001; Stanley et al., 1996). Rates of 
treatment response and high end state functioning at one-year follow-up were 
determined and compared between treatment groups using 2 analyses.
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Predictor analyses were conducted for two moments in time: at post-treatment and at 
one-year follow-up. To investigate the prognostic value of predictor variables 
measured at pre-test for treatment outcome of anxiety, residual gain scores (Steketee 
& Chambless, 1992) were used for the HARS, which was chosen as the main outcome 
variable. The residual gain score has several advantages over raw outcome scores or 
change scores, because it takes into account both pre-treatment differences and 
measurement error, by using the following formula: residT2 = z2-z1*r12 (residT2 is 
the residual gain score at post-test (T2); z2 is the standardized score at post-test(T2); 
z1 is the pre-treatment standardized score, and r12 is the correlation between z1 and 
z2). A series of linear regression analysis were run, using residual gain scores on the 
HARS at post-treatment and follow-up as outcome variables. Data for CBT and 
sertraline completers were analyzed separately. First, all predictor variables were 
entered individually in a univariate linear regression model. Next, all predictors 
showing a significant effect in the univariate regression analyses were entered in a 
forward multivariate regression model, to see which of the variables showed an 
independent contribution to treatment outcome and to establish the magnitude of 
this contribution (the amount of variance in residual gain scores explained). 
Results
Loss to follow-up and differences between treatment groups 
For post-treatment analyses, data from 47 participants were available who completed 
CBT (n=30) and sertraline (n=17) conditions. Eight participants refused to cooperate 
with assessment at one-year follow-up, leaving a sample of 39 (25 CBT and 14 
sertraline) participants who were included in follow-up analyses. Those who were 
lost to follow-up scored lower on the perceived health scale at baseline than those 
who participated in one-year follow-up assessments (t(42)=2.09, p<.05). No other 
significant differences between participants and those lost to follow-up were found 
for any of the demographic or predictor variables included in this study. Also, 
ANCOVA’s on the post-treatment outcome measures using pre-treatment scores as a 
covariate did not show differences in treatment effectiveness between participants 
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and those lost to follow-up. Sertraline use was maintained during follow-up in at 
least 7 of 14 participants (50%). Unfortunately, data on sertraline use during follow-
up are missing in 4 of 14 participants (28.6%). During follow-up, 7 participants (3 
CBT and 4 sertraline participants) sought additional treatment at the research centre, 
4 of which received an alternative psychopharmacological treatment and 3 of which 
received CBT. 
A comparison on all pre-treatment demographic and predictor variables using t tests 
and 2 tests demonstrated no significant differences between those randomized to 
CBT or sertraline at baseline. However, sertraline completers did have a higher rate 
of comorbid depression at baseline than CBT completers (44.4 versus 10.0 %; 
2(1)=7.56, p<.05). 
Treatment outcome at one-year follow-up 
Paired t tests were performed to assess within-treatment effects for each group 
between pre-treatment and one-year follow-up. Table 2 presents t and p values, effect 
size estimates and percentage of change over time by condition. 
Table 2. Paired t tests (t), effect size estimates (d) and percentage of change over time(%) 





 t p d % df   t p d % df 
BAI 1.92 .07 .28 19 23   4.01 <.01 .60 38 12 
HARS 4.42 <.001 .70 34 24   5.18 <.001 1.62 62 13 
CES-D 1.07 .30 .22 12 23   3.15 <.01 .82 29 12 
WDQ 3.18 <.01 .27 10 24   4.12 <.01 .95 23 12 
At one-year follow-up, improvement from baseline scores was significant on all 
outcome measures for sertraline completers. For CBT completers, improvement from 
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baseline scores was significant on the HARS and the WDQ, but not on the BAI or the 
CES-D. Effect size estimates were calculated as the difference between mean pre-and 
one-year follow-up scores divided by the pooled standard deviations from baseline 
and follow-up scores (Cohen’s d; Cohen, 1988). In general, effect sizes for CBT at one-
year follow-up remained relatively small (mean d at one-year follow-up=.37 versus 
post-treatment mean d = .42 and three-month follow-up mean d = .35 (see chapter 4), 
whereas effect sizes for sertraline remained in the large range (one-year follow-up 
mean d = 1.00 versus post-treatment mean d = .94 and three-month follow-up mean 
d = 1.02).
For a direct comparison of the effectiveness of treatment conditions, we conducted 
ANCOVAs on the follow-up scores of all completers with pre-treatment scores as the 
covariate. Results favored sertraline on the HARS (F(1,37)= 5.54, p<.05) and the WDQ 
(F(1,36)= 5.35, p<.05), but not on the BAI (F(1,35)= 2.02, p=.16) and the CES-D (F(1,35)= .62, 
p=.44). At post-treatment, rates of treatment response (57% for sertraline versus 44% 
for CBT participants) and high end state functioning (47% for sertraline and 48% for 
CBT participants) did not differ significantly between treatment groups (see chapter 
4). At one-year follow-up, 67% of sertraline participants and 39% of CBT participants 
could be classified as treatment responders ( 2 (1)=2.39, p=.12). Fifty-seven percent of 
sertraline participants and 44% of CBT participants fit criteria for high end state 
functioning at one-year follow-up ( 2(1)=.62, p=.43). 
Predictors of treatment outcome for CBT 
Regression analyses on post-treatment scores of the HARS using pre-treatment 
scores on the HARS as an independent variable revealed that 57.3% of the variance in 
post-test scores on the HARS was explained by the pre-test ( =.77, p<.001). 
Regression analyses on residual gain scores at post-treatment revealed several 
significant predictors for an unsuccessful treatment outcome for CBT participants. 
These included comorbid depressive symptoms, neuroticism and lower perceived 
health scores (table 3). A multiple forward regression analyses incorporating these 
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predictors revealed that only lower perceived health had a significant independent 
contribution to the prediction of an unsuccessful treatment outcome ( =-.63, p<.01), 
explaining 40.0% of the variance in residual gain scores.
At one-year follow-up, 45.3% of the variance in HARS scores was explained by the 
pre-test scores ( =.69, p<.001). Regression analyses on residual gain scores at one-
year follow-up again revealed lower perceived health and neuroticism as significant 
predictors for an unsuccessful treatment outcome (table 3). Comorbid depressive 
symptoms were not found to be predictive for long-term treatment outcome. In 
contrast to post-treatment analyses, a multiple forward regression analyses 
incorporating perceived health and neuroticism revealed that only neuroticism had a 
significant independent contribution to the prediction of an unsuccessful treatment 
outcome at one-year follow-up ( =-.63, p<.01), explaining 22.0% of the variance in 
residual gain scores.
Predictors of treatment outcome for sertraline 
Regression analyses on post-treatment HARS scores using pre-treatment scores as an 
independent variable revealed that 36.5% of the variance in post-treatment HARS 
scores was explained by the pre-test ( =.60, p<.05). Residual gain score analysis at 
post-treatment revealed one significant predictor of treatment effect; a higher pre-test 
anxiety score (as measured with the BAI) predicting more improvement (explained 
variance 41%, =.64, p<.05). 
Regression analyses on HARS scores at one-year follow-up revealed that only 13% of 
the variance in follow-up HARS scores was explained by the pre-test ( =.36, p=.20). 
Regression analyses on residual gain scores at one-year follow-up revealed no 
significant predictors for treatment outcome. 
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Table 3. Predictors of post-treatment and one-year follow-up residual gain scores on the 
HARS for CBT and sertraline participants. 
Predictor variables Post-treatment 1-year follow-up 
CBT r2  p r2  p 
Age at pre-test .11 .34 .07 .10 .31 .13 
Educational level .02 -.12 .53 .01 -.11 .62 
Duration of symptoms  .00 .03 .88 .00 -.04 .87 
Anxiety symptoms (BAI) .05 .23 .24 .13 .35 .09 
Depressive symptoms .21 .46 <.05 .07 .26 .22 
Agoraphobic symptoms .01 .11 .57 .04 .20 .36 
Neuroticism .26 .51 <.01 .22 .47 <.05 
Perceived health .40 -.63 <.001 .18 -.43 <.05 
       
Sertraline       
Age at pre-test .00 .07 .79 .03 .19 .53 
Educational level .03 -.18 .50 .01 .08 .78 
Duration of symptoms  .06 -.25 .36 .02 -.13 .68 
Anxiety symptoms (BAI) .41 .64 <.05 .13 .34 .23 
Depressive symptoms .00 .06 .84 .01 -.09 .76 
Agoraphobic symptoms .09 .29 .31 .03 .17 .56 
Neuroticism .00 .00 .99 .00 .01 .98 
Perceived health .05 -.22 .45 .01 -.10 .76 
Regression analyses in bold typeface represent significance at p<.05 
Discussion
Treatment outcome at one-year follow-up 
Data comparing short-term effectiveness of CBT and sertraline for late-life anxiety, 
described in a previous report by our research group (see chapter 4), revealed higher 
effect sizes and a better result on worry symptoms for sertraline. Long-term 
treatment outcome reflects similar results with sertraline showing more 
improvement on worry symptoms, but also on anxiety symptoms as measured with 
the HARS. Effect sizes for sertraline remained in the moderate to large range 
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(Cohen’s d= .60 – 1.62), while effect sizes for CBT were small to moderate (Cohen’s 
d= .22 - .70).
Variables predicting treatment response 
Our study provides support for several predictors for the treatment outcome of CBT 
for late-life anxiety, including comorbid depressive symptoms, poor perceived health 
and neuroticism. Poor perceived health seems to be predictive for treatment failure 
in CBT, but not in sertraline participants. This is a rather remarkable finding, since 
several papers have argued that psychological interventions are preferential to drug 
treatment for late-life anxiety (Mohlman, 2004; Nordhus et al., 2003; Hersen et al., 
1992), because poor health is supposed to be detrimental to drug treatment effect in 
older adults. Neuroticism was found to be the strongest predictor for an unsuccessful 
long-term treatment outcome. Neuroticism has also been found to be predictive of a 
natural long-term persistent outcome of anxiety disorders in late-life (see chapter 3; 
Schuurmans et al., 2005) and it has been found to be related to the onset and 
prognosis of mood and anxiety disorders in mixed-age populations in several other 
studies (for an extensive review of these studies see Clark et al., 1994). Higher pre-
test anxiety was found to be predictive of greater short-term improvement of anxiety 
symptoms in sertraline participants. Unfortunately, we were not able to discern any 
predictors for long-term treatment outcome in sertraline participants. Some of the 
documented predictors of treatment effect found in mixed-age populations, such as 
duration of symptoms for both CBT and pharmacological treatment outcome 
(Solvason et al., 2003; Slaap et al., 2001; Stein et al., 2001; Scheibe et al., 1997; 
Katschnig et al., 1995), and depressive symptoms for pharmacological treatment 
outcome (Denys et al., 2003; Stein et al., 2001) were not found to be related to 
outcome in our study. It should be noted however, that some of the analyses 
reported in this study may have failed to reach statistical significance due to small 
sample size (see section on ‘limitations’). 
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Limitations
The main limitation to the present study was its lack of power due to small sample 
size, differences in sample size between treatment conditions (see chapter 4) and loss 
of subjects for follow-up measurements. As a consequence, certain predictors of 
treatment effect may have been overlooked.  
Although treatment results for sertraline in this study seem promising, it should be 
held into account that all analyses in the present study were based on completers and 
that the use of sertraline was maintained during follow-up in at least 50% of 
sertraline participants, which may have biased the comparison with CBT. 
Furthermore, since the review board for medical ethics did not grant us permission 
to allocate older adults to a placebo condition, we can not be certain if treatment 
effect should be solely attributed to the use of sertraline. However, the fact that 
treatment results were maintained during a one-year follow-up period makes it less 
plausible that treatment effect is attributable to a placebo-effect (Quitkin et al., 1987).
No significant predictors of long-term sertraline treatment effect were found in this 
investigation. However, some of the predictors of drug treatment effect reported in 
studies in mixed-age populations were not included in the present study, such as the 
presence of certain early side effects (Solvason et al., 2003) and unfamiliarity with 
psychopharmacological treatment (Solvason et al., 2003; Stein et al., 2001). Also, the 
sertraline group was markedly smaller than the CBT group, resulting in a substantial 
difference in statistical power to detect possible predictors of treatment effect 
between the two conditions. 
Finally, it should be noted that participants were not requested to refrain from 
seeking additional treatment during follow-up and seven participants received 
additional treatment during follow-up at one of our research centres, which may 
have biased our results. 
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Recommendations and conclusions 
Long-term outcome analyses of the present study suggest that sertraline might be 
more beneficial for the treatment of late-life anxiety than CBT. Our results clearly call 
for more studies on the pharmacological treatment of late-life anxiety with SSRIs, 
involving larger samples and a placebo condition to establish true drug response. For 
anxious older adults, the barrier to seeking psychotherapeutic treatment from a 
mental health care specialist is high, due to logistic problems (e.g. transportation), the 
psychological strain involved in psychotherapy and the stigma on psychiatric care 
for this generation. Drug treatment with SSRIs may provide a solution to this 
problem, as in most cases the medication can be prescribed by the general 
practitioner. However, for those anxious older adults who are reluctant to take 
medication or who have a somatic disease that provides a contra-indication for the 
use of SSRIs, psychological interventions are necessary. Short-term psychological 
interventions provided in a primary care setting may be more cost-effective and 
moreover, more accessible to this particular group, than a relatively long and 
straining cognitive behavioral treatment in a psychiatric setting. One study provides 
limited support for a short-term CBT intervention for late-life anxiety in primary care 
(Stanley et al., 2003b), but more research is needed to develop effective primary care 
interventions for this population. 
Poor perceived health and neuroticism seem to be predictive of CBT treatment 
failure in anxious older adults. Greater initial severity of anxiety seems to be 
predictive of a greater short-term treatment effect of sertraline in anxious older 
adults. Future comparative treatment studies of CBT and SSRIs for late-life anxiety 
should include other possible predictors of treatment effect, such as the presence of 
certain (early) side effects, unfamiliarity with drug treatment, comorbid medication 
use and medical conditions. This could provide more cues for clinical practice to 
establish the preferred type of treatment for a certain individual. 
CHAPTER 5  LONG-TERM EFFECTIVENESS AND PREDICTION OF TREATMENT OUTCOME 
IN CBT AND SERTRALINE FOR LATE-LIFE ANXIETY DISORDERS
113
References
American Psychiatric Association (1994). Diagnostic and statistical manual of mental 
disorders-text revision. (4th ed.) Washington, DC: Author. 
Barrowclough, C., King, P., Colville, J., Russell, E., Burns, A. & Tarrier, N. (2001). A 
randomized trial of the effectiveness of cognitive-behavioral therapy and supportive 
counseling for anxiety symptoms in older adults. J.Consult Clin.Psychol., 69, 756-762. 
Beck, A. T. & Steer, R. A. (1990). Manual for the Beck Anxiety Inventory. San Antonio, TX: 
Psychological Corporation. 
Butler, G. (1993). Predicting outcome after treatment for generalised anxiety disorder. 
Behav.Res.Ther., 31, 211-213. 
Clark, L. A., Watson, D. & Mineka, S. (1994). Temperament, personality, and the mood and 
anxiety disorders. J.Abnorm.Psychol., 103, 103-116. 
Cohen, J. (1988). Statistical power analysis for the behavioral sciences. (2nd ed.) Hillsdale, NJ: 
Erlbaum.
Denys, D., Burger, H., van Megen, H., de Geus, F. & Westenberg, H. (2003). A score for 
predicting response to pharmacotherapy in obsessive-compulsive disorder. 
Int.Clin.Psychopharmacol., 18, 315-322. 
Eysenck, H. J. & Eysenck, S. B. (1968). Manual for the Eysenck Personality Inventory. San 
Diego: Educational and Industrial Testing Service. 
Eysenck, S. B. G., Eysenck, H. J. and Barret, P. (1985). A revised version of the psychoticism 
scale. Personality and Inidividual Differences, 6, 21-29. 
Flint, A. J. (1994). Epidemiology and comorbidity of anxiety disorders in the elderly. Am J 
Psychiatry, 151, 640-649. 
Folstein, M. E., Folstein, S. E. and McHugh, P. R. (1975). Mini-mental state: a practical 
method for grading the cognitive state of patients for the clinician. Journal of Psychiatric 
Research, 12, 189-198. 
CHAPTER 5  LONG-TERM EFFECTIVENESS AND PREDICTION OF TREATMENT OUTCOME 
IN CBT AND SERTRALINE FOR LATE-LIFE ANXIETY DISORDERS
114
Gibbons, R. D., Hedeker, D., Elkin, I., Waternaux, C., Kraemer, H. C., Greenhouse, J. B. et al. 
(1993). Some conceptual and statistical issues in analysis of longitudinal psychiatric data. 
Application to the NIMH treatment of Depression Collaborative Research Program dataset. 
Arch.Gen.Psychiatry, 50, 739-750. 
Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical 
Psychology 32, 50-55. Hersen, M. and van Hasselt, V. B. (1992). Behavioral assessment and 
treatment of anxiety in the elderly. Clin.Psychol.Rev., 12, 619-640. 
Katschnig, H., Amering, M., Stolk, J. M., Klerman, G. L., Ballenger, J. C., Briggs, A. et al. 
(1995). Long-term follow-up after a drug trial for panic disorder. Br.J.Psychiatry, 167, 487-
494.
Mohlman, J. (2004b). Psychosocial treatment of late-life generalized anxiety disorder: current 
status and future directions. Clin.Psychol.Rev., 24, 149-169. 
Nordhus, I. H. & Pallesen, S. (2003). Psychological treatment of late-life anxiety: an empirical 
review. J.Consult Clin.Psychol., 71, 643-651. 
Ost, L. G. (1990). The Agoraphobia Scale: an evaluation of its reliability and validity. 
Behav.Res.Ther., 28, 323-329. 
Quitkin, F. M., Rabkin, J. D., Markowitz, J. M., Stewart, J. W., McGrath, P. J. & Harrison, W. 
(1987). Use of pattern analysis to identify true drug response. A replication. 
Arch.Gen.Psychiatry, 44, 259-264. 
Radloff, L. S. (1977). The CES-D scale: a self-report depression scale for research in the 
general population. Applied Psychological Measures, 1, 385-401. 
Rijsoort, S. van, Emmelkamp, P. M. G. and Vervaeke, G. (1999). The Penn State Worry 
Questionnaire and the Worry Domains Questionnaire: structure, reliability and validity. 
Clinical Psychology and Psychotherapy, 6, 297-307. 
Scheibe, G. & Albus, M. (1996). Predictors of outcome in panic disorder: a 5-year prospective 
follow-up study. J.Affect.Disord., 41, 111-116. 
Scheibe, G. & Albus, M. (1997). Predictors and outcome in panic disorder: a 2-year 
prospective follow-up study. Psychopathology, 30, 177-184. 
CHAPTER 5  LONG-TERM EFFECTIVENESS AND PREDICTION OF TREATMENT OUTCOME 
IN CBT AND SERTRALINE FOR LATE-LIFE ANXIETY DISORDERS
115
Scholing, A. & Emmelkamp, P. M. (1999). Prediction of treatment outcome in social phobia: a 
cross-validation. Behav.Res.Ther., 37, 659-670. 
Schuurmans, J., Comijs, H. C., Beekman, A. T. F., de Beurs, E., Deeg, D. J. H., Emmelkamp, P. 
M. G. et al. (2005). The outcome of anxiety disorders in older people at 6 year follow-up: 
results from the Longitudinal Aging Study Amsterdam. Acta Psychiatr.Scand., 111, 420-428 
Seivewright, H., Tyrer, P. & Johnson, T. (1998). Prediction of outcome in neurotic disorder: a 
5-year prospective study. Psychol.Med., 28, 1149-1157. 
Slaap, B. R. & den Boer, J. A. (2001). The prediction of nonresponse to pharmacotherapy in 
panic disorder: a review. Depress.Anxiety., 14, 112-122. 
Solvason, H. B., Ernst, H. & Roth, W. (2003c). Predictors of response in anxiety disorders. 
Psychiatr.Clin.North Am., 26, 411-433. 
Stanley, M. A., Beck, J. G. and Glassco, J. D. (1996). Treatment of generalized anxiety in older 
adults: A preliminary comparison of cognitive-behavioral and supportive approaches. 
Behavior Therapy, 27, 565-581. 
Stanley, M. A., Hopko, D. R., Diefenbach, G. J., Bourland, S. L., Rodriguez, H. & Wagener, P. 
(2003). Cognitive-behavior therapy for late-life generalized anxiety disorder in primary care: 
preliminary findings. Am.J.Geriatr.Psychiatry, 11, 92-96. 
Stein, D. J., Montgomery, S. A., Kasper, S. & Tanghoj, P. (2001a). Predictors of response to 
pharmacotherapy with citalopram in obsessive-compulsive disorder. 
Int.Clin.Psychopharmacol., 16, 357-361. 
Stein, D. J., Stein, M. B., Pitts, C. D., Kumar, R. & Hunter, B. (2002). Predictors of response to 
pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine 
trials. J.Clin.Psychiatry, 63, 152-155. 
Steketee, G. and Chambless, D. L. (1992). Methodological issues in prediction of treatment 
outcome. Clinical Psychology Review, 15, 317-346. 
Stewart, A. L., Hays, R. D. & Ware, J. E., Jr. (1988). The MOS short-form general health 
survey. Reliability and validity in a patient population. Med.Care, 26, 724-735. 
CHAPTER 5  LONG-TERM EFFECTIVENESS AND PREDICTION OF TREATMENT OUTCOME 
IN CBT AND SERTRALINE FOR LATE-LIFE ANXIETY DISORDERS
116
Wetherell, J. L., Gatz, M. & Craske, M. G. (2003). Treatment of generalized anxiety disorder 
in older adults. J.Consult Clin.Psychol., 71, 31-40. 


CHAPTER 6  ATTRITION AND RECRUITMENT IN A LATE-LIFE ANXIETY TREATMENT STUDY
119
Attrition and recruitment in a
late-life anxiety treatment study. 
Abstract 
Objective: To study variables related to acceptability of treatment and to investigate a 
possible bias in treatment studies of late-life anxiety as a result of high attrition rates and the 
recruitment of participants from the general population. Method: Data from a randomized 
controlled trial of CBT versus sertraline for late-life anxiety were used to analyze differences 
between treatment refusers and dropouts versus completers and between recruited and 
clinically referred participants. Results: CBT dropouts were found to have a higher 
neuroticism score and a higher rate of comorbid depression at baseline than CBT completers, 
whilst sertraline dropouts showed lower rates of comorbid depression than sertraline 
completers. Recruited participants were found to be more educated and less severely 
impaired, both physically and mentally, than referred participants. Conclusions:
Recruitment of participants from the general population may lead to a selection bias of 
relatively healthy subjects for late-life anxiety treatment studies. SSRIs may be more 
acceptable to anxious older adults with comorbid depression whilst CBT might be more 
appropriate to those low in neuroticism and without a comorbid depression.  
Schuurmans, J., Comijs, H.C., Emmelkamp, P.M.G., Weijnen, I.J.C., van Hout, M.A., van Dyck, R.  
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Treatment studies of late-life anxiety (Stanley et al., 2003a; Stanley et al., 1996; 
Wetherell et al., 2003a) tend to have two characteristics in common: high attrition 
rates and a painstaking recruitment process, which is often largely accomplished 
through media announcements (Akkerman et al., 2001; Wetherell et al., 2001). The 
fact that both characteristics carry a risk for potential bias of research findings is a 
disregarded area in the literature on late-life anxiety treatments. 
Reported dropout rates in CBT treatment studies of late-life anxiety vary from 23% to 
33% (Stanley et al., 2003a; Stanley et al., 1996; Wetherell et al., 2003a), whereas 
reported dropout rates in similar treatment studies in mixed-age populations center 
around 10% (Gould et al., 2004). High attrition poses a problem for treatment studies 
of late-life anxiety in two ways: 1) It affects the validity and generalizability of results 
from treatment studies; 2) it has serious implications for the effectiveness of 
treatment of late-life anxiety in everyday practice, for what good is any given 
treatment if approximately a quarter to a third of your target population will not 
even complete treatment? It is important to take into account here that attrition rates 
in non-trial settings may be even higher, since researchers tend to put more effort 
into retaining patients for their study than a therapist would do in a ‘normal’ 
psychotherapeutic setting. Hunt and Andrews (1992) suggest that the dropout rate in 
treatment studies may not be attributable to patient characteristics, but should 
instead be viewed as a performance indicator of the treatment. They claim that 
dropout rates might be related to treatment factors, such as the level of effectiveness 
and efficiency (level of structure, time-limits) of the treatment given. In concordance, 
a meta-analysis of dropout in psychological outreach programmes for depressed 
older adults found that the dropout rate was particularly high in cognitive 
behavioral therapies when compared to several other interventions (including 
behavior therapy, psychodynamic therapy, bibliotherapy). The dropout rate was also 
higher in group interventions when compared to individual interventions and in 
lengthier versus shorter interventions (Cuijpers, 1998). In any case, dropout rates can 
be viewed as a measure of how acceptable a given treatment is to a particular group 
and in that respect, the performance of CBT for late-life anxiety leaves much to be 
desired. It has been suggested that logistic problems (e.g. transportation), resulting 
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from a higher prevalence of poor health and disability among older adults, are 
responsible for the differences in attrition rates between treatment studies of anxiety 
in younger versus older adults (Stanley et al., 2003), but this hypothesis awaits 
scientific testing. Poor health has been found to be related to dropout in one study of 
attritition in a mixed-age outpatient clinic for anxiety disorders (Issakidis et al., 2004).
With respect to the treatment of late-life anxiety with SSRIs, data on effectiveness and 
attrition rates are scarce. Researchers and clinicians have advocated the development 
of psychotherapeutic interventions (Nordhus et al., 2003; Hersen et al., 1992), because 
SSRIs might not be well-tolerated by older adults, especially in case of somatic 
comorbidity. It would be interesting to investigate whether physical health is indeed 
related to early termination of pharmacological treatment in older adults. Recently, 
the authors of the present study completed the first randomized controlled trial of 
cognitive behavioral therapy (CBT) versus an SSRI (sertraline) for the treatment of 
anxiety in older adults. Although dropout rates did not differ significantly between 
the two treatment conditions, dropout rates were marginally higher for sertraline 
(28%) than for CBT (23%). Seventeen percent (n=5) of participants originally 
randomized to sertraline reported adverse side effects as a reason for dropping out of 
the trial.
In order to become aware of a possible bias in treatment studies of late-life anxiety 
and to develop avenues for improving treatment adherence in anxious older adults, 
it is vital to know why people drop out of treatment and what characteristics set 
them apart from completers. Until now, no systematic study has been undertaken to 
this effect. Furthermore, determining differential characteristics of CBT dropouts and 
SSRI dropouts might also provide us with information on which treatment is more 
acceptable to which type of patient. 
Another possible bias lies in the fact that most available treatment studies of late-life 
anxiety e.g. (Stanley et al., 2003; 1996; Wetherell et al., 2003a) actively recruited a 
large proportion or all of their participants through media announcements. 
Recruitment among referrals from mental health care centres is problematic, because 
anxious older adults are rarely appropriately referred and even when they are, 
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anxiety disorders often go unrecognized (Akkerman et al., 2001; Wetherell et al., 
2001). However, the fact that most participants of treatment studies of late-life 
anxiety are actively recruited by the researchers does endanger the generalizability of 
results. Some have argued that actively recruited participants might not define 
themselves as needing psychiatric help (Covi, Lipman, McNair & Czerlinsky, 1979), 
which might in turn affect motivation for treatment. Available data on this subject, 
although scarce and contradictory, suggest that active recruitment of subjects for 
clinical outcome studies might lead to considerable bias. Comparative studies 
between solicited and nonsolicited (mixed-age) populations in mental health 
treatment trials have reported pre-treatment symptomatology differences, 
demographic differences, differences in past psychiatric treatment, differences in 
illness duration and differences in attrition rates (Rapaport et al., 1996; Aronson, 
1987; Krupnick et al., 1986).
The present study uses data from a randomized controlled trial of CBT versus 
sertraline for late-life anxiety (see chapter 4) in order to investigate a possible bias in 
treatment studies of anxious older adults by determining the characteristic features 
of dropouts versus completers and of recruited versus clinically referred patients 
from mental health care centres in the treatment of late-life anxiety. Emmelkamp and 
van der Hout (1983) have made a distinction between nonacceptance (a refusal to 
start the treatment offered) and dropout during treatment. Most studies tend to 
disregard nonacceptance in their attrition analyses, stating that those who refuse 
treatment are different than treatment dropouts. Although this might be true, both 
treatment refusal and early termination of treatment can be regarded as a type of 
treatment failure (Emmelkamp et al., 1983) and it is well worth investigating whether 
and how treatment refusers are different from those who complete treatment and 
those who drop out of treatment. Therefore, treatment refusers are included in the 
present study as a separate group. However, results from these analyses should be 
interpreted with caution as treatment refusers constitute a very small subsample 
(n=3 in the CBT and n=4 in the sertraline condition). 
Method 
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Sample
Over a 3.5-year recruitment period, 160 older adults (aged 60 years and over) 
received a diagnostic interview, of whom 115 people (72%) fit the inclusion criteria 
and were invited to participate in a randomized controlled trial of CBT versus 
sertraline and a wait-list control group. Thirty-one patients (27%) refused before 
providing preliminary data. Eighty-four participants remained who read and signed 
an informed consent form prior to being randomly assigned to CBT (n=42), sertraline 
(n=29) and wait-list (n=13). Sample sizes are unequal because 1) we planned for 
fewer subjects in the wait-list condition and 2) we planned for 150 subjects in our 
randomization procedures, but despite great efforts to contact participants for the 
study, unfortunately we were unable to reach these numbers (see chapter 4 for more 
details on the randomization procedures). Participants included 84 adults, aged 60 
years and over, with a principal Diagnostic and Statistical Manual of Mental 
Disorders (4th ed., American Psychiatric Association, 1994) diagnosis of panic 
disorder (either with or without agoraphobia) (n=38; 45.2%), GAD (n=29; 34.5%), 
social phobia (n=9; 10.7%) or agoraphobia without a history of panic disorder (n=8; 
9.5%). Exclusion criteria were the presence of an organic condition that provided a 
contra-indication for the use of selective serotonin reuptake inhibitors, current use of 
antidepressant medication, a comorbid diagnosis of alcohol dependency, current 
participation in psychotherapy, a history of psychosis or cognitive impairment as 
indicated by clinical impression and a score of less than 26 on the Mini-Mental State 
Examination (Folstein et al., 1975). The presence of comorbid depression, dysthymia, 
or other anxiety disorders was not a basis for exclusion from the study, as long as the 
principal diagnosis was GAD, panic disorder, agoraphobia or social phobia. Principal 
diagnosis was defined as the most severely disabling disorder at the present time. 
Participants were recruited from 2000 to 2003 through various types of media 
announcements (articles in regional newspapers, interviews broadcasted on radio 
and television), distribution of information leaflets in pharmacies and clinics for 
general practice (the actively recruited participants) and among referrals for 
treatment to community mental health centres and out-patient clinics in five cities in 
the western and southern part of the Netherlands (the clinically referred 
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participants). All participants were selected on the basis of a structured diagnostic 
interview (SCID 2.0; First et al., 1999), administered by psychologists who had 
received extensive training in this instrument. 
Participants were predominantly female (n=62; 73.8%) and 47 participants were 
married (56.0%). Age at entering the treatment study ranged from 61 to 83 years, 
with a mean age of 69.8 years. Age of onset of anxiety was ‘late’ (at or after the age of 
60) in 29 cases (34.5%). Duration of anxiety ranged from two months to 63 years, with 
a mean duration of 26 years. Thirty-three participants (39.3%) were clinically referred 
to one of the participating mental health care centres, 51 participants (60.7%) 
responded to media announcements or information leaflets. Sixty-seven participants 
(79.8%) suffered from some form of chronic disease. Chronic diseases that were most 
common among participants were hypertension (n=28; 33.3%), cardiovascular 
diseases (n=19; 22.6%) and arthritis (n= 28, 33.3%). Forty-one participants (48.8%) 
used one or more benzodiazepines. Comorbid psychiatric diagnoses consisted 
mainly of specific phobia (n=24; 28.6%), other anxiety disorders (n=36; 42.9%), and 
depression (n=17; 20.2%).
Ten (11.9%) of 84 patients refused participation in the trial immediately after 
randomization, four of whom were assigned to sertraline, three to CBT and three to 
the wait-list condition. Another 17 participants (20.2%) dropped out of the trial 
before completing CBT (n=9), sertraline (n=7) or wait list conditions (n=1), 
culminating in a total attrition rate of 32% (27 of the initial sample of 84 participants). 
There were no significant differences in attrition rates across treatment groups. 
Reasons mentioned for dropout from CBT included: Treatment was found to be too 
straining or confronting (n=2); treatment was found to be too time-consuming (n=2); 
participants did not agree with the treatment rationale (n=5) and spontaneous 
remission of symptoms (n=4). Reasons mentioned for dropout from sertraline 
included: long-term illness (n=1), deceased due to natural causes before starting 
medication (n=1), side-effects (n = 4), anticipated side-effects before actually starting 
medication (n=1) and spontaneous remission of symptoms (n=1) (see chapter 4). 
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The treatment conditions 
Participants in the CBT condition received 15 weekly individual one-hour sessions by 
a certified behavior therapist. CBT consisted of relaxation training, cognitive 
restructuring and exposure. Treatment protocols for CBT were derived from 
prevailing treatment protocols of panic disorder (Clark et al., 1986), GAD (Borkovec 
et al., 1993) and social phobia (Scholing et al., 1995) in mixed-age populations which 
were adapted for use with older adults (e.g. 15 in stead of the regular eight or ten 
sessions, examples were made more suitable for an older population, more attention 
to psycho-education and repeated explanation and revision of new information and 
newly learned coping skills). Participating therapists attended regular supervision 
meetings, which were led by certified supervisors for behavior therapy (P.M.G. 
Emmelkamp and I.J.C. Weijnen). Participants in the sertraline condition were treated 
by a psychiatrist or a resident-psychiatrist in eight 20-minute sessions over a period 
of 15 weeks. Dosage schedules for sertraline were adapted for older adults; the 
starter dose was lower (25 mg) and the dosage was built up more gradually than in 
the customary procedure (up to a minimum dose of 100 mg which had to be reached 
within 4 weeks and a maximum dose of 150 mg on the basis of tolerability and lack 
of clinical response).
Demographic and clinical characteristics 
Completers, treatment refusers and treatment dropouts were compared on several 
demographic and clinical characteristics which were measured at baseline. 
Demographic characteristics include age, sex, marital status (married versus not 
married) and level of education (classified as low, medium or high). Perceived health 
was measured with a subscale of the MOS-20 (Stewart et al., 1988; Cronbach’s alpha= 
.86). Clinical variables include the presence of comorbid depression as established 
with the SCID 2.0, duration of illness in years and pre-test scores on the Hamilton 
Anxiety Rating Scale (HARS; Hamilton, 1959; Cronbach’s alpha = .82) and the 
neuroticism subscale of the Eysenck Personality Questionnaire-revised, (EPQ-R; 
Eysenck et al., 1968; Eysenck et al., 1985, Cronbach’s alpha = .78).
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Data analyses 
Wait-list participants were excluded from analyses of attrition, but not from analyses 
involving the type of referral. We hypothesized that different factors would be 
involved in refusal or dropout from a psychopharmacological treatment as opposed 
to a psychological intervention. Therefore, the attrition analyses were performed 
seperately for each treatment modality. Treatment dropouts and treatment refusers 
were compared to completers on all relevant demographic and clinical variables 
measured at baseline in two separate series of analyses using 2 tests and t tests. 
Recruited and clinically referred participants were compared on the same variables 
using 2 tests and t tests. 
Results
Number of sessions 
For CBT dropouts, the number of sessions attended ranged from one to seven (out of 
a total number of 15 sessions). For sertraline dropouts, the number of sessions 
attended ranged from one to three (out of a total number of eight sessions). 
Characteristics of dropouts and refusers versus completers 
Dropouts and refusers were compared to completers on all relevant pre-treatment 
characteristics using separate 2 tests and t tests for each treatment condition. 
CBT dropouts and refusers 
Treatment dropouts were not significantly different from completers with respect to 
age, distribution of sex, marital status, education and perceived health (see table 1; 
next page). However, CBT dropouts had a shorter duration of illness (mean duration 
12.9 versus 27.9 years; t(36) = 2.33, p<.05) than CBT completers. Also, pre-test scores 
on the Neuroticism subscale of the EPQ-R (t(35)= -3.87, p<.01) were significantly 
higher in CBT dropouts than in CBT completers and CBT dropouts had a higher rate 
of comorbid depression (44.4% versus 10.0%; 2(1) =5.58, p<.05).
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Similarly, CBT refusers had a shorter duration of illness (mean duration 6.1 versus 
27.9 years; t(31)=3.53, p<.01) than CBT completers. However, CBT refusers did not 
differ from CBT completers on any measure of illness severity or the presence of 
comorbid depression as measured at baseline.
Table 1. Distribution of pre-test characteristics between 
completers, refusers and dropouts in CBT 
Variable CBT (n=42) 






Age M (SD) 70.60 (6.52) 73.67 (9.02) 70.11 (6.60) 
Female n (%) 21 (70.0) 3 (100.0) 7 (77.8) 
Married n (%) 17 (56.7) 2 (66.7) 4(44.4) 
Education M (SD) 1.87 (.90) 1.67 (1.16) 2.11 (.93) 
Perceived health M (SD) 15.63 (5.54) 20.90 (4.90) 11.47 (4.84) 
Duration of illness (yrs) M (SD) 27.85 (25.20) 6.06 (7.14)** 12.88 (12.65)* 
Comorbid depression n (%) 3(10.0) 0 (0) 4(44.4)* 
Anxiety score (HARS) M (SD) 14.48 (8.00) 14.33 (4.93) 19.75 (6.14) 
Neuroticism (EPQ-R) M (SD) 7.37 (3.32) 6.67 (4.16) 10.56 (1.59)** 
*Significant 2 or t test of refusers or dropouts versus completers at p<.05 level 
** Significant 2 or t test of refusers or dropouts versus completers at p<.01 level 
Sertraline dropouts and refusers 
Table 2 (next page) shows that none of the sertraline dropouts suffered from a 
comorbid depression, whereas 44% of sertraline completers suffered from a 
comorbid depression ( 2 = 6.75, p<.01). Sertraline dropouts did not differ from 
completers on any of the other clinical or demographic variables. No significant 
differences were found between sertraline refusers and sertraline completers on any 
of the variables. However, as can be seen in table 2, sertraline refusers were similar to 
sertraline dropouts with respect to the absence of comorbid depression. 
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Table 2. Distribution of pre-test characteristics between 
completers, refusers and dropouts in the sertraline condition 
Variable Sertraline (n=29) 






Age M (SD) 69.72 (5.92) 70.75 (1.89) 69.43 (6.24) 
Female n (%) 13 (72.2) 4 (100.0) 5 (71.4) 
Married n (%) 13 (76.5) 2 (50.0) 3 (42.9) 
Education M (SD) 1.94 (.80) 2.00 (1.16) 1.43 (.54) 
Perceived health M (SD) 13.69 (4.81) 10.99 (1.41) 16.52 (4.11) 
Duration of illness (yrs) M (SD) 31.79 (23.42) 22.63 (26.05) 29.29 (22.46) 
Comorbid depression n (%) 8 (44.4) 0 (0) 0 (0)* 
Anxiety score (HARS) M (SD) 18.32 (8.20) 14.67 (.58) 19.56 (9.32) 
Neuroticism (EPQ-R) M (SD) 9.27 (2.40) 9.33 (1.53) 8.33 (.82) 
*Significant 2 or t test of refusers or dropouts versus completers at p<.05 level 
Characteristics of recruited versus clinically referred participants 
There was a significant difference in the distribution of sex between recruited and 
referred participants, with more males in the recruited group versus the referred 
group (see table 3 on the next page: 35.3% versus 12.1%; 2(1)= 5.57, p<.05). Recruited 
participants were also more educated than clinically referred participants (t(82)= -
2.94, p<.01). Perceived health was higher (t(71)=-2.89, p<.01) and neuroticism 
(t(73)=2.39, p<.05) and anxiety scores (t(79)=5.12, p<.001) were lower in recruited 
participants. Rates of comorbid depression (11.8% versus 33.3%; 2(1)=5.77, p<.05) 
were significantly lower in recruited participants than in clinically referred 
participants.
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Table 3. Distribution of pre-test characteristics between 
recruited and clinically referred participants 
Variable  Recruited (n=51) Clinically referred (n=33) 
Age M (SD) 69.61 (6.42) 70.09 (5.94) 
Female n (%) 33 (64.7) 29 (87.9)* 
Married n (%) 30 (58.8) 17 (53.1) 
Education M (SD) 2.08 (.85) 1.55 (.75)** 
Perceived health M (SD) 15.86 (5.11)) 12.32 (4.80)** 
Duration of symptoms (yrs) M (SD) 27.08 (22.54) 24.61 (25.27) 
Comorbid depression n (%) 6 (11.8) 11 (33.3)* 
Anxiety score (HARS) M (SD) 13.67 (5.96) 21.86 (8.41)** 
Neuroticism (EPQ-R) M (SD) 7.74 (2.64) 9.31 (3.02)* 
*Significant 2 or t test at p<.05 level 
** Significant 2 or t test at p<.01 level 
Discussion
Attrition 
The present study is the first to systematically study differences in variables related 
to attrition in CBT versus variables related to attrition in pharmacological treatment 
(sertraline) for late-life anxiety disorders. Our most salient finding pertaining to this 
subject is that CBT dropouts seemed to suffer from higher rates of comorbid 
depression and showed higher trait anxiety (reflected in higher neuroticism scores) 
than CBT completers, whilst in contrast, sertraline dropouts showed lower rates of 
comorbid depression and did not differ from sertraline completers on neuroticism 
scores. In fact, none of the sertraline dropouts suffered from a comorbid depression 
compared to 44% of sertraline completers. These findings suggest that SSRIs might 
be more acceptable to anxious older adults with comorbid depression, whilst CBT 
may be more acceptable to anxious older adults low in neuroticism who do not suffer 
from such comorbidity. Our research group has also found neuroticism to be related 
to a persistent long-term outcome of late-life anxiety (see chapter 3) and to an 
unsuccesful treatment outcome of CBT for late-life anxiety (see chapter 5). 
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Apparently, anxious older adults high in neuroticism constitute a group that is 
particularly difficult to treat.
The fact that our results suggest that those with higher trait anxiety and a higher rate 
of comorbid depression tend to drop out of CBT prematurely bears several 
consequences, not only for the practice of treatment for late-life anxiety disorders, but 
also for the interpretation of treatment studies (especially since comorbid depression 
is highly prevalent in late-life anxiety (van Balkom et al., 2000). 
Contrary to suggestions that poor health might be an obstacle to the acceptability of 
both CBT (Stanley et al., 2003) and pharmacological interventions (Nordhus et al., 
2003; Hersen et al., 1992) for late-life anxiety, we did not find perceived health to be 
related to treatment dropout or refusal in either treatment condition. However, 
findings pertaining to this subject are inconclusive as we failed to take into account 
other possibly more objective health related variables (e.g. number and nature of 
chronic illnesses) and our sample size was relatively small. 
On a different note, we found that both CBT dropouts and refusers had a shorter 
duration of illness (mean duration 12.9 and 6.1 years respectively versus 27.9 years) 
than CBT completers. This finding runs contrary to the frequently voiced clinical 
impression that a long duration of illness in older adults might lead them to be less 
motivated for treatment. 
Interestingly, refusal and dropout were not found to be related to the same variables, 
apart from illness duration in those randomized to CBT. In fact, in some respects 
treatment refusers seem to be more comparable to treatment completers than to 
treatment dropouts. CBT refusers did not differ from completers on rates of 
comorbid depression or neuroticism. Maybe those who refuse CBT after 
randomisation tend to do so simply because they do not agree with this choice of 
treatment, while those who end CBT prematurely tend to do so because they find it 
too straining. However, CBT refusers constituted a very small subsample in the 
present study (n=3) and studies investigating larger samples are needed to confirm 
these findings. 
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Characteristics of recruited participants versus referred mental health 
care patients 
Although some studies have examined possible recruitment biases in treatment 
studies in mixed-age populations, ours was the first to study variables related to 
recruitment strategy in the treatment of late-life anxiety disorders. Media recruitment 
is frequently employed in this type of research, since older adults with anxiety 
disorders do not tend to seek specialized treatment for psychological symptoms and 
are seldomly referred to mental health care centres. In the treatment study by our 
research group (see chapter 4), participants were both actively recruited and 
clinically referred, making it possible to study differences between both groups. 
Recruited participants were found to be less severly impaired in several respects; 
with regard to initial severity of anxiety (as measured with the HARS), neuroticism, 
rates of comorbid depression and perceived health. Furthermore, recruited 
participants generally had a higher level of education than clinically referred 
participants. These results imply that findings from treatment studies of late-life 
anxiety might be based on a select population of anxious older adults who are 
relatively healthy, have relatively mild symptoms and are relatively well educated 
(Stanley et al., 2003b). Alternatively, one could claim that anxiety in older adults only 
leads to appropriate referral when symptoms are very severe. It would be interesting 
in this respect to compare illness severity between older and younger anxious adults 
who are presented to mental health care settings. 
On a different note, the fact that there were more males among the recruited group 
than among the clinically referred group suggests that media recruitment might be 
an effective way to lower the threshold for older men to enter therapy. 
Recommendations and conclusions 
Treatment trials of late-life anxiety that have been conducted in the last ten years 
focus on media recruited populations, which may lead to a selection bias of relatively 
healthy subjects (both physically and mentally), who actually might not need such an 
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intensive and time-consuming intervention. This may also partly explain why studies 
of this kind tend to find lower effect sizes and higher attrition rates than those found 
in similar studies with mixed-age populations. Also, the threshold for a 
psychological intervention at a mental health care centre appears to be very high for 
anxious older adults. We may need to present treatment in other, more neutral 
settings, and in more neutral terminology (e.g. ‘tension’ in stead of ‘anxiety’, 
‘courses’ in stead of ‘therapy’; Wetherell et al., 2001).
Our results also suggest that SSRIs may be the treatment of choice for anxious older 
adults with comorbid depressive symptoms. However, older adults tend to be 
reluctant to take medication for psychological symptoms and it is vital that patients 
are closely informed and monitored by their physician, in order to eliminate 
prejudice and increase treatment adherence (Wetherell & Unutzer, 2003b). 
Consultation from a psychiatrist preceding the administration and monitoring of 
SSRIs by the general practitioner would be advisable. 
Psychological interventions might be more appropriate and acceptable to older 
adults low in neuroticism and without a comorbid depression. The question we are 
faced with is whether CBT is the psychological intervention of choice for this 
particular group and whether this treatment may not be too time-consuming, 
complicated and straining for those with relatively mild symptoms. Short-term 
primary care interventions (based on behavioural techniques with less focus on 
complicated cognitive techniques) may constitute an effective and efficient 
psychological treatment which is more acceptable to this particular group. Future 
research efforts in the field of late-life anxiety treatments might do well to focus on 
comparative trials of such interventions versus pharmacological treatment with 
SSRIs monitored by the general practitioner. 
In interpreting the results of the present study, it is important to take into account 
that analyses were performed on a relatively small study sample, increasing the risk 
of chance-findings. Studies involving larger samples (for example by performing a 
meta-analysis of attrition and recruitment in the available treatment studies of late-
life anxiety to date) are needed to confirm our findings.  
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General discussion. 
Moving toward a tailored treatment for anxiety in late life 
Preface
The present thesis originated from the notion described in chapter 1, that 1) anxiety 
in late life is an important problem that merits separate study; and 2) the treatment of 
late-life anxiety is a feasible enterprise which can be achieved with roughly the same 
treatments that are successfully applied to younger populations.  
In the course of our investigations, some of our assumptions have been confirmed, 
while others have been severely tested and modified in the process. In the present 
chapter, findings from the studies described in chapter 2 through chapter 6 are 
integrated and discussed. We specifically address the consequences of our findings 
for the assumptions with which we entered our investigations. A critical appraisal is 
given of the extent to which our endeavors contribute to the development of a 
tailored treatment of anxiety in late life. Attention is also paid to the methodological 
limitations of our studies and the implications of our findings for clinical practice. 
Finally, we provide specific recommendations for further research efforts that are 
needed to complete the journey toward a tailored treatment for late-life anxiety 
disorders.
Implications of the main findings of the present thesis 
Cues for the existence of a specific age-related phenomenology of late-
life anxiety 
One of the main obstacles in providing adequate treatment to anxious older adults is 
the fact that anxiety is often not appropriately identified in late life. We hypothesized 
that differences in the phenomenology of anxiety between younger and older adults 
might partly be accountable for this problem, and therefore we conducted a study in 
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the general population that investigated this issue. A new questionnaire, the Senior 
Anxiety Scale (SAS), was specifically constructed to measure those cognitive contents 
of worry that we felt might differentiate older adults from their younger 
counterparts. Our findings implied that older adults tend to be more afraid than both 
young and middle-aged adults of possible physical and mental decline, the loss of 
autonomy and of life-threatening situations, such as criminal assault and death. 
These findings can probably be attributed to the fact that late life is a life phase that is 
typically related to a high rate of physical and mental decline and older adults are 
more often confronted with death and decline in their direct environment than 
young adults. The challenge in late life is not to let these fears become so 
overwhelming that the quality of life is more impaired by fears than by the reality of 
physical or mental decline.
Interpretation of our findings are limited by the fact that we had no data on actual 
physical or mental health of our sample, which makes it impossible to determine 
whether the higher rate of worry about these topics in the older sample may be solely 
interpreted as realistic. Our clinical impression is that older adults tend to 
overestimate certain risks, such as the risk of (for example) mental decline and the 
possibility that they might be admitted to a nursing home in the future. Our findings 
stress the importance of specific inquiry into the fear of physical and mental decline 
and life-threatening situations when diagnosing an older adult referred to mental 
health care.
Interestingly, we also found similarities on certain factors that we hypothesized 
would be different in older adults. The SAS incorporated items referring to worries 
about financial problems and worries about social isolation and disapproval because 
we expected older adults to score higher on these items than younger adults. This 
was not found to be the case. In fact, young and middle-aged adults seemed to show 
greater concern with regard to financial issues than older adults. Although we did 
find several age-related differences with regard to feared stimuli on the FSS, these 
differences seemed to have an onset in middle-aged adulthood rather than in late 
life. The only clear distinction between middle-aged and older adults we found was a 
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greater fear of sex and aggression in older adults, which is partly related to the 
greater fear of life-threatening situations found on the SAS. These results clearly 
stress the importance of testing our clinical impressions with regard to age-related 
fears in empirical studies. 
Prediction of the long-term outcome of late-life anxiety disorders 
In order to establish whether anxiety disorders have a similar tendency to show a 
persistent long-term outcome in late life as has been established in younger 
populations (Angst et al., 1991), chapter 3 reports on the outcome of anxiety 
disorders in a cohort of anxious older adults after a follow-up period of six years. 
Although 23% of our sample met criteria for an anxiety disorder and a further 47% 
met criteria for sub-clinical anxiety at six-year follow-up, we also found that a 
relatively high proportion (31%) of our sample met criteria for full remission at six-
year follow-up. If we may conclude that approximately one third of our target 
population recovers spontaneously, the question is raised which patients are at risk 
for a persistent outcome and should therefore be the focus of intervention programs 
to prevent chronicity.
Results described in chapter 3 indicate that those high in neuroticism are at greater 
risk for persistence of anxiety. Interestingly, neuroticism is also found to be strongly 
predictive of an unsuccessful long-term outcome of CBT for late-life anxiety 
disorders in chapter 5 and is found to be related to early termination of CBT for late-
life anxiety disorders in chapter 6. We also established that the meaning of 
neuroticism for long-term outcome can not be construed as a reflection of initial 
severity of anxiety symptoms. Neuroticism is generally regarded as a personality 
trait, reflecting negative affectivity (Clarke et al., 1982). However, as neuroticism was 
measured by self-report questionnaires (the DPV; Luteijn et al., 1985) in chapter 3 
and the EPQ-R (Eysenck et al., 1968; Eysenck et al., 1985) in chapter 5 and chapter 6, 
high neuroticism scores may also reflect the tendency to perceive oneself as a 
generally nervous and unstable person, i.e. the tendency to perceive one’s symptoms 
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as an unchangeable character trait rather than as something that may be cured. To 
illustrate, example items of the EPQ-R include ‘Do you regard yourself as a nervous 
person’ and ‘do you regard yourself as a worrisome person’. As described in chapter 
1, our clinical impression is that older adults tend to regard their symptoms as an 
unchangeable part of their personality, especially when these symptoms have an 
onset in early adulthood and have never been adequately treated. This disbelief in 
the possibility of change may hinder both spontaneous remission as well as the 
effective psychological treatment of anxiety in late life. High neuroticism scores do 
not seem to have any implications for the effectiveness of pharmacological treatment 
of late-life anxiety with an SSRI (see chapter 5). 
The treatment of anxiety disorders in older adults 
As described in chapter 1, the most common treatment of late-life anxiety disorders 
consisted of the prescription of benzodiazepines by the general practitioner. Findings 
described in chapter 3 imply that benzodiazepine use is still abundant among older 
adults with an anxiety disorder, while the use of SSRIs and mental health care 
facilities remains low, despite efforts made in recent years to enhance appropriate 
referral and treatment of late-life anxiety. Special interventions to aid the 
discontinuation of benzodiazepines in older adults may be necessary. A recent 
publication on long-term benzodiazepine use in a mixed-age population (mean age 
63.6 years) shows positive results of an intervention consisting of a letter sent by the 
general practitioner containing the advice to gradually discontinue benzodiazepine 
use (Gorgels et al., 2005). This letter was followed by a written invitation to arrange 
an appointment with the general practitioner to evaluate the actual use of 
benzodiazepines.
However, in older adults with an anxiety disorder, merely tapering off 
benzodiazepine use without offering a better alternative is not sufficient. In an effort 
to find support for alternative interventions for the treatment of anxiety in late life, 
chapter 4 and chapter 5 of the present thesis report on short-term and long-term 
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treatment outcome in the first comparative trial of CBT versus an SSRI (sertraline) for 
anxiety disorders in older adults. The main findings of this trial may be summarized 
by stating that CBT did not perform as well as expected and that sertraline might be 
more beneficial for the treatment of late-life anxiety than standard individual format 
CBT. Furthermore, our study provides added proof against the reluctance of 
clinicians and researchers to examine any kind of pharmacological intervention for 
late-life anxiety disorders. To some extent, findings regarding the effectiveness of 
CBT found in our RCT are in line with other late-life anxiety treatment studies, as 
CBT seems to produce lower effect sizes and higher attrition rates in anxious older 
adults than in similar younger populations (Stanley et al., 2003a; Wetherell et al., 
2003a; Stanley et al., 1996). However, CBT in our study did not perform as well as has 
been reported in other late-life anxiety treatment trials. This might partly be 
attributed to the fact that we included clinically referred participants as well as 
recruited participants in our trial, while most other treatment trials primarily 
recruited their participants through media announcements (Stanley et al., 2003a; 
Wetherell et al., 2003a; Stanley et al., 1996). As described in chapter 6, we found that 
clinically referred participants were less educated and more severely impaired at 
baseline in several respects than recruited participants. Clinically referred 
participants scored higher on initial anxiety and neuroticism and had a higher rate of 
comorbid depression. Moreover, clinically referred participants were found to score 
lower on a perceived health scale.
Results with regard to the prediction of treatment outcome (see chapter 5) indicate 
that neuroticism and poor perceived health are predictive of less improvement after 
CBT in anxious older adults. Also, neuroticism and comorbid depression are found 
to be related to early termination of CBT (chapter 6). These findings imply that other 
treatment studies of late-life anxiety might overestimate the effectiveness of CBT due 
to a selection bias of relatively healthy subjects.  
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What works for whom? 
When we set out our investigations for the present thesis, our aim was not merely to 
establish which treatment would be most effective for late-life anxiety disorders in 
general, but also to find indicators that might guide the preferred choice of treatment 
for a certain individual in clinical practice. Early termination of treatment can be 
regarded as a type of treatment failure (Emmelkamp et al., 1983) and in that respect, 
when trying to establish what works best for whom, it is important to study factors 
related to treatment dropout as well as factors related to a decrease in symptoms. 
When summarizing findings from our study on the prediction of treatment effect 
(chapter 5) and our study on factors related to attrition (chapter 6), it appears that 
CBT might be more appropriate for those that perceive themselves as fairly healthy, 
with low neuroticism scores and without a comorbid depression. Sertraline seems to 
be more appropriate for anxious older adults with a comorbid depression and 
greater initial severity of anxiety. The meaning of neuroticism has been addressed in 
a previous section of this chapter. With regard to the meaning of perceived health for 
the prediction of treatment effect, a recent publication on factors related to the self-
perception of health sheds an interesting light on this subject. In this study, subjective 
health was found to be highly correlated with self-report measures of subjective well-
being (life satisfaction, anxiety and depression) and the sense of coherence8, while 
correlations with objective health-related variables were insubstantial (Schneider et 
al., 2004). These findings imply that perceived health in older adults may be a 
reflection of certain coping mechanisms and psychological factors rather than an 
accurate measure of objective health. Therefore, we should be careful in concluding 
from our study that disabled or chronically ill older adults with anxiety disorders 
should not be referred to CBT. 
8 The sense of coherence (SOC) is defined as a personality orientation that “expresses the extent to 
which a person has a pervasive, enduring feeling of confidence that 1) the stimuli deriving from one’s 
internal and external environments in the course of living are structured, predictable and explicable 
(comprehensibility), (2) resources are available to meet the demands posed by these stimuli 
(manageability) and (3) these demands are challenges, worthy of investment and engagement 
(meaningfulness). Thus, SOC should be a personality orientation that facilitates coping with the health 
problems and disabilities of old age, influencing subjective health perception” (Schneider et al., 2004). 
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Feasibility of treatment for late-life anxiety disorders 
As described in chapter 6, the RCT that we conducted and other treatment studies of 
late-life anxiety share two common features; high attrition rates and an arduous 
recruitment process. Although the fact that anxious older adults are rarely seen in 
mental health care settings may be ascribed to a lack of appropriate diagnosis and 
referral as described in chapter 1, this only partly explains the difficulties that we 
encountered when trying to recruit and retain eligible patients for our study. Our 
RCT was a multi-center trial, which took place in two regions of the Netherlands: an 
urban region (Amsterdam) and a primarily rural region in the South of the 
Netherlands (Limburg). Seven mental health care centres participated in the RCT. 
Among patients that were clinically referred to one of these centres, we were able to 
include only 33 participants in the RCT over a period of 3.5 years. The other 51 
participants were recruited through announcements and interviews on television, 
radio and in local newspapers and through information leaflets distributed among 
pharmacies and general practitioner’s offices. Of the total sample of 84 participants, 
27 participants (32%) either refused treatment immediately after randomization 
(n=10) or ended treatment prematurely (n=17). On the basis of available data on the 
prevalence of anxiety disorders in late life, we set out to include 150 participants, but 
despite all our efforts we were not able to reach these numbers.  
How do we explain the discrepancy between available data on the prevalence and 
impact of late-life anxiety and the apparent reluctance of anxious older adults to 
enter into a specialized treatment in a mental health care setting? A frequently heard 
explanation is that older adults often suffer from physical difficulties that hinder the 
frequent visits to a mental health care setting. Although this may partly explain the 
discrepancy, in our own clinical experience and the numerous phone calls that we 
answered in response to our recruitment efforts, this was not an explanation that we 
encountered on a regular basis. Among those who dropped out of treatment 
prematurely, no-one indicated that physical limitations had anything to do with their 
decision (see chapters 4 and 6). Furthermore, treatment dropout was not found to be 
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related to perceived health in either treatment condition of our RCT (see chapter 6). 
Therefore, we have come to believe that other factors contribute to this phenomenon.  
As described in chapter 1, older adults may tend to interpret anxiety symptoms as 
signs of physical illness. For example, some patients who were referred to our RCT 
claimed not to suffer from panic attacks even though they fit all the criteria. In their 
minds, they just felt really sick when leaving the house, especially when taking a 
tram or a bus, and the thing to do when you are feeling sick, is to stay inside and rest, 
especially when you’re older. Also, the majority of anxiety disorders in late life 
represent a continuation of symptoms that started in early or middle adulthood. The 
mean duration of anxiety symptoms in our RCT sample was 26 years (see chapter 4). 
Presumably due to this long duration, symptoms are often experienced as a 
personality trait: e.g. ‘I do not suffer from anxiety, I simply am a worrisome 
individual and have been so all my life. Nothing can change that’. Furthermore, 
symptoms have often gone untreated through all these years, or the treatment 
received was inadequate. We frequently encountered stories of people receiving 
pharmacological treatments in the 1950s and 1960s comprised of enormous quantities 
of tranquilizers (according to today’s standards), which led to addiction and a 
subsequent withdrawal syndrome. These people do not tend to think of mental 
health care professionals as experts who are able to cure them. 
The reluctance encountered in anxious older adults to receive specialized treatment 
also implies that the treatments that we offer do not concur with their specific needs 
and expectations. With regard to CBT, treatment refusers and dropouts have often 
proclaimed that they did not ascribe to the treatment’s rationale or that they found 
the treatment too straining. Especially the cognitive elements in CBT and the 
abundance of forms and homework assignments seem to breed resistance in older 
adults. However, older adults are also inclined to be suspicious of pharmacological 
treatments for psychological problems (Wetherell et al., 2003b); older adults often 
already use a lot of different medications and tend to be afraid of adverse effects. 
This fear may be particularly strong in older adults suffering from an anxiety 
disorder.
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Modifications needed for treatment of late-life anxiety 
As described in the preface of the present chapter, the concept of this thesis was born 
from the conviction that common treatments for anxiety disorders in younger 
populations would also be successful in older adults. Due to the problems we faced 
when recruiting and retaining patients for our RCT and the disappointing results of 
CBT in our trial, we have come to the conclusion that this assumption is incorrect 
and that in fact, modifications or even alternative interventions may be necessary in 
order to improve the feasibility as well as the effectiveness of treatment for late-life 
anxiety disorders. Until now, no systematic study has been performed to assess if 
and what modifications are necessary, but several options have been put forward by 
prominent researchers in the field of late-life anxiety and our own investigations 
have also provided us with some new hypotheses with regard to this issue. 
Modifications that have been put forward in chapter 1 of the present thesis will not 
be repeated here, since these modifications were incorporated in our CBT treatment 
protocols and have proven insufficient. 
First of all, it may be necessary to provide treatments in a primary care rather than a 
specialized mental health care setting. Terms and settings related to psychiatry are 
often associated with taboo in the current generation of older adults. As mentioned 
in chapter 1, older adults tend to remain in primary care settings, and instead of 
trying to persuade them to enter into a specialized setting, it may be more 
appropriate to adjust our treatment effort to this fact. Also, our studies suggest that 
anxious older adults who might benefit most from a psychological intervention are 
those without a comorbid depression, with low neuroticism scores and high 
perceived health. This may represent a group with less illness severity that actually 
does not need a time-consuming, intensive and costly specialized mental health 
intervention. Short-term interventions based on behavioral techniques with less focus 
on complicated cognitive techniques may constitute a more feasible and efficient 
psychological intervention (see chapter 6). A recent pilot study provides some 
support for a short-term CBT intervention for late-life anxiety in primary care 
(Stanley et al., 2003b). Treatment with SSRIs also does not necessarily need to take 
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place in a specialized setting, although consultation from a psychiatrist preceding the 
administration of SSRIs by the general practitioner is advisable.
As described in the previous paragraph, forms and homework assignments that 
accompany a CBT intervention tend to breed resistance and tension in anxious older 
adults. A large proportion of the current generation of older adults has received a 
relatively low level of education and therefore, they may be afraid to make mistakes 
in the exercises. Also, the nature of the exercises (for example exposure) is often 
meant to raise anxiety levels and this may be a very demanding task for someone 
who has adopted reasonably effective avoidance strategies during the last 20 or 30 
years of his life. Therefore, anxious older adults may need more assistance and 
reinforcement in order to improve adherence to homework assignments. A recent 
pilot study (Mohlman et al., 2003) compared standard CBT to an ‘enhanced’ CBT 
intervention for older adults. Patients in the enhanced condition received weekly 
telephone calls from the therapist in between sessions in which the therapist inquired 
about the homework assignments and offered to help them if necessary. Although 
preliminary, results suggest that the enhanced CBT protocol might lead to better 
results.
In light of our own findings and the fact that the superiority of CBT over other 
treatment methods has not been firmly established for late-life anxiety disorders 
(Mohlman, 2004), it seems appropriate that future research efforts will not merely 
focus on possible modifications of CBT, but will also examine whether other 
interventions may not provide a more suitable alternative for this particular group. 
CBT tends to focus on the present and on specific techniques to learn how to handle 
anxiety, disregarding the past, since the origin of anxiety is presumed to be of less 
importance. However, in a sense this may conflict with one of the main features and 
tasks of late life: to look back on your life and to evaluate what life and your own 
actions have brought you. The fact that CBT tends to disregard this need may result 
in a lack of appeal to an older population. Interventions in which these features of 
late life are reinforced may be more acceptable to anxious older adults. Recently, 
reminiscence therapy has come into focus for the treatment of late-life depression, 
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yielding positive results (Bohlmeijer et al., 2003) but this intervention may also be 
applicable to anxiety disorders. Reminiscence therapy does not focus on specific 
symptoms of depression or anxiety. Instead, older adults come together in a group to 
talk and write about how they have coped with certain issues (e.g. experiences of 
loss) during their life. The memories called forth by these proceedings may be used 
in two different ways: 1) if the memories carry a negative quality: e.g. “I have always 
been a weak person”, the therapist attempts to redefine memories in more positive 
terms. 2) Coping mechanisms that have proven effective in the person’s past are 
applied to current problems (Watt & Cappeliez, 2000).  
Limitations of the present thesis 
Methodological limitations of the studies described in the present thesis have already 
been extensively addressed in the previous chapters. Therefore, the present 
paragraph will only provide a short summary of the main limitations.
Conclusions regarding the appropriate identification and treatment of late-life 
anxiety disorders that can be drawn from our study on the phenomenology of 
anxiety in older adults described in chapter 2 are limited by the fact that we studied 
anxiety in a normal rather than a clinical population. Since age was a-priori classified 
in three different groups, it was not possible to deduct at what age the differences 
found in relation to feared stimuli measured by the FSS actually emerged.  
Our study on the long-term outcome of anxiety disorders in the LASA-study 
(chapter 3) is limited by the loss of subjects for follow-up and the fact that analyses of 
outcome were restricted to one point in time, six years after baseline measurements. 
Our RCT (chapters 4 through 6) mainly suffered from small sample size and 
differences in sample size between treatment conditions which resulted in a lack of 
statistical power. The absence of a placebo condition and lack of an appropriate 
measure of adverse effects are important disadvantages. The heterogeneity of our 
sample may also be considered as a limitation, although as Nordhus and Pallesen 
(2003) have put forward in their systematic review of psychological interventions for 
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late-life anxiety: “the downside of homogeneity is that it yields a picture of patients 
that may be very different from their no-research counterparts, thus compromising 
generalization”. Finally, observer ratings in our RCT were not blind and 
measurement strategy relied heavily on self-report measures (three of four outcome 
measures), which may be problematic since older adults may tend to underreport 
psychological symptoms (Godderis et al., 1992). In the RCT, we found higher effect 
sizes for sertraline and a better long-term outcome of sertraline on anxiety symptoms 
as measured with the HARS (a clinician-rated instrument) and on worry symptoms 
(see chapters 4 and 5). Our study on attrition described in chapter 6 suggests that 
selective dropout of CBT participants with comorbid depression and high 
neuroticism scores and of sertraline participants without comorbid depression may 
have influenced these findings. We did not find any significant differences with 
regard to measures of illness severity at baseline between the active treatment 
conditions, either before or after attrition (chapter 4). However, we did find a 
significant difference in the rate of comorbid depression, and due to the lack of 
statistical power we cannot completely exclude the possibility that CBT completers 
represented a subgroup of participants with less ilness severity at baseline than 
sertraline completers. 
Recommendations for further research 
With regard to establishing differences in the phenomenology of anxiety in late life, it 
would be interesting to replicate the study described in chapter 2 in a clinical 
population in order to find more cues to improve identification and treatment for 
late-life anxiety disorders. The long-term course of late-life anxiety should be closely 
examined in a longitudinal design, using measurements at regular time intervals in a 
larger sample of anxious older adults in order to make up for the inevitable loss of 
subjects. With regard to the treatment of late life anxiety, our findings call for more 
pharmacological treatment trials of SSRIs, using larger samples and a placebo 
condition, adequate measurement of adverse effects and attrition related to adverse 
effects. Our findings also call for the development and investigation of a tailored CBT 
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intervention, both with regard to setting (primary care versus mental health care) 
and contents (e.g. more guidance in homework assignments). Additionally, 
comparative trials of CBT versus SSRIs as well as alternative psychological 
interventions such as reminiscence therapy are needed to firmly establish the 
preferred choice of treatment for this group. Trials incorporating stepped-care 
interventions may provide more information with regard to which older adults may 
benefit from a short-term primary care intervention and which older adults need a 
more intensive intervention. 
Final remarks 
In conclusion, we feel that studies have confirmed the assumption that anxiety in late 
life is an important problem that merits separate study. The second part of our 
hypothesis, which stated that the treatment of late-life anxiety is a feasible enterprise 
which can be achieved with roughly the same treatments that are successfully 
applied to younger populations, has partly been revised in the process of our 
investigations. In order to establish a feasible and effective treatment for late-life 
anxiety disorders, state of the art treatments for younger adults need to be modified. 
Alternative psychological interventions may even be more appropriate for this 
specific population than CBT. Our findings with regard to the effectiveness of the 
pharmacological treatment of late-life anxiety with an SSRI (sertraline) are 
promising. However, the lack of adherence to treatment is a complicated problem in 
both psychological and pharmacological interventions for late-life anxiety (Wetherell 
et al., 2003b). More research is needed to resolve this issue.  
The challenge facing us now is to bridge the gap between science and clinical practice 
(Wetherell, Maser & van Balkom, 2005), which has been proven to be a difficult task. 
As has been proposed in the first chapter of the present thesis, several false notions 
with regard to the nature of late-life anxiety are still abundantly present in clinical 
practice, even though these notions have been refuted by epidemiological studies. 
Researchers and clinicians need to join efforts to improve the acknowledgement of 
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late-life anxiety as a serious problem and to continue on the road toward  a tailored 
treatment for anxious older adults.
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Angst op latere leeftijd 
Op weg naar een passend behandelaanbod 
Tot voor kort werd er in de klinische praktijk en in de wetenschap weinig aandacht 
besteed aan angststoornissen op latere leeftijd. Verschillende factoren hebben hiertoe 
bijgedragen.
Ouderen met een angststoornis lijken zelden in contact te komen met de geestelijke 
gezondheidszorg, hetgeen een van de redenen is dat er lange tijd werd aangenomen 
dat angststoornissen bij ouderen niet zo vaak voorkwamen, of dat angst bij ouderen 
beschouwd moet worden als een secundair symptoom van depressie of een 
voorloper van dementie. Daarnaast is er lange tijd vanuit gegaan dat angst bij 
ouderen weinig lijdensdruk met zich mee zou brengen. Echter zelfs bij duidelijke 
aanwezigheid van lijdensdruk, lijkt er al sinds jaar en dag een vaak onuitgesproken 
idee te bestaan, dat het überhaupt niet haalbaar en weinig zinvol is om ouderen met 
angstklachten adequaat te behandelen. Een lange klachtenduur en de hypothese dat 
ouderen te weinig flexibel zouden zijn om hun gedragspatronen nog te kunnen 
doorbreken worden vaak ten tonele gevoerd als redenen om maar niet meer aan een 
dergelijke interventie te beginnen.  
Veel van de bovenstaande assumpties zijn inmiddels verworpen door recent 
epidemiologisch onderzoek. Angststoornissen komen meer voor bij ouderen dan 
welke andere psychiatrische stoornis ook, inclusief depressie, dysthymie en 
dementie. De prevalentie van angststoornissen bij ouderen ligt zo omstreeks de 10%, 
hetgeen niet erg afwijkt van de prevalentie van 12.4% die wordt aangetroffen bij 
jongere volwassenen. Bovendien is aangetoond dat de impact van angst op kwaliteit 
van leven en zorggebruik bij ouderen groot is en vergelijkbaar met de impact van 
depressie.
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Het huidige proefschrift stelt zich ten doel een bijdrage te leveren aan de correcte 
identificatie, prognose en in het bijzonder de effectieve behandeling van 
angststoornissen bij ouderen. 
De moeizame herkenning van angststoornissen bij ouderen wordt vaak aangewezen 
als mogelijke oorzaak voor het feit dat deze doelgroep niet adequaat behandeld 
wordt. Om te onderzoeken of verschillen in de fenomenologie van angst bij ouderen 
wellicht bijdragen aan deze moeizame herkenning, hebben we een studie uitgevoerd 
(beschreven in hoofdstuk 2), waarin jong volwassenen, volwassenen van middelbare 
leeftijd en oudere volwassenen met elkaar vergeleken werden met betrekking tot de 
stimuli die angst op roepen en de cognitieve inhouden van angst. Daartoe werd een 
mailsurvey afgenomen bij een representatieve steekproef van 513 proefpersonen in 
Nederland, die gelijk verdeeld waren in 3 leeftijdsgroepen van 1) 18-44 jaar; 2) 45-64 
jaar en 3) 65 jaar en ouder. De mate van angst die door specifieke stimuli wordt 
opgeroepen werd gemeten met de ‘Fear Survey Schedule’ (FSS). Cognitieve 
inhouden van angst werden gemeten met de ‘Worry Domains Questionnaire-
Revised’ (WDQ-R) en een nieuw samengesteld instrument, de ‘Senior Anxiety Scale’ 
(SAS). ANCOVA’s en post-hoc Bonferroni gecorrigeerde t-toetsen werden 
uitgevoerd op alle totaalscores en subschaal-scores om eventuele verschillen tussen 
de leeftijdsgroepen vast te kunnen stellen. Alhoewel ouderen en volwassenen van 
middelbare leeftijd met betrekking tot gevreesde stimuli op meerdere dimensies 
leken te verschillen van jongere volwassenen, werden er weinig verschillen 
gevonden tussen ouderen en volwassenen van middelbare leeftijd op de FSS. Het 
enige duidelijke onderscheid tussen ouderen en de beide jongere leeftijdsgroepen op 
dit punt, was dat ouderen over het algemeen hoger scoorden op angst voor sex en 
agressie. Met behulp van een principale componenten analyse werden vier factoren 
geïdentificeerd op de SAS, die samen 54.7% van de totale variantie in scores 
verklaarden. Ouderen scoorden hoger dan jong volwassenen op twee van de vier 
factoren van de SAS. Een van die factoren kan geïnterpreteerd worden als de angst 
voor achteruitgang van lichamelijke en geestelijke gezondheid, de andere kan 
geïnterpreteerd worden als de angst voor levensbedreigende situaties. Met 
betrekking tot de WDQ bleek dat ouderen zich minder zorgen lijken te maken over 
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financiën dan hun jongere tegenpolen. Daarnaast werden er op de WDQ geen 
verschillen tussen de leeftijdsgroepen gevonden. Concluderend kan gezegd worden 
dat ouderen zich meer zorgen lijken te maken over mogelijke achteruitgang van hun 
lichamelijke en geestelijke gezondheid, de dood en de mogelijkheid het slachtoffer te 
worden van een misdrijf dan jong volwassenen en volwassenen met een middelbare 
leeftijd.
Er is tot op heden weinig bekend over het lange termijn beloop van angststoornissen 
bij ouderen en van de factoren die hierbij mogelijk een rol spelen. Om vast te stellen 
of angststoornissen bij ouderen net als angststoornissen bij jonge volwassenen over 
het algemeen op lange termijn een negatieve uitkomst hebben, hebben we een studie 
uitgevoerd waarin bij een cohort van 112 angstige ouderen (55 jaar en ouder) na een 
follow-up periode van 6 jaar werd vastgesteld of er sprake was van 1) een 
persisterende angststoornis; 2) subklinische angstklachten of; 3) een volledige 
remissie van de angstklachten (hoofdstuk 3). Daarnaast werd bestudeerd welke 
variabelen een voorspellende waarde hadden voor de lange termijn uitkomst van 
angststoornissen op latere leeftijd.  Tot slot werd bekeken hoeveel van deze mensen 
na 6 jaar adequate hulp ontvingen, om vast te stellen of inspanningen in de afgelopen 
jaren om passende verwijzing van angstige ouderen te verbeteren, het beoogde effect 
hebben gehad. Drieëntwintig procent van onze sample voldeed na 6 jaar aan de 
criteria voor een angststoornis en 47% voldeed aan de criteria voor subklinische 
angstklachten. Een hogere score op neuroticisme bij aanvang van de studie bleek 
geassocieerd te zijn met de aanwezigheid van een angststoornis na 6 jaar, ook als er 
gecorrigeerd werd voor de ernst van angstklachten bij aanvang van de studie. Het 
gebruik van benzodiazepinen was hoog (43%), terwijl het gebruik van faciliteiten 
voor geestelijke gezondheidszorg (14%) en antidepressiva (7%) laag was bij degenen 
met een persisterende angststoornis. Deze resultaten impliceren dat neuroticisme 
ouderen kwetsbaar maakt voor een ongunstige lange-termijn uitkomst van 
angststoornissen. Inspanningen om ouderen met angst beter te verwijzen lijken niet 
het gewenste effect te hebben gesorteerd.
In antwoord op het therapeutisch nihilisme waarmee ouderen met angst ook nu nog 
vaak bejegend worden, is er een tegenstroming ontstaan. Deze tegenstroming stelt 
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zich ten doel aan te tonen dat dezelfde behandelingen die effectief zijn gebleken bij 
jongere volwassenen met angst, toegepast kunnen en behoren te worden bij ouderen 
met soortgelijke klachten. Behandelstudies die vanuit dit idee geïnitieerd zijn, 
hebben zich voornamelijk gericht op het vast stellen van de effectiviteit van 
cognitieve gedragstherapie (CGT) bij ouderen met angst, aangezien de effectiviteit 
van deze interventie bij jongere volwassenen ruimschoots is aangetoond. Alhoewel 
dergelijke studies aanleiding geven tot een gematigd positieve houding ten aanzien 
van de toepassing van CGT bij deze doelgroep, zijn hierbij toch enkele kritische 
kanttekeningen te plaatsen. Er zijn namelijk geen overtuigende bewijzen voor de 
superioriteit van CGT boven andere interventies voor angstklachten bij ouderen en 
de gevonden effectgroottes zijn beduidend lager dan de effectgroottes die worden 
aangetroffen bij soortgelijk onderzoek met jongere populaties. Tot op heden is er 
nauwelijks onderzoek gedaan naar farmacologische interventies voor 
angststoornissen bij ouderen. Ouderen met angst maken veelvuldig gebruik van 
benzodiazepinen en omdat het langdurig gebruik van deze middelen grote risico’s 
met zich meedragen voor ouderen, wordt er in de literatuur vaak beweerd dat 
psychologische interventies de voorkeur verdienen. Zelfs tegen modernere 
middelen, zoals de serotonerge antidepressiva die bewezen effectief zijn bij jongere 
populaties met angst, wordt gewaarschuwd, omdat ouderen onder andere door een 
langzamere stofwisseling meer last zouden hebben van bijwerkingen. Om de 
effectiviteit van CGT bij ouderen met angst nader te onderzoeken en om vast te 
stellen of genoemde terughoudendheid jegens farmacologische interventies terecht 
is, hebben we een vergelijkende behandelstudie van CGT versus een SSRI (sertraline) 
uitgevoerd bij deze doelgroep. Het betrof een multi-center trial dat plaats vond in 7 
GGZ-instellingen in twee verschillende regio’s van Nederland; Amsterdam en 
omstreken en Limburg. Vierentachtig patiënten van 60 jaar en ouder met een 
gegeneraliseerde angststoornis, paniekstoornis, agorafobie of sociale fobie als 
hoofddiagnose werden at random toegewezen aan een van de volgende drie 
condities: CGT, sertraline of een wachtlijst controlegroep. Primaire uitkomstmaten 
(angst) en secundaire uitkomstmaten (piekeren en depressieve symptomen) werden 
afgenomen op vier verschillende tijdstippen: voorafgaand aan de behandeling, een 
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week na het afsluiten van de behandeling, drie maanden na afsluiten van de 
behandeling en een jaar na afsluiten van de behandeling. Hoofdstuk 4 beschrijft de 
hoofdbevindingen van deze trial, terwijl hoofdstuk 5 zich richt op de lange termijn 
effecten van beide behandelingen. Daarnaast wordt in hoofdstuk 5 verslag gedaan van 
een studie naar differentiële predictoren voor het effect van beide behandelingen. 
Hoofdstuk 4. De uitval van proefpersonen was in beide behandelcondities relatief 
groot. Daardoor zijn onze bevindingen gebaseerd op een relatief kleine sample van 
‘completers’ (n=52). Hoewel zowel CGT als sertraline een significante verbetering in 
angst, piekeren en depressieve symptomen tot gevolg hadden, gingen deelnemers in 
de sertraline groep meer vooruit met betrekking tot piekeren dan deelnemers in de 
CGT groep. Effectgroottes voor CGT waren klein tot middelgroot, zowel vlak na de 
behandeling (gemiddelde d=.42) als na een follow-up van 3 maanden (gemiddelde 
d=.35). Effectgroottes voor sertraline daarentegen waren groot te noemen, 
(gemiddelde d(nameting)= .94 en gemiddelde d(follow-up)=1.02. De wachtlijst 
conditie vertoonde geen beduidende verbetering of verslechtering van klachten 
(gemiddelde d(nameting)= .03).
In hoofdstuk 5 worden onder andere de lange termijn uitkomsten van de 
behandelstudie beschreven. Na een follow-up van 1 jaar blijken deelnemers in de 
sertraline groep meer vooruit gegaan te zijn op angst (gemeten met de HARS) en 
piekeren (gemeten met de WDQ) dan deelnemers in de CGT conditie. Om vast te 
stellen welke factoren bepalen of een deelnemer gunstig reageert op een van beide 
behandelingen werd door middel van een regressie-analyse op residual gain scores 
bestudeerd of er een associatie is tussen leeftijd, opleiding, duur van de klachten, 
angstsymptomen, depressieve symptomen, neuroticisme en gezondheid bij aanvang 
van de behandeling enerzijds en de afname van klachten tussen voor en nameting en 
tussen de voormeting en een follow-up van 1 jaar anderzijds. Een geringere 
inschatting van de eigen gezondheid, de aanwezigheid van depressieve symptomen 
en een hoge score op neuroticisme bleek voorspellend te zijn voor een slechter 
behandelresultaat in de CGT groep. De sterkste voorspeller voor een slecht 
behandelresultaat op korte termijn na CGT was een geringe inschatting van de eigen 
160
gezondheid, hetgeen 40% van de variantie in scores verklaarde. De sterkste predictor 
voor een slecht behandelresultaat op lange termijn in de CGT groep was 
neuroticisme, hetgeen bij de follow-up 20% van de variantie in residual gain scores 
verklaarde. In de sertraline groep bleek een hogere angstscore bij aanvang 
voorspellend te zijn voor een grotere afname van klachten op korte termijn. 
Angstscore bij aanvang verklaarde 41% van de variantie in residual gain scores bij de 
nameting. Er werden geen significante predictoren voor lange termijn effecten 
gevonden in de sertraline groep.
Concluderend kan gezegd worden dat onze bevindingen suggereren dat sertraline 
een effectievere behandeling zou kunnen zijn dan CGT voor ouderen met een 
angststoornis, althans wanneer CGT wordt aangeboden in een individuele setting 
met minimale aanpassingen voor ouderen. Een geringe inschatting van de eigen 
gezondheid en neuroticisme bleken voorspellend te zijn voor minder verbetering ten 
gevolge van CGT. Ernstigere angstklachten bleken voorspellend te zijn voor een 
grotere verbetering op korte termijn bij een behandeling met sertraline.
De werving van proefpersonen voor behandelstudies naar angst bij ouderen is uiterst 
moeizaam gebleken. Deze werving komt veelal tot stand door middel van de 
verspreiding van advertenties en interviews in de media. Daarnaast worden de 
beschikbare behandelstudies naar angst bij ouderen gekarakteriseerd door een hoge 
uitval van proefpersonen. Het is belangrijk om hier aandacht aan te besteden bij het 
evalueren van de effectiviteit van een bepaalde interventie, aangezien het vroegtijdig 
staken van een behandeling opgevat kan worden als een falen van die behandeling. 
De actieve werving en de hoge uitval van proefpersonen kan bovendien een bias van 
de onderzoeksresultaten tot gevolg hebben. Mensen die een behandeling vroegtijdig 
staken blijken vaak op verschillende factoren te verschillen van mensen die de 
behandeling wel afmaken. Mensen die actief geworven worden voor onderzoek via 
de media wijken vaak af van mensen die zichzelf aanmelden of die verwezen 
worden naar een instelling voor geestelijke gezondheidszorg. 
In hoofdstuk 6 wordt een studie gerapporteerd waarin nader werd onderzocht of er 
verschillen waren tussen weigeraars, drop-outs en completers in beide 
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behandelcondities van de door ons uitgevoerde trial. Ook wordt in dit hoofdstuk 
beschreven in hoeverre deelnemers die actief waren geworven voor het onderzoek 
verschilden van deelnemers die werden verwezen naar een instelling voor geestelijke 
gezondheidszorg. 
Drop-outs in de CGT conditie bleken een hogere score te hebben op neuroticisme en 
zij hadden vaker een comorbide depressie bij aanvang van de studie dan CGT 
deelnemers die de behandeling afmaakten. Drop-outs in de sertraline conditie 
hadden juist minder vaak een comorbide depressie bij aanvang dan sertraline 
deelnemers die de behandeling afmaakten. Deelnemers die actief geworven waren 
via radio, tv, krant of foldermateriaal bleken hoger opgeleid te zijn en minder 
ernstige klachten te hebben (zoweel lichamelijk als psychisch) dan deelnemers die 
verwezen waren naar een van de aan de trial deelnemende GGZ-instellingen. 
Concluderend kan gezegd worden dat de werving van deelnemers uit de algemene 
bevolking wellicht leidt tot een selectie van relatief gezonde proefpersonen voor 
behandelstudies naar angst bij ouderen. SSRI’s zijn wellicht meer acceptabel voor 
angstige ouderen met een comorbide depressie terwijl CGT een meer passende 
interventie kan zijn voor angstige ouderen zonder comorbide depressie en een lage 
score op neuroticisme.
In hoofdstuk 7 worden de belangrijkste bevindingen van bovenstaande studies 
geïntegreerd en bediscussieerd. In dit hoofdstuk wordt onder andere expliciet 
aandacht geschonken aan de betekenis van neuroticisme in onze studie, de 
haalbaarheid van psychologische en farmacologische interventies van angst bij 
ouderen en aan de vraag of en zo ja, welke aanpassingen er nodig zijn voor de 
adequate toepassing van CGT op een oudere populatie.
Ons onderzoek heeft naar onze mening voldoende aangetoond dat de aanname, dat 
angst bij ouderen een belangrijk probleem is dat aparte aandacht verdient in de 
wetenschap en de praktijk, juist is. Het tweede deel van onze hypothese bij aanvang 
van dit promotietraject, dat de behandeling van angst bij ouderen een haalbare 
onderneming is waarvoor in grote lijnen de bij jongere volwassenen effectief 
gebleken behandelingen toepasbaar zijn, is deels herzien naar aanleiding van onze 
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bevindingen. Om ervoor te zorgen dat de behandeling van angst bij ouderen een 
haalbare en effectieve onderneming wordt, moeten state of the art behandelingen 
voor angststoornissen op een meer ingrijpende wijze worden aangepast voor het 
gebruik bij een oudere doelgroep. Onze bevindingen ten aanzien van de effectiviteit 
van de behandeling van angst bij ouderen met een SSRI zijn veelbelovend. Het 
gebrek aan therapietrouw vormt echter bij zowel psychologische als farmacologische 
interventies een gecompliceerd probleem. Er is meer onderzoek nodig om voor deze 
vraagstukken een bevredigende oplossing te vinden.
De uitdaging die nu voor ons ligt, is te zorgen dat de kloof tussen wetenschap en 
klinische praktijk overbrugd wordt. Veel van de inmiddels door wetenschappelijk 
onderzoek weerlegde assumpties ten aanzien van de aard van angst op latere leeftijd 
zijn nog steeds volop in zwang in de klinische praktijk. Onderzoekers en clinici 
moeten hun krachten bundelen om de herkenning en vooral de erkenning van angst 
bij ouderen als serieus probleem te bewerkstelligen en om de ingeslagen weg naar 




Dit proefschrift is opgedragen aan mijn opa, Bach Schuurmans, en zijn motto: ‘Mens, 
durf te leven’. Hij was zo’n warme en levenslustige persoonlijkheid dat ik lange tijd 
wilde geloven dat Magere Hein aan hem voorbij zou gaan. Tegen alle wetten der 
rechtvaardigheid in stierf hij natuurlijk toch, in 2001, het jaar dat ik aan dit promotie 
onderzoek begon. Een liedjeszanger die afgelopen jaar overleed was echter van 
mening dat je pas dood bent, als men je is vergeten. Ik heb geprobeerd de 
herinnering aan mijn opa in meerdere aspecten van mijn promotie en proefschrift 
terug te laten komen.
De weg naar een proefschrift is lang en begint eigenlijk bij de liefde voor een vak. Op 
die weg zijn er veel mensen geweest die mij op verschillende manieren hebben 
geholpen.
Alan Davies, die mij voor het eerst liet kennis maken met de psychologie. Ik was 
meteen verkocht. Pieter de Beurs en Theo Hoytink. Inspirerende docenten aan de 
VU. Arnoud van Loon, mijn stagebegeleider op de Valeriuskliniek, die door mijn 
onzekerheid heen prikte en me aanspoorde als ik dacht dat ik het niet kon.  
Christine van Boeijen, Patricia van Oppen, Ton van Balkom, Loes Marquenie en 
Annemiek Schadé, die mij een kans gaven door mij aan te nemen als 
onderzoeksassistent en van wie ik heb kunnen afkijken hoe je goed onderzoek opzet 
en uitvoert.
Hannie Comijs, mijn copromotor, jou als vaste begeleider te hebben bij mijn 
promotietraject was eigenlijk een enorme luxe. Je had altijd tijd voor me, mijn 
mailtjes werden altijd bijna direct beantwoord (en dat waren er soms meerdere op 
een dag), je had waardevolle input bij de moeizame werving en je 
becommentarieerde mijn stukken zeer gedegen en gedetailleerd. En bovendien 
waren onze begeleidingsgesprekken ook altijd zo gezellig, ik mis je nu echt.  
Richard van Dyck en Paul Emmelkamp. Jullie vulden elkaar goed aan als 
promotoren en hebben beiden een onmisbare bijdrage geleverd aan dit proefschrift. 
Dank voor de snelheid waarmee jullie de door mij ingestuurde stukken 
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becommentarieerden (met name in de eindfase van mijn promotietraject, toen ik 
jullie bijna iedere week iets stuurde dat om een reactie vroeg!) en voor jullie 
waardevolle bijdragen aan alle stukken. Richard, van jou heb ik veel geleerd over het 
reageren op commentaar van referenten, vooral als dit niet zo positief was. Paul, 
dank voor je inzet als supervisor van de gedragstherapeuten in Amsterdam en voor 
je voortdurende vertrouwen in de succesvolle afronding van dit project, ook in tijden 
dat het minder goed ging. 
 Patries, jou moet ik minstens twee keer bedanken. Mijn promotietraject was zeker in 
de beginjaren een vaak frustrerende bezigheid, maar ik kon altijd bij jou binnen 
komen lopen om stoom af te blazen en om vervolgens, gewapend met jouw nuchtere 
adviezen, de strijd weer aan te gaan. Zonder jou weet ik echt niet of ik het wel had 
volgehouden en je bent dan ook met recht mijn paranimf vandaag. 
Ingrid Weijnen en Marcel van den Hout, die jarenlang vanuit Limburg het onderzoek 
dat daar plaats vond coördineerden. Zonder de samenwerking met jullie zou deze 
studie nooit tot een goed einde hebben kunnen komen.  
Edwin de Beurs. Vooral in de beginfase heb je bij het ontwerpen van deze studie en 
de gebruikte behandelprotocollen een belangrijke rol gespeeld. Er was op dat vlak al 
veel werk verricht voordat ik bij het project betrokken raakte. 
Zonder het geduld en doorzettingsvermogen van alle deelnemende behandelaars, 
die met een uitdagende en soms veeleisende doelgroep moesten werken, was dit 
project nooit van de grond gekomen. Gezien de vele instellingen die aan dit project 
deel hebben genomen zal ik ongetwijfeld iemand vergeten, maar ik noem in 
Amsterdam en omstreken: Jacomien van der Linden, Marga Kuipers, Jari Hariju, 
Paul Korstens, Saskia Ohlin, Jorinde van der Kloek, Peter de Ruig, Dorien Postma, 
Caroline Sonnenberg, Sannie Hamerlink, Eric van Exel, Kathleen Thomaes, Ethy 
Dorrenpaal, Willeke van Zelst. In Limburg: Mike Verkaaik, Joyce Straalman, Aimee 
Janssen, Hanneke Zuiderveld, Jan Oosterwijk en natuurlijk Ingrid Weijnen. 
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Alle deelnemende instellingen; RIAGG Midden Limburg, RIAGG Noord Limburg, 
RIAGG Maastricht, RIAGG Sittard, GGZ Buitenamstel, de Geestgronden en de 
afdelingshoofden van de desbetreffende afdelingen voor ouderen, veel dank voor de 
medewerking en het in ons onderzoek gestelde vertrouwen. 
De patiënten die hebben deelgenomen aan de behandelstudie en het fenomenologie-
onderzoek wil ik uitdrukkelijk bedanken voor hun medewerking, hun inzet en de 
moed die zij hebben getoond door de stap naar de hulpverlening te zetten. 
Len Hillen, die aan het begin van dit project de eerste intakes in Amsterdam deed en 
andere gegevens verzamelde , Dagmar Vink, die data verzamelde in Limburg en 
Astrid Dello, die aan het eind van het project de metingen in Limburg overnam van 
Ingrid, veel dank voor jullie bijdrage. 
Marijke van der Toolen en Anneke Hermans. Veel dank voor jullie nauwgezetheid, 
snelheid en inspanningen bij het opsporen van talloze artikelen. 
Jan Smit, die zelf vindt dat hij helemaal geen geduld heeft voor het gezeur van 
andere mensen, maar ik weet wel beter. 
Pim Cuijpers, Theo Hoytink en Marianne Ouwehand; dank voor de ruimte die ik heb 
gekregen om mijn proefschrift af te ronden en voor jullie begrip en steun bij de door 
slapeloze nachten soms wat moeizame start van mijn nieuwe baan op de afdeling 
klinische psychologie van de VU.
Bij het schrijven van dit dankwoord bemerk ik dat er veel mensen zijn die ik mijn 
dank wil betuigen voor dingen die, althans in directe zin, niets met het schrijven van 
dit proefschrift van doen hebben.  
Auke en Joke. Eigenzinnige ouders maken eigenzinnige kinderen, en dat is maar 
goed ook. Als ik jullie opvoeding in een zin zou moeten samenvatten, dan is het denk 
ik; ‘doe het maar zoals je het zelf wil doen, dan doe je al gewoon genoeg’. Door jullie 
non-conformisme en ruimdenkendheid heb ik geleerd niet snel iets raar te vinden of 
te veroordelen en dat komt me bij mijn werk nu erg goed van pas. 
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Joke en Riet, oftewel de Mobiele Oma Brigade, die files, weer en wind trotseerden om 
Abel en later ook Jip bij ziekte of andere noodgevallen voor ons op te vangen. Zonder 
jullie had dit proefschrift er gewoon nog lang niet gelegen. 
Gijs. De Allerbeste Grote Broer die een Zus zich wensen kan en een van de laatste 
Echte Ridders. Je staat vandaag naast me op dat enge grote podium, dus mij kan 
niets gebeuren. 
Willem en Liesbeth, mijn oudste kameraadjes. Zo lang ik jullie bij me heb raak ik 
nooit de weg kwijt. Willem, jou wil ik ook enorm bedanken voor al je hulp bij het 
scannen en bewerken van de illustraties. Liesbeth, wat heerlijk voor je dat je nu 
eindelijk die lange reis met Joris maakt waar je al zo lang naar uitkeek, maar wat zal 
ik je missen vandaag. 
Sas en Noor, iets nieuwere kameraadjes. Aan jullie allebei veel dank voor alle 
opbeurende mails, gesprekken en attenties als ik het even niet meer zo zag zitten. 
Sas, zonder jou had ik het weerbarstige programma ‘Word’ nooit kunnen bedwingen 
en je hebt ook nog eens mijn hele proefschrift nagekeken op redigeerfouten! 
Sommige mensen markeren een keerpunt in je leven. Zonder hen zou alles anders 
zijn geweest. Voor mij zijn dit twee mensen, die ik omstreeks dezelfde tijd ontmoette, 
nu ongeveer twaalf jaar geleden: Mevrouw Martijn, Maurice. 
Mevrouw Martijn, ik heb eindelijk dat boek dat steeds onder mijn bed lag maar eens 
weggegooid. 
Maurice, twaalf jaar geleden liep je op jouw nonchalante wijze binnen bij het 
gezinstherapiepracticum op de VU. Met een te ruim zittende blouse en idem broek 
aan, je haren naar achteren gekamd en die Jack Nicholson wenkbrauwen. Nu zijn we 
ruim tien jaar verder en zijn we zelf een gezin geworden. Promoveren, werk en 
kinderen combineren kan prima, mits je iemand naast je hebt staan die ook 
daadwerkelijk in alle facetten van zo’n druk bestaan naast je gaat staan. Dat kan je als 
geen ander. Bedankt daarvoor. Dat drukke bestaan zorgt er soms wel voor dat we 
weinig tijd over houden om weer even terug te gaan naar hoe het allemaal begon; 
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gewoon wij met zijn tweetjes, door de stad zwalkend tot ’s ochtends vroeg, omdat we 
allebei geen afscheid konden nemen. Maar iedere keer als we de tijd nemen en de 
wereld even verdwijnt, voelt alles weer net zoals toen. Ik hoop dat dat altijd zo mag 
blijven.
Het allerbeste en allerleukste wat me ooit is overkomen; moeder worden. Abel. Jouw 
enthousiasme over de gewone dagelijkse dingen (‘Kijk, mamma, het stoplicht is 
groen! GROEN!’ of ‘JAAAA! wij gaan BOODSCHAPPEN doen!’) is geweldig 
aanstekelijk. En als ik ergens pijn heb krijg ik er van jou altijd een kusje op en dan is 
het ook echt meteen over. Jip. Het liefste kleine vrouwtje van Nederland. 

Je leeft maar heel kort, maar een enkele keer  
En als je straks anders wilt, kun je niet meer  
Mens durf te leven
Vraag niet elke dag van je korte bestaan:  
Hoe hebben m'n pa en m'n grootpa gedaan?  
Hoe doet er m'n neef en hoe doet er m'n vrind?  
En wie weet, hoe of dat nou m'n buurman weer vindt?  
En - wat heeft 'Het Fatsoen' voorgeschreven?  
Mens, durf te leven! 
De mensen bepalen de kleur van je das  
De vorm van je hoed, en de snit van je jas  
En - van je leven  
Ze wijzen de paadjes, waarlangs je mag gaan  
En roepen 'o foei!' als je even blijft staan  
Ze kiezen je toekomst en kiezen je werk  
Ze zoeken een kroeg voor je uit en een kerk  
En wat j'aan de armen moet geven  
Mens, is dat leven? 
De mensen - ze schrijven je leefregels voor 
Ze geven je raad en ze roepen in koor: 
Zo moet je leven!  
Met die mag je omgaan, maar die is te min  
Met die moet je trouwen - al heb je geen zin  
En daar moet je wonen, dat eist je fatsoen  
En je wordt genegeerd als je 't anders zou doen  
Alsof je iets ergs had misdreven  
Mens, is dat leven? 
Het leven is heerlijk, het leven is mooi  
Maar - vlieg uit in de lucht en kruip niet in een kooi  
Mens, durf te leven 
Je kop in de hoogte, je neus in de wind  
En lap aan je laars hoe een ander het vindt 
Hou een hart vol van warmte en van liefde in je borst  
Maar wees op je vierkante meter een Vorst! 
Wat je zoekt, kan geen ander je geven  
Mens, durf te leven! 
tekst van Jean-Louis Pisuisse



